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Abstract 
Diabetes mellitus (DM) is a major health problem currently affecting over 225 million 
people worldwide. It is often described as a major metabolic disorder, which can result 
in numerous long-term complications including retinopathy, nephropathy, neuropathy 
and cardiomyopathy. DM is due to a deficiency of insulin or insulin resistance. Of the 
225 million diabetic patients, around 5-10% suffer from type 1 DM (T1DM) and the 
remaining 90-95% suffer from type 2 diabetes (T2DM). T1DM is due to insulin 
deficiency whereas T2DM is due to either a reduction in insulin secretion or insulin 
resistance. Patients with both T1DM and T2DM normally require insulin and 
hypoglycaemic drugs, respectively. Changes in life style habits, regular exercise and 
healthy diets can also help to control blood glucose in T2DM patients. Mediators that 
can help to increase the health of pancreatic islets to synthesize and secrete insulin will 
be of tremendous benefit to diabetic patients. This study investigated the beneficial 
effects of incretins, substances such as glucagon-like peptide-1 (GLP-1) and its 
synthetic agonist, exenatide on the diabetic rat pancreas compared to healthy, age-
matched controls.  These incretins exert their beneficial effects by repairing the 
pancreatic islets. Thus, increasing pancreatic beta (β) cell mass and in turn it will help 
to synthesize and secrete insulin into the circulation. The rationale of this study was to 
find out how these two incretins can improve insulin secretion both in vivo and in vitro 
employing the rat model of T1DM following injection with streptozotocin (STZ). The 
project employed six groups of rats, with three groups serving as age-matched, healthy 
controls and the other three groups rendered diabetic. One set of rats from each group 
was untreated while the rats from the other four groups were given either GLP-1(50 
nmol/kg body weight) or exenatide (1 μg/kg body weight) over 10 weeks. The project 
measured body weight, levels of blood glucose and insulin. The plasma levels of liver 
and kidney markers were also determined. The in vitro study measured insulin secretion 
from pancreatic fragments, the distribution of insulin- and glucagon-positive cells in 
pancreatic islets, granules, co-localization of different peptides in the islets, 
biochemical, and molecular biological changes, which may occur in the pancreas 
during the experimental period. 
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For the in vivo study, the results have shown mild gain in body weight and no change in 
blood glucose levels in both treated and untreated age-matched normal control rats. 
Furthermore, the results show a significant reduction in blood glucose levels in diabetic 
rats treated with either GLP-1 or exenatide, but the beneficial effect was more 
pronounced following GLP-1 treatment. The results also show no changes in glucose 
handling between normal treated or normal untreated rats following blood glucose 
tolerance test (GTT). However, in diabetic rats, the results show that the GTT reveals a 
better glucose tolerance in these diabetic animals treated with either GLP-1 or exenatide 
but the effect was more significant with GLP-1 compared with untreated diabetic rats. 
The present study shows that diabetic rats secreted significantly less insulin in the blood 
than normal healthy rats and a significant increase in serum insulin was detected in both 
normal and diabetic  rats treated with either GLP-1 or exenatide  compared to untreated 
controls. The results also show significant reductions in the liver enzymes, aspartate 
transferase and alanine transferase in the diabetic rats. A similar beneficial effect on 
kidney function was obtained owing to a small reduction in blood urea nitrogen, serum 
creatinine and serum uric acids in both normal and diabetic rats treated with either 
GLP-1 or exenatide. In the lipid profile study, the results show a mild reduction in 
serum cholesterol and a marked reduction in serum triglyceride in both normal and 
diabetic rats treated with either GLP-1 or exenatide.  
The results from the in vitro study show that either GLP-1 or exenatide can evoke 
marked dose-dependent release (secretion) of insulin from pancreatic tissue fragments 
of normal and diabetic rats, indicating that there is a clear role for either GLP-1 or 
exenatide in inducing insulin secretion.       
In this study, an attempt was also made to investigate both the number and distribution 
of endocrine cells in the control and diabetic rat pancreas using immnohistochemistry. 
The results show a significant increase in the number of cells containing either insulin 
or GLP-1 in both normal and diabetic treated rats. However, in the case of exenatide, 
catalase and glutathione reductase-positive cells were only significantly increased in 
diabetic rats, but the increase was not significant in normal rats treated with either GLP-
1 or exenatide. These results show that the significant increase in number of catalase 
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and glutathione-positive cells in diabetic rats treated with either GLP-1 or exenatide 
reveal the beneficial antioxidant effect of both GLP-1 and exenatide in treatment of 
oxidative stress, which usually occurs in DM. On the other hand, there was a significant 
decrease in glucagon-positive cells in both normal and diabetic rats treated with either 
GLP-1 or exenatide.  
The immunohistochemical and immunofluorescent studies also revealed that insulin-
positive cells were distributed both in the central and peripheral portions of the islets of 
Langerhans in normal pancreas. In contrast, glucagon-positive cells were located in the 
peripheral part of the islets of Langerhans. After the onset of diabetes, the number of 
insulin-positive cells was reduced significantly. In contrast, the number of glucagon-
positive cells increased significantly with abnormal pattern of distribution compared to 
normal pancreas. The pattern of distribution of both GLP-1 and exenatide has indicated 
co-localization not only with insulin, but also with glucagon. Furthermore, catalase and 
glutathione reductase-positive cells were distributed homogenously all over the islet of 
Langerhans with no specific co-localization with specific type of endocrine cell.    
In the gene expression study, the results show significant increases in the levels of 
mRNA of pancreatic duodenal hoeobox-1, heat shock protein-70, glutathione 
peroxidase, insulin receptor and glucagon like peptide-1 receptor in both normal and 
diabetic rats treated with either GLP-1 or exenatide. However, the increase was not 
significant in mRNA gene expression of either insulin receptor or glucagon like 
peptide-1 receptor in normal rats treated with GLP-1. On the other hand, the gene 
expression results show that glucagon mRNA level was significantly decreased in both 
normal and diabetic rats treated with either GLP-1 or exenatide. 
In conclusion, the results of this study have clearly demonstrated that both GLP-1 and 
exenatide have marked beneficial effects on pancreatic islet cells, especially β- and α-
cells, which produce insulin and glucagon, respectively. The two incretins seem to 
repair the diabetic pancreas, which in turn secretes more insulin and less glucagon. 
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1.1 The pancreas 
 
The pancreas is located in the upper part of the abdominal cavity. It is attached to the 
duodenum, the first part of the small intestine via the common pancreatic bile duct. The 
gland is also extended towards the spleen (Figure 1.1-A). The pancreas is an elongated 
nodular organ of about 15-25 cm length and approximate 80 g in weight. The pancreas 
is formed by a broad head attached to the duodenum, a cylindrical body and a small tail 
near the spleen (Martini and Nath, 2009). 
The pancreas is a mixed gland, composed of a major exocrine part and minor endocrine 
portion (Figure 1.1). The exocrine portion of the pancreas is composed of about 98% 
and this part is studied mainly by the Gastroenterologists while, the endocrine part is 
formed of approximately 2% of the pancreatic architecture and studied by the 
Endocrinologists. The exocrine pancreas is formed of a collection of acini that secrete 
digestive enzymes and alkaline buffer and open into the pancreatic duct which release 
its secretions into the duodenum. Pancreatic juice helps in the digestion of 
carbohydrates, fats and proteins and it also neutralize the acidic chyme from the 
stomach. Pancreatic juice secretion is regulated by cholinergic, adrenergic and 
peptidergic nerves as well as by the gut hormones, cholecystokinin (CCK) and secretin 
(Hug et al., 2003; Liddle, 2006; Chu et al., 2006; Amber and Bloom, 2007). In the 
endocrine pancreas a scattered groups of pancreatic islet cells, known as islets of 
Langerhans secrete pancreatic hormones. Normally, the pancreas contains 
approximately one million pancreatic islets, which are supplied with a capillary 
network that conveys its hormones directly into the blood circulation (Martini and 
Nath, 2009). The islets of Langerhans, include four distinct cell types that are 
innervated heavily with autonomic and peptidergic nerve endings (Tan, 2008). 
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Figure 1.1: Diagrams showing (A) the position of the pancreas and its relationship with 
the duodenum and (B) a histological picture of the endocrine and exocrine components 
of the pancreas (Modified from Martini and Nath, 2009). 
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1.1.1 The endocrine pancreas 
Since this thesis is related mainly to the endocrine pancreas, then much emphasis will 
be made on the endocrine pancreas. The endocrine part of the pancreas is composed of 
tiny units of islets with a rich supply of blood capillaries. The islets are scattered 
randomly within the exocrine pancreas. Paul Langerhans initially discovered pancreatic 
islet cells in 1869 and they carried his name (Bishop and Polack, 1997). The release of 
hormones from islets of Langerhans is controlled by rich innervations via cholinergic, 
adrenergic and non-cholinergic, non-adrenergic nerves (Toda and Herman, 2005). The 
medium-sized islets of Langerhans of human pancreas are formed from about 2500 
cells. In most mammals, the islets contains 4 major types of cells (α, β, δ and PP) with a 
central core of insulin-producing β-cells and a peripherally located glucagon-producing 
α-cells, somatostatin-secreting δ-cells and pancreatic polypeptide-synthesizing PP-cells 
(Eberhard et al., 2008). The human pancreatic islet is a little bit different because β-
cells mainly in the central area while α-, δ- and PP-cells can be either found within the 
central core or in the peripheral part of the islets (see Figure 1.2) (Brissova et al., 2005). 
The islets are not only composed of endocrine cells but also endothelial cells in contact 
with blood capillaries and dendritic cells. The dendritic cells reveal phagocytic actions. 
They may also be involved in the initiation of T1DM and play an important role in β-
cells transplantation rejections (Bertelli and Bendayan, 2005). However, the islets of 
Langerhans comprise only about 2% of the total pancreatic mass; they are heavily 
supplied with blood vessels, which, account for 10% of the entire pancreatic blood 
circulation (Richards et al., 2010). 
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Figure 1.2: Schematic representation of optical sectioning of pancreatic islets. Islet cell 
types are illustrated in four different colours: β-cells, green; α-cells, red; δ-cells, blue; 
PP-cells, yellow (Modified from Brissova et al., 2005). 
 
1.1.2 Cells types in pancreatic islets of Langerhans  
Each islet contains basically four different cell types (Figure 1.2) and they include:- 
Beta-cells: These cells produce insulin and they are the most common type of 
endocrine cells in the pancreas. The β-cells are situated mostly in the central area, also 
some are located in the peripheral regions of the islet. The percentage of β-cells is 
around 70% of the whole cell population in a definite islet of Langerhans (Adeghate 
and Ponery, 2003).  
Αlpha-cells: Glucagon-producing cells compose approximately 20% of all cells in the 
endocrine pancreas. They are detected in the outer part of the islets of Langerhans 
(Adeghate and Ponery, 2003). 
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Delta-cells: Somatostatin pancreatic producing δ-cells are positioned mostly in the 
marginal portion of the islets of Langerhans with about 8% of the islet cells (Adeghate 
and Ponery, 2003). 
Pancreatic polypeptide-cells: Pancreatic polypeptide (PP) producing cells are found 
mainly in the outer area of the pancreatic islets of Langerhans comprising of about 2% 
of the total islet cells (Adeghate and Ponery, 2003). 
 
1.1.3 Innervation of the pancreas 
The pancreas is supplied by adrenergic, cholinergic and as well as peptidergic nerves. 
These nerves contain acetylcholine, noradrenaline, serotonin and a variety of peptides 
such as neuropeptide-Y, vasoactive intestinal polypeptide, galanin and leucine-
enkephalin (Rossi et al., 2005). The nerve cells in the pancreas contain not only 
parasympathetic cholinergic and sympathetic adrenergic but also other 
neurotransmitters and neuropeptides. These categories of pancreatic innervations are 
involved in pancreatic functions in many ways and play a role in resolving pain in 
certain pancreatic illness like chronic pancreatitis (Rabinovich et al., 2006). 
 
1.2 Pancreatic hormones 
1.2.1 Insulin 
Normal body growth, development and maintenance of nutrient balance are among the 
powerful anabolic actions of insulin. Insulin controls the metabolism of carbohydrates, 
lipids and amino acids within various body tissues. However, liver, muscle, and adipose 
tissue are the essential affected tissues. The traditional general function of insulin is to 
regulate carbohydrate metabolism and its specific action is to control plasma sugar 
level. One of the lethal causes of the diabetic patients with insulin deficiency is the 
disturbance of lipid metabolism, which leads to arthrosclerosis and acidosis (Kumar 
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and Clark, 2007). In T1DM, there is a pronounced reduction of insulin concentration 
that causes a potent inhibition in the production and secretion of pancreatic enzymes 
with related reduction in food digestion. Inadequate insulin secretion or insulin 
resistance may ultimately cause the establishment of DM (Patel et al., 2006). 
 
1.2.2 Insulin structure 
Human insulin is a type of protein hormone of low molecular weight of about 5,800 
KD as seen in figure 1.3. The structure of insulin molecule consists of 51 amino acids 
of two polypeptide chains (A and B). The A-chain is the smaller one and consists of 21 
amino acids and the second larger B-chain is formed from 30 amino acids. Both A- and 
B-chains are attached together through two disulphide links found between cysteine 
amino acids. In the A-chain a similar internal disulphide link is found between two 
cysteine amino acids. The main function of these disulphide links is to give the three-
dimensional form of insulin molecule and guarantee the precise physiological action of 
insulin hormone (Weiss, 2009). 
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Figure 1.3: Diagram showing the structure of human insulin molecule (Modified from 
Guyton and Hall, 2005). 
 
1.2.3 Insulin synthesis 
There are several stages in the regulation of insulin synthesis in β-cell of the endocrine 
pancreas. This control system involves the transcriptional, translational and post-
translational steps. The mechanism of insulin production is shown in figure 1.4. 
According to the human genome, insulin gene is found on the small arm of 
chromosome number 11 (Xu et al., 2009). 
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Figure 1.4: Schematic diagram showing multiple steps in the transcriptional and 
translational synthesis of insulin (Modified from Montague, 1993).  
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The essential function of the β-cell is to produce, store and secrete insulin. The fully 
formed insulin granule is made of two A and B polypeptide chains, which are not 
produced as single polypeptide chains but are formed by precise proteolytic processing 
of a bigger precursor, proinsulin (Steiner, 2004).   
Insulin gene transcription via RNA polymerase forms a mRNA which is processed in 
the nucleus to generate a mature mRNA that is translated into pre-proinsulin in the 
cytoplasm. The translation of the mRNA into amino acid sequence of pre-proinsulin 
takes place in the ribosomes. Pre-proinsulin translation starts with the signal peptide, 
which is recognized via binding of signal recognition part to the ribosomes, and 
attaches it to the endoplasmic reticulum (ER) to initiate the synthesis of the molecule of 
pre-proinsulin. The pre-proinsulin is transported from ER membrane into its cisternal 
cavity to be changed to proinsulin, which then achieves chain folding and binding with 
disulphide bonds to develop an enclosed microvesicle, which is then conveyed to the 
Golgi apparatus. In the Golgi apparatus, proinsulin is packaged into storage granules 
(Wicksteed et al., 2001). 
Through a proteolysis process, the recently synthesized proinsulin in Golgi apparatus is 
slowly changed to insulin granules, which finally, under the effect of certain proteases 
are converted to mature insulin granules with equivalent quantities of C-peptide, four 
basic amino acids and single peptide (see Figure 1.5). The maturely formed storage 
granules are transported from the Golgi apparatus to β-cell cytoplasm waiting for the 
secretory signals. These secretory granules contain mainly mature insulin with minor 
quantity of unconverted proinsulin (Steiner et al., 2005). 
The most effective signal on insulin synthesis by β-cell is the blood glucose 
concentration. Low fasting blood glucose level (2-4 mM) leads to decreased synthesis 
level of proinsulin. On the other hand, increased level of blood glucose above the 
threshold concentration (4-6 mM) causes a remarkable enhancement of proinsulin 
production and under different body needs, a sufficient store of insulin is constantly 
accessible (Steiner et al., 2009). 
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Proinsulin 
 
 
       
Figure 1.5: Diagram showing the conversion of proinsulin to signal peptide, insulin, C-
peptide, and four basic amino acids (Modified from Montague, 1993). 
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Mammalian insulin gene expression is mostly associated with β-cell of the pancreas. 
The insulin promoter area is located 400 bp, upstream from the insulin gene, where the 
transcription initiation process starts.  Insulin gene transcription may be controlled via 
tissue-specific expression and metabolic factors. Several transcription factors operate 
through this area, creating a transcriptional network, which ensures precise control of 
insulin gene transcription. The greatest critical acting DNA factors associated with 
transcriptional initiation are related to the A3, C1 and E1 sites (Poitout et al., 2006). 
 
The production and release of insulin via the pancreatic β-cells is highly critical in 
preserving normoglycaemia. This is achieved by accurate regulation of insulin 
synthesis and secretion via β-cells under the influence of variations in blood glucose 
concentrations. The production of insulin is regulated by blood glucose concentration at 
the transcriptional and post-transcriptional stages. Although great number of 
transcription factors correlate with the role of insulin gene transcription, three β-cell-
specific transcriptional factors, pancreatic duodenal homeobox-1 (PDX-1), neurogenic 
differentiation-1 (NeuroD1) and V-maf musculoaponeurotic fibrosarcoma oncogene 
homologue A (MafA), are reported to have an essential effect on glucose stimulation of 
insulin gene transcription and β-cell activities in the pancreas (Poitout et al., 2006). 
These three transcription regulators enhance insulin gene expression in accordance to 
elevated blood glucose levels. Fluctuations in blood glucose concentration change the 
activity of these transcription factors at different stages. Likewise, variations in calcium 
concentrations, food accessibility and hormone secretion also stimulate changes in the 
activity of these three transcription regulators (Chalmers and Cooper, 2008). These 
comprise modifications of the expression rates, DNA-binding action, transcription 
capacity, changing the location of some cellular organelles, and reactions between 
different proteins (Andrali et al., 2008).  Glucose sensitivity to the insulin promoter is 
essentially controlled by A3, E1 and C1 boxes, which bind to the transcription factors 
PDX-1, NeuroD1 and MafA, respectively (Kataoka, 2007). These three transcription 
regulators enhance insulin gene expression under the effect of hyperglycaemia (Song et 
al., 2007). 
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Glucose modifies the activity of these three transcription regulators via different 
mechanisms. Alteration of glucose levels has a critical role in changing the localization 
of PDX-1 in β-cell either to decrease or increase the rate of insulin gene expression 
through their effect on DNA-binding and the interaction of PDX-1 with different cell 
proteins. At low glucose (1-3 mM), concentrations PDX-1 is mostly found in the 
nucleus periphery of β-cell and few unphosphorylated PDX-1 molecules bind to co-
repressors protein at A box of insulin gene promoting area that leads to suppression of 
insulin gene transcription. However, high glucose concentrations (10-30 mM), activate 
the phosphorylation and translocation of PDX-1 to bind to co-activator protein at A box 
that enhances insulin gene transcription (Stanojevic et al., 2004). 
In case of NeuroD1, it is suggested that NeuroD1 changed its position under the effect 
of various glucose levels. At low glucose levels (1-3 mM), NeuroD1 is mostly located 
in the cytoplasm of the β-cell. While under elevated glucose concentrations (10-30 
mM), this can lead to an increase in the entrance of NeuroD1 into the nucleus. Inside 
the nucleus, NeuroD1 phosphorylation occurs and its binding to co-activator protein at 
E1 box within the insulin promoter causes enhancement of insulin gene transcription 
(Andrali et al., 2007).  
The expression of MafA gene requires elevated glucose levels in β-cell. Therefore, 
MafA transcription is reduced at low glucose levels (1-3 mM). However, elevated 
glucose concentrations (10-30 mM), lead to an increase in MafA translocation to the 
nucleoplasm and its binding to C1 box at the promoter area of insulin gene that elevates 
insulin gene transcription (Vanderford et al., 2007). 
 
1.3 Glucose transporters 
There are thirteen members of the facilitative glucose transporter family (GLUT-1-12) 
and H
+
-coupled myo-inositol transporter (HMIT). In addition, the sodium-dependent 
glucose transport is mediated by Na
+
/glucose co-transporters (SGLT). There are about 
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six individuals of this family, however, only SGLT-1 and SGLT-2 have been 
extensively studies (Wright and Turk, 2004). The GLUTs basic structure is composed 
of twelve transmembrane-domains areas with intracellular situated carboxyl- and 
amino-termini (Figure 1.6) (Gorovits and Charron, 2003). GLUTs operate with 
facilitative diffusion gradient of sugar through the cell plasmalemma and reveal diverse 
substrate kinetic properties (Km), specificities and tissue expression systems. The 
specific substrate kinetic (Km) or Michaelis constant is an indicator of the affinity of 
the glucose transporter receptor for glucose molecules; a lower Km value suggests a 
higher affinity. This affinity determines the degree of glucose and other sugars uptake 
into different cells. Each GLUT exerts variable degrees of insulin dependence and 
affinity (Joost et al. 2002). The expression of different sugar transporter isoforms in 
different body tissues, and cells are summarized in table 1.1 (Wood and Trayhurn, 
2003; Zhao, and Keating, 2007). 
All the GLUT family members have „sugar transporter signatures‟. GLUT family 
members (Figure 1.6) may be classified into three subclasses (I-III) according to the 
sequence and motifs arrangement (Joost and Thorens, 2001). 
 
Figure 1.6: Diagram showing the glucose transporter of twelve hydrophobic 
transmembrane domains (TM rectangles) which are linked by hydrophilic loops. The 
COOH and NH2 termini are directed intracellularly (Modified from Gorovits and 
Charron, 2003). 
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Table 1.1: Summary of the facilitative transporters family (GLUTs) (Modified from 
Wood and Trayhum, 2003; Zhao, and Keating, 2007). 
 
Facilitative 
Transporter 
Class Tissue Expression 
Substrate & 
Affinity (Km) 
Insulin 
Sensitive 
Function 
(Transport) 
GLUT-1 I 
Erythrocytes, 
Brain, Liver, 
Skeletal muscle, 
Adipose tissue 
Glucose 1-2 mM No 
Basal glucose 
uptake 
GLUT-2 I 
Liver, β-cells, 
Intestine, Kidney 
Glucose 15-20 
mM 
No 
Glucose & Fructose 
sensing & 
transport by liver 
& pancreas 
GLUT-3 I Brain (Neurons) Glucose 1-2 mM No 
Basal glucose 
uptake 
GLUT-4 I 
Adipose tissue, 
Skeletal muscle, 
Heart, Brain 
Glucose 5 mM Yes 
Insulin-stimulated 
glucose uptake 
GLUT-5 II 
Intestine, Kidney, 
Sperm, Skeletal 
muscle, Adipose 
tissue 
Fructose 10-13 
mM 
No 
Transport of 
fructose from 
intestinal lumen 
into the cells & into 
sperm 
GLUT-7 II 
Small intestine, 
Colon, Testis 
(Glucose & 
Fructose) < 0.5 
mM 
Unknown Glucose & Fructose 
GLUT-9 II Liver, Kidney Urate ≈ 0.6 mM Unknown Urate 
GLUT-11 II 
Skeletal muscle, 
Heart, Liver, 
Trachea, Lung, 
Brain 
Glucose & 
Fructose 
No 
Glucose (Short 
isoform) - Fructose 
(Long isoform) 
GLUT-6 III 
Brain, Spleen, 
Leucocytes 
Glucose 5 mM No Glucose 
GLUT-8 III 
Brain, Testis, 
Mammary Gland 
Glucose 2 mM 
No (Yes in 
Blastocytes) 
Glucose 
GLUT-10 III 
Liver, Pancreas 
Skeletal muscle, 
Heart,  
Glucose 0.3 mM Yes Glucose 
GLUT-12 III 
Heart, Prostate, 
Muscle, Small 
intestine, Adipose 
tissue 
Glucose Yes Glucose 
HMIT III Brain 
H
+
-Myo-Inositol 
~100 mM 
Unknown H
+
-Myo-Inositol 
 
Na+/Glucose 
Cotransporters 
Tissue Expression 
Substrate & 
Affinity (Km) 
Function (Transport) 
SGLT-1 Intestine, Kidney Glucose 0.2 mM 
Glucose reabsorption in intestine and 
kidney 
SGLT-2 Kidney Glucose 2 mM Glucose reabsorption in kidney  
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1.3.1 Class I facilitative transporters 
The class I facilitative transporters have GLUT-1-4, and these have been widely 
categorized in relation to tissue distribution, structure and function. GLUT-1 is found 
mainly in the brain and erythrocytes and to a smaller extent in skeletal muscle, adipose 
tissue and liver. GLUT-1 is located in the plasmalemma of cells, as it is responsible for 
maintaining a basal rate of glucose uptake. The Km of GLUT-1 is low (1-2 mM) with 
high glucose affinity (Zimmerman et al., 2001). In contrast, GLUT-2 has a high Km 
value (15-20 mM) and therefore a low affinity for glucose. GLUT-2 is found in the 
plasmalemma of cells and it is also involved in preserving a basal glucose uptake rate. 
GLUT-2 is mostly expressed in β-cells, liver and kidneys. In the pancreatic β-cells, 
GLUT-2 is responsible for the glucose-sensing system. GLUT-2 is expressed in the 
liver under hormonal regulation and it permits for glucose transport in and out of 
hepatocytes. GLUT-2 is expressed on the proximal convoluted tubules and enterocytes 
in the kidney, where it plays a role in fructose and glucose secretion and reabsorption. 
GLUT-2 is also found in basolateral and brush border membranes of the small intestine 
(Stolarczyk et al., 2010). GLUT-3 exhibit a great affinity for glucose (Km 1-2 mM) and 
it is located in the plasmalemma of cells. GLUT-3 is expressed in brain tissues where 
there is ultimate need for reserving a basal rate of glucose uptakes as an essential source 
of fuel for brain cells (Simpson et al., 2008). GLUT-4 is an insulin-responsive glucose 
transporter and it is expressed in skeletal muscle, adipose tissue, heart and brain. As 
muscle is an essential storage site for glucose and adipose tissue for triglyceride (into 
which glucose can be transformed for storage). The main function of GLUT-4 in these 
tissues is to lower the postprandial increase in blood glucose concentrations. After a 
meal, insulin stimulates the mobilization of GLUT-4-containing vesicles from 
cytoplasmic stores to the cell plasma membrane. Integration of GLUT-4 to the 
plasmalemma leads to fast elevation of glucose influx of about 10-20-fold (Bryant et al. 
2002). A decreased expression of GLUT-4 in adipose tissue is detected in different 
diabetic animal models and human. GLUT-4 knockout mouse models show the 
involvement of GLUT-4 in the pathophysiology of T2DM (Abel et al. 2001).  
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1.3.2 Class II facilitative transporters 
Class II GLUTs include GLUT-5, GLUT-7, GLUT-9 and GLUT-11. GLUT-5 is a 
fructose transporter of low affinity (Km 10-13 mM). GLUT-5 is found mainly in the 
small intestine, kidneys and sperms. GLUT-5 mediates diffusion of fructose from the 
brushborder membrane of the intestinal lumen into the intestinal epithelial cells. 
GLUT-5 is also expressed in skeletal muscle and adipose tissue. The expression of 
GLUT-5 in human muscle is associated with the muscle ability to use fructose as a 
source of glycolysis and glycogenesis without involvement of GLUT-4 and GLUT-1 
(Ferraris, 2001). GLUT-7 is expressed in the small intestine, colon and testis. GLUT-7 
has a great affinity (< 0.5 mM) for glucose and fructose. The closest GLUT to GLUT-7 
is GLUT-5. The accumulation of GLUT-7 in the small intestine matches the 
concentration of carbohydrate in the diet. However, the expression of GLUT-7 in the 
colon was not changed by the concentration of carbohydrate in the diet (Cheeseman, 
2008). GLUT-9 is found in the liver and kidney. GLUT-9 regulates urate homeostasis 
by its double role in urate reabsorption in the kidney and urate degradation in the liver. 
Defect in GLUT-9 is one of the main causes of hyperuricaemia-induced gout (So and 
Thorens, 2010). GLUT-11 has two isoforms and each one is tissue-specific. The short 
isoform of GLUT-11 has reduced-affinity to glucose transport and is competed for by 
fructose. This type of GLUT-11 is found mainly in heart and skeletal muscle (Doege et 
al. 2001). The long isoform of GLUT-11 is found in liver, trachea, lung and brain. All 
of which help to elevate fructose transport (Wu et al. 2002). GLUT-5 is a fructose 
sensitive GLUTs and its structure is very close to GLUT-11. This explains the possible 
role of GLUT-11 as a compensatory glucose transport in GLUT-4 (-/-) muscle (Doege 
et al., 2001). 
 
1.3.3 Class III facilitative transporters 
Class III of facilitative transporters contain five members: GLUT-6, GLUT-8, GLUT-
10, GLUT-12 and HMIT (Joost et al. 2002). GLUT-6 has a low affinity for glucose 
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(Km 5 mM). GLUT-6 is expressed in the brain, spleen and leucocytes (Doege et al. 
2000). GLUT-6 is insensitive to insulin-stimulated glucose transport cytoplasmic 
translocation to the cell plasma membrane (Lisinski et al., 2001). GLUT-8 is present in 
the testis and brain (Ibberson et al. 2000). However, initiation of GLUT-8 translocation 
by insulin has been detected only in blastocytes. GLUT-8 may also play a main role in 
the delivery of glucose to mature sperm. GLUT-8 expression in mammary gland is 
intense throughout late pregnancy to early lactation, indicating its role in glucose 
uptake for milk production (Membrez et al., 2006). GLUT-10 is expressed in the liver 
and pancreas (McVie-Wylie et al. 2001). GLUT-10 is also found in the insulin-
sensitive tissues such as skeletal and heart muscles. GLUT-10 is associated with the 
development of T2DM (Dawson et al. 2001).  GLUT-10 deficiency may lead to arterial 
tortuosity syndrome and this relation may explain its mechanisms in causing 
microangiopathy normally seen in T2DM (Coucke et al., 2006). High affinity glucose 
transporters has been reported (Km 5, 2, and 0.3 mM) for GLUT-6 (Doege et al. 2000), 
GLUT-8 (Ibberson et al. 2000) and GLUT-10 (Dawson et al. 2001), respectively. 
GLUT-12 transporter is found in the heart, small intestine, prostate, adipose tissue and 
insulin-sensitive tissues. GLUT-12 transporter is a part of insulin-responsive glucose 
transport system, which influences its translocation to the cell membrane (Rogers et al. 
2002). GLUT-12 is also expressed in the distal tubules and collecting ducts of the 
nephron and may play an important role in glucose reabsorption in the kidneys (Linden 
et al., 2006). On the other hand, HMIT is a H
+
-coupled myo-inositol transporter (Km 
~100 mM) with no transport effect on glucose.  HMIT is found mainly in the brain. 
HMIT exists in neuronal cytoplasm and may lead to the movement of myo-inositol the 
cell membrane resulting in cell depolarization, stimulation of protein kinase C or 
elevated intracellular calcium levels (Uldry et al., 2004). The intracellular actions for 
this transporter may be relevant to mood control in the brain (Di Daniel et al. 2009).  
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1.3.4 Sodium-dependent glucose transporters 
At the small intestine epithelial cell brush border and the proximal convoluted tubules 
of the kidney, glucose is either absorbed or reabsorbed against its concentration 
gradient as a co-transporter with Na
+
 down its concentration gradient (Figure 1.7). 
These transport systems are in continuous association with Na
+
/K
+
/ATP pump 
machinery (Zhao and Keating, 2007).  
SGLT-1 shows a strong glucose and galactose affinity (Km ~0.4). SGLT-1 is largely 
expressed in the brush border membrane of the epithelial cells of the intestinal lumen 
and it is essentially involved in the absorption of the glucose and galactose in the meal 
(Suzuki et al., 2001). Expression of SGLT-1 has been detected in numerous body 
tissues such as the kidney, the liver and the mammary gland, which are associated with 
glucose uptake via different types of facilitative transports (Zhao et al., 2005). Not only 
sugar transporter but also, SGLT-1 plays an active role as a co-transporter for water and 
thus, it may be a multifunctional co-transporter (Wright et al., 2003). 
SGLT-2 is expressed mainly in the kidney (Km 2 mM) where it reabsorbs glucose from 
the luminal membrane of the proximal convoluted tubules of the nephron by Na
+
 
coupling via down inward gradient flow of Na
+
 across the luminal epithelium. The 
process is continued by active transport of Na
+
 through the basolateral membrane back 
to the blood circulation (Figure 1.7). Glucose is passively transported outside the cell 
down its concentration gradient via GLUT-2 (90%) and the remaining 10% by GLUT-1 
(Wright, 2001). SGLT-2 inhibitors could be a novel therapeutic target for the treatment 
of T2DM (Chao and Henry, 2010). 
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Figure 1.7: Schematic diagrams showing sodium-dependent glucose transporters 
(Modified from Caccia et al., 2007; Nair and Wilding, 2010). 
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1.4 Glucose metabolism 
The concentration of plasma glucose is tightly controlled throughout different normal 
body activities. The normal range of glucose in the plasma is 3.5-8.0 mM/L (63-144 
mg/dl) regardless of extreme conditions such as intake of large quantities of food, 
starvation and intense physical activities (Arciero et al., 1999). The process of glucose 
uptake by different body tissues is under the influence of two factors including the 
physiological requirements of the tissue and accessibility of glucose. The two systems 
in which glucose uptake occur are facilitated transport (a passive way) down the 
glucose concentration gradient and secondary active diffusion against glucose 
concentration gradient (an active way that indirectly needs adenosine triphosphate, 
ATP, as a source of energy). The liver controls glucose tolerance via glucose uptake 
and then converting it to glycogen. The liver later releases glucose into blood 
circulation between meals according to the need of peripheral tissues. The liver may 
also change glycerol and protein as non-carbohydrate molecules via gluconeogenesis 
into glucose (Beauvieux et al., 2008). 
The brain is the main organ for glucose use. The rate of glucose uptake via the brain is 
about 1 mg/kg body weight/minute. This is a compulsory process and it is insulin 
independent (Mealey and Ocampo, 2007). Large quantity of glucose is also used up by 
muscle and adipose tissue. Muscle cells store glucose as glycogen and adipose tissue 
use glucose as a substrate for fuel or for the production of triglycerides (Gomes et al., 
2009).  
Although influenced by other hormones, insulin is a key determinant peptide in the 
regulation of glucose metabolism. At decreased plasma insulin concentration (e.g. 10 
IU µl
-1
), glucose release is at highest level and its use is at lowest. On the other hand, at 
high insulin level (e.g. 300-500 IU µl
-1
), glucose use and uptake are at the highest level. 
While, at intermediate plasma insulin level (e.g. 40-50 IU µl
-1
), hepatic and peripheral 
glucose release is reduced. Glucagon, adrenaline and growth hormones have an 
antagonistic effect on insulin action. They increase the production of glucose and 
reduce its utilization by the body (Kumar and Clark, 2007). 
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Insulin is not needed for the entrance of glucose into many body cells including the 
liver, kidney, retina, lens, Schwann cells of peripheral nerves, placenta, red blood cells, 
seminal vesicles and cells of the ovaries (Wiernsperger, 2005). As insulin is not needed 
for glucose uptake to the mentioned cells, high levels of glucose could be taken by 
these cells during hyperglycaemia especially during DM. The main type of facilitative 
glucose transporter (GLUT-1) in the plasma membrane of brain and liver cells is non-
insulin dependent and it is responsible for maintaining a basal rate of glucose uptake for 
these tissues. The Km value of GLUT-1 is low (1-2 mM) with high glucose affinity 
(Zimmerman et al., 2001). Raised cytosolic glucose level and a sufficient amount of 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) can lead to aldose 
reductase to form sorbitol, which unlike glucose, cannot diffuse through cell 
membranes and consequently it is kept stocked inside the cell (Kumar and Clark, 2007). 
This is worsened when sorbitol dehydrogenase is either reduced or absent in such 
tissues as the retina, lens, kidney and peripheral nerve cells. As a result, sorbitol 
accumulates in the mentioned cells, leading to elevated osmotic pressure and cell 
swelling due to holding of much water. Many of the pathological changes related to 
DM can be referred to this phenomenon, with cataract formation, peripheral neuropathy 
and vascular problems leading to nephropathy, retinopathy and cardiomyopathy 
(Maritim et al., 2003). 
 
1.4.1 Stimulation of insulin secretion by β-cells 
The pancreatic β-cell is a greatly specialized cell that synthesizes, stores and secretes 
insulin under the effect of increased blood glucose level. To achieve this function, β-
cell has a sensory system for detecting blood glucose level in order to regulate the rate 
for either the synthesis or the release of insulin. β-cell glucose sensing system depends 
on glucose metabolic products that form a second messenger which in turn stimulates 
the exocytosis of insulin granules (Leroux, et al., 2001).  
Glucose is the main secretagogue for insulin release. Glucose enters into the β-cell 
cytoplasm at high rate via GLUT-2 and it is quickly phosphorylated into glucose-6-
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phosphate (G-6-P) by glucokinase enzyme. Glucokinase acts as a key factor for glucose 
sensation and it determines the speed of glycolysis. At the end of glycolysis, pyruvate is 
formed and it enters into the Kreb‟s cycle in mitochondria (Mt). This in turn leads to an 
elevation of the ATP/ADP ratio, which in turn activates the ATP-sensitive K
+
 channels 
closure. Decrease of K
+
 levels in the cytoplasm results in both the initiation and 
propagation of action potentials and membrane depolarization, thus enhancing the 
opening of voltage-dependent Ca
2+
 (VDC) channels and increases Ca
2+
 entry into the β-
cell. The elevated cytosolic Ca
2+
 level enhances the binding of insulin-containing 
secretory vesicles to the cell plasma membrane (figure 1.8). Then, insulin granules are 
released by a process called exocytosis (Dunne, et al., 2004). 
 
Figure 1.8: Schematic diagram showing the process of glucose-stimulated insulin 
secretion from an endocrine pancreatic β-cell (Modified from Jensen et al., 2008). 
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1.4.2 Insulin receptor (IR) 
Insulin receptor (IR) is a heterotetrameric cell membrane binding protein receptor that 
consists of two extracellular α-subunits that bind insulin and two transmembrane β-
subunits, with tyrosine kinase domain (Saltiel and Kahn, 2001). Figure 1.9 shows the 
relationship between insulin receptor and glucose transporter. IR is a member of 
tyrosine kinase receptor. IR is a glycoprotein and it is located on chromosome 19. The 
α-subunits of IR have three sub-domains ligand binding sites. Minimally, two epitopes 
overlap to create binding surfaces to insulin molecule, and in this way, insulin can bind 
asymmetrically with the two α-subunits receptors (Meyts et al., 2007). The β-subunit 
contains a part that is extracellular and binds to α-subunits by disulphide bonds, a part, 
which contains the trans-membrane portion of the receptor, and a region that is 
intracellular. The αβ-dimeric receptor is capable of binding with insulin granules; 
however, the ααββ-tetrameric receptor binds insulin with higher affinity. The β-
subunits have the intrinsic tyrosine-protein-kinase enzymatic action (Amessou et al., 
2010). IR gene is expressed all over the body tissues and cells, the concentrations of IR 
mRNA and its protein, differ between cells and tissues types and are controlled by 
variant elements and environmental factors (Amessou et al., 2010). The chief insulin 
target tissues are liver, adipose tissue, and skeletal muscle. IR is found in further tissues 
like brain, kidney, heart, pancreatic acini, pulmonary alveoli, placental vascular 
endothelium, erythrocytes, granulocytes, monocytes, and fibroblasts. The wide 
distribution of insulin receptor in numerous tissues of the body shows that IR has a 
distinctive effect in different organs (Belfiore et al., 2009). Insulin granule binds with 
the α-subunit to enhance tyrosine phosphorylation of the IR β-subunit (see Figure 1.9). 
The stimulated IR then phosphorylates its substrates (tyrosine phosphorylation). Insulin 
receptor substrates (IRSs) have four forms, IRS-1, IRS-2, IRS-3 and IRS-4 (White, 
2002). The phosphorylated proteins activate downstream effectors cascades that induce 
various signalling reactions (Saltiel and Kahn, 2001). IRS-1 shows an essential effect in 
metabolic activities of insulin, while IRS-2 contributes mainly in controlling of glucose 
levels (Withers et al., 1999). After binding between insulin and its receptor, GLUT-4 
glucose transporter moves towards the cell plasmalemma. Insulin enhances glucose 
uptake by muscle and adipose tissue via activating the translocation of GLUT-4. Insulin 
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binding to its IR initiates tyrosine phosphorylation of IRS-1/2 downstream signallings 
in the cytoplasm leading to stimulation of phosphatidylinositol 3-kinase (PI-3K), 
protein kinase B (PKB) and protein kinase C-δ (PKC-δ) downstream cascades (Figure 
1.9). These protein kinases activate the translocation GLUT-4 into the cell membrane, 
which later contribute to glucose influxes into the cytoplasm (Huang and Czech, 2007). 
Finally, the IR complex is then moved into the cytosol where insulin is degraded and 
the IR move back to the cell membrane to be re-used (Kumar and Clark, 2007). 
 
 
Figure 1.9: Diagram showing the relationship between the effect of insulin binding to 
its IR in the plasmalemma of adipocytes and muscle cells and cascade of events 
resulting in translocation of GLUT-4 to the cell membrane and increase in glucose 
uptake. IRS-1/2, insulin receptor substrate 1 or 2; PI-3K, phophatidylinositol 3-kninase; 
PKB and PKC-δ, protein kinase A and C-δ (Modified from Schulingkamp et al., 2000). 
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1.5 Glucagon 
Glucagon is produced in the endocrine pancreas from α-cells of islets of Langerhans. 
Glucagon is a polypeptide hormone formed of a single polypeptide chain of 29 amino 
acids (Figure 1.10) (Guyton and Hall, 2005). Proglucagon gene is expressed into 
glucagon in the pancreas while in the intestine it processed into GLP-1 and GLP-2. 
Glucagon has antagonistic effect to insulin action. At low glucose concentration, 
glucagon is released leading to a reduction in glucose oxidation and an increase in 
blood glucose concentration. Glucagon also increases blood glucose level mostly 
through enhancing the breakdown of glycogen in the liver via glycogenolysis. On the 
other hand, glucagon elevates blood glucose via enhancing lipolysis in both liver and 
adipose tissue. To a lesser extent, glucagon promotes proteolysis (Kumar and Clark, 
2007). At regular situation, glucagon does not induce glucose uptake via either muscle 
or adipose tissue. Muscle glycogen acts as an energy store for muscular action and 
glycogen consumption is regulated by muscle contraction through catecholamines. 
Glucagon generally, has no effect on muscle glycogen (Carneiro and Amaral, 1983; 
Roach, 2002; Rivera et. al., 2007). 
Glucagon enhances energy production more than storage especially from glucose, to 
maintain normal blood glucose level at different body needs. Glucagon exerts its effect 
on liver by binding to the hepatic cell membrane receptor and initiates a sequence of 
intracellular reactions through cAMP as a second intracellular messenger to induce or 
inhibit either kinase or phosphatase enzymes. These in turn inhibit glycogenesis, 
promote glycogenolysis and elevate glucose synthesis. At the same time, glucagon 
stimulates gluconeogenesis and reduces glycolysis. On the other hand, glucagon 
promotes β-oxidation of non-esterified fatty acids and reduces triglyceride production 
causing ketogenesis. Glucagon also inhibits coenzyme A reductase that leads to 
reduction of cholesterol production in liver cells. Glucagon has other effects on 
different organs of the body. Glucagon elevates cardiac output by stimulation of the 
adenylate cyclase enzyme of heart cells. Glucagon increases sodium levels in urine by 
reducing tubular reabsorption in the kidney and finally, it enhances lipase action in 
adipose tissue (Tan, 2008). 
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Figure 1.10: A diagram showing the amino acid sequence of glucagon (Modified from 
Guyton and Hall, 2005). 
 
1.5.1 Glucagon synthesis and secretion 
Glucagon is produced mainly by pancreatic α-cells. It is also synthesized by different 
cells of gastrointestinal tract (stomach and intestine). Glucagon secretion is induced by 
various types of amino acids like alanine and arginine with different rate. Some other 
compounds, which can stimulate glucagon secretion, include catecholamines and gut 
hormones like gastrin, cholcytokinin and gastroinhibitory peptide. The autonomic 
nervous system (sympathetic and parasympathetic) also controls the secretion of 
glucagon by enhancement of its secretion at low blood glucose level and inhibits its 
release during hyperglycaemia (Kumar and Clark, 2007). 
 
1.5.2 The interaction between insulin and glucagon 
The pancreatic hormones control the metabolism of glucose, non-esterified fatty acids 
and amino acids. Both insulin and glucagon have antagonistic actions on substrate 
fluctuations, which are controlled by the insulin-glucagon ratio. The normal molar ratio 
is 2:1 however, it is converted to 1:2 at increased demand for mobilization of 
endogenous substrates, in case of fasting or extended exercise. The decrease in insulin 
release and the increase in glucagon release can lead to glycogenolysis and 
gluconeogenesis in the liver and lipolysis in adipose tissue in addition to increasing the 
liver metabolism of non-esterified fatty acids needed for β-oxidation (Tan, 2008). 
H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-
Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
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After a meal, the insulin-glucagon ratio is elevated to about 10:1, mainly due to 
enhanced insulin release. This leads to activation of glucose uptake associated with 
oxidation and conversion of glucose to glycogen in either liver or muscle. 
Postprandially, there is no need for non-esterified fatty acids since in the adipose tissue 
lipolysis is suppressed (Cahova et al., 2007). 
The pancreatic endocrine action is controlled through many factors including glucose. 
This controlling action involves the parasympathetic nervous system that enhances 
insulin and glucagon release, while the sympathetic pathway which enhances glucagon 
but reduces insulin release. The pancreas responds differently according to various 
body conditions (Quesada et al., 2008). 
 
1.6 Somatostatin 
Somatostatin is a pancreatic hormone synthesized in the form of prosomatostatin from 
δ-cells of islets of Langerhans. The 14-amino acid peptide of somatostatin (SS14) is a 
powerful suppressor of the release of insulin, glucagon and pancreatic polypeptide. The 
cells of the intestine also synthesise prosomastatin but process it in another way into 28 
amino acid (SS28). SS28 suppresses the movements of gall bladder, stomach and 
intestine. Additionally, SS28 decreases gut secretions (Tostivint et al., 2008).  
In the case of increased body physical activity with reduced blood glucose level, 
somatostatin decreases the secretion of growth hormones and thyroid stimulating 
hormone. Somatostatin reduces the volume of blood reaching to the stomach and spleen 
and inhibits the secretion of hydrochloric acid from the stomach and digestive enzymes 
from the pancreas (Bosch et al., 2009).  
There are many stimulants for the release of somatostatin from either δ-cells of the 
pancreas or intestine. They include glucose, ketone bodies, amino acids, 
cholecystokinin, secretin and gastin hormones. Somatostatin release is induced by 
insulin only at increased blood glucose levels. As somatostatin has inhibitory effect on 
insulin production and secretion, so insulin can inhibit its own release via inducing 
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somatotatin secretion (Brunicardi et al., 2001). On the other hand, decreased blood 
glucose level induces somatostatin release under the effect of glucagon-mediated 
secretion. Generally, it appears that there is a negative feedback relationship of 
somatostatin with either glucagon or insulin (Muroyama et al., 2004; Strowski and 
Blake, 2008). An elevated count of δ-cells has been detected in either T1DM or T2DM. 
This condition is associated with disturbed glucose-induced somatostatin release.  In 
diabetic patients, both counts of δ- and α-cells are increased, but the elevation of α-cells 
is much more than that of δ-cells. In addition, the ratio of δ/α-cell is decreased due to 
increased α-cell hyperproliferation. This in turn can lead to disturbance in δ/α-cell ratio 
and causes impairment in glucose-stimulated somatostatin secretion. Somatostatin 
inhibitory effect on glucagon secretion is abolished and this condition worsens the 
hyperglycaemia in diabetes. The basal level of somatostatin secretion is normal in 
T2DM while it is elevated in T1DM. This difference may be due to the abolished 
secretion of insulin in T1DM as an essential controlling element for the normal 
secretion of somatostatin from pancreatic δ-cells (Strowski and Blake, 2008). 
Somatostatin may be an additional treatment of diabetes though its suppressing effect 
on glucagon releases (Madsen et al., 2002). 
 
1.7 Pancreatic polypeptide 
Pancreatic polypeptide (PP) is a peptide formed from 36 amino acids. PP is released 
from the pancreatic polypeptide cells in islets of Langerhans and is also secreted from 
the islet cells directly linked to acini cells. In contrast to glucagon, PP is mainly more in 
the head of the pancreas compared to the tail. PP is expressed chiefly in pancreatic 
endocrine cells and at low levels in gut cells (Ekblad and Sundler, 2002). The essential 
function of PP is to reduce the release of pancreatic bicarbonate and proteins. PP is 
released under the effect of the autonomic nervous system. In addition, PP leads to 
dilatation of the gallbladder and a reduction of hepatic bile release (Hennig et al., 
2002). PP demonstrates a suppressory effect on pancreatic exocrine release. PP 
increases the secretion of glucocorticoid and changes gastric acid release and 
gastrointestinal movement. The quantity of PP secretion is altered with the condition of 
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digestion. The level of PP secretion is reduced during fasting and is elevated greatly 
after a meal. The secretion of PP is stimulated by the reduced concentration of blood 
glucose. PP can be stimulated by vagal cholinergic reflex because vagotomy and 
treatment with muscarinic receptor antagonists inhibit this action, thus supporting a role 
for the vagal-cholinergic system in PP release. Accordingly, PP may induce vagal 
stimulus to pancreas and many organs in the gut. PP is also involved in modifying 
ingestion mode to control energy equilibrium. PP secretion after a meal leads to 
reduction of food ingestion via decreasing the rate of stomach-emptying (Katsuura et 
al., 2002). 
 
1.8 Diabetes mellitus (DM) 
1.8.1 History of DM 
DM is one of the oldest recognized diseases. The ancient Egyptians described the 
clinical symptoms similar to DM more than 3000 years ago. The word, diabetes was 
first used in 81-133AD. Then, the term mellitus (honey sweet) was firstly discovered by 
ancient Indians. Mellitus was established in 1675 following the detection of sweetness 
in the patient's urine and blood. The evidence of the existence of increased sugar level 
in patient's urine and blood as a source of sweetness was only established in 1776. The 
detection of the pancreas pathogenesis as a cause DM was firstly recognized in 1889 
(Ahmed, 2002). 
 
1.8.2 Epidemiology of DM  
About 6% of the world‟s population are suffering from DM. There is a significant 
increase in the prevalence of DM (Townsend, 2000). The estimated number of diabetic 
people all over the world was about 225 million in the year 2010. This number is 
expected to rise to 350 million in 2030 (Zimmet, 2003; Benera et al., 2009). DM is 
classified mainly into T1DM and T2DM. Globally, 95% of all diabetic patients have 
T2DM while 55 suffers from T1DM (Adeghate, 2001). In the UK, around 3 million 
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people are diabetic and another 1 million are undiagnosed. It costs the UK National 
Health Service around £6 billion annually to diagnose, treat and care for diabetic 
patients. If this figure is extended worldwide then it will cost the world‟s economy 
around £560-£670 billion annually to fund diabetic cases. DM is a multifactorial 
disease, which is caused by several environmental and genetic factors leading to insulin 
dysfunction or decreased secretion. Physical inactivity, obesity, infection, drugs and 
toxic chemicals, are among the most common factors that lead to the development of 
the disease (Giovannucci et al., 2010). 
T1DM is not mainly associated with hereditary. While, hereditary is the most important 
factor that leads to development of T2DM in association with environmental and life 
style factors. Modern inactive life style, environmental pollution and stress increase the 
susceptibility of the related genes and explain the high prevalence of diabetes now 
(Kumar and Clark 2007). There is a different prevalence of T1DM according to the age 
and it infrequently appears during in the first 6 months of birth. The frequency of 
T1DM increase greatly starting after 9 months of age with prolonged increase at age 
12-14 years, and followed by a decrease in its prevalence. The occurrence of T1DM 
over the last 50 years in the United States has increased from about 5% in 1940 to 20% 
in 1980 (Ma and Chan, 2009). Several previous studies on the prevalence of T1DM 
according to the geographical distribution in the world showed that the occurrence rates 
of T1DM are smallest in Japan, the Caribbean, and Southern Europe. However, the 
largest occurrences are in the Scandinavian countries, especially Finland (Adeghate et 
al., 2006). The prevalence of T1DM in the white American population is greater than 
Northern Europe countries, but considerably less than in Sweden and Finland. The 
occurrence of T1DM in African Americans was less than in white Americans (Maahs et 
al., 2010). The prevalence of T1DM throughout the previous 20 years show that T1DM 
arises in the majority of races and ethnicity however, the largest incidence is detected 
among white population (Adeghate et al., 2006). The variations within races could be 
related to genes. The big differences between the white populations are similar to that 
detected between different races. All variations explain the effect of genetic and 
environmental factors in the aetiology of diabetes. Another study demonstrates the role 
of climate in the aetiology of T1DM (Liese et al., 2006). 
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The general incidence of T2DM in population aged 20-74 years in United States was 
6.6% in 1980. Only one-half of these cases are diagnosed as T2DM. The incidence of 
T2DM was to a less extent more in women than in men, excluding the age group 65-74 
years. The incidence of T2DM between black populations was more than between 
white population for both sexes and at all ages (Fagot-Campagna et al., 2005).   
The predominance of T2DM in the European population is moderately less than that 
detected in the American populations. In European populations, the incidence of T2DM 
is slightly below the half of the incidences detected in American populations (Parra et 
al., 2004). The aetiology of T2DM in Saudi Arabia is about the same like that recorded 
in United States populations. However, in Central Asia the incidence of T2DM between 
men of 50 years old and over is about the same detected in European men (Wild et al., 
2004). 
The large variation in the prevalence of DM between white populations, mostly among 
those in Europe and North America, indicates the role of environment in the progress of 
DM. The role of environment is evidenced by the fact that the incidence of T2DM is 
higher in Chinese living out of Asia than the Chinese living inside China. As an 
example for this, there is 21% increased prevalence of T2DM between Chinese livings 
in the island of Mauritius than the recorded rate among native population (Adeghate et 
al., 2006). 
 
1.8.3 Definition and description of diabetes 
DM is a chronic metabolic illness associated with hyperglycaemia (Kumar and Clark 
2007). DM influences the metabolism of carbohydrates, protein, fat, water, and 
electrolytes, causing structural alterations in tissues of numerous organs and systems 
particularly the vascular system (Adeghate et al., 2006). DM leads to disorder in lipid 
metabolism particularly, an elevated vulnerability to lipid peroxidation (Sedhrouchni et 
al., 2002). Symptoms of DM such as weight loss, thirst, polyuria and sweet-smelling 
urine were recorded from very long time starting from the ancient Greek, Roman, and 
Egyptian Physicians (Adeghate et al., 2006; Frank, 1957). 
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According to the American Diabetes Association (ADA, 2010), DM is a mixture of 
metabolic disorders associated with elevated blood glucose levels. This sustained 
hyperglycaemia, if not controlled for many years may lead to long-term complications 
such as nephropathy, neuropathy, retinopathy and cardiovascular disorders (Larsen, 
2009). 
The aetiopathogenesis of DM may include autoimmune damage of pancreatic β-cells or 
impairment in production and release of insulin by other factors, leading to abnormal 
carbohydrate, fat, and protein anabolism and catabolism (Cejkova et al., 2009).  
Symptoms observed in diabetic patients include, polydipsia, polyuria, occasional 
weight loss, and polyphagia.  Poorly controlled DM may lead to severe conditions such 
as ketoacidosis or non-ketotic hyperosmolar crisis (Kumar and Clark 2007). 
 
1.8.4 Classification of DM  
In 2010, the American Diabetes Association (ADA, 2010) described a recent diagnostic 
and classification principles concerning the diagnosis of disturbed fasting plasma 
glucose concentration. The new diagnostic and classification principles may be 
summarized as follows: 
1. T1DM (pancreatic β-cell damage, usually resulting in total insulin deficiency). 
2. T2DM (increased deficiency in insulin secretory capacity associated with 
insulin resistance). 
3. Type 3 diabetes (the relationship between T2DM and Alzheimer‟s disease is 
lately cited as diabetes type 3, T3DM). 
4. Gestational DM (GDM) (a diagnosis of diabetes is detected usually at 
pregnancy). 
5. Other types of DM may be caused by other factors such as genetic abnormalities 
in pancreatic β-cell function, impaired genetic coding of insulin action, cystic 
fibrosis, and toxic drugs and chemicals. 
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1.8.4.1 Type 1 diabetes mellitus (T1DM) 
1.8.4.1.1 Immune-mediated diabetes 
T1DM was formerly referred to as insulin dependent diabetes mellitus (IDDM) or 
juvenile-onset diabetes. It recorded in about 5-10% of all patients suffering from 
diabetes. T1DM is caused mainly via cell-mediated autoimmune damage to pancreatic 
β-cells. This is detected by the presence of immune markers that points to β-cell 
destruction. These immune markers include among others; islet cell autoantibodies, 
insulin autoantibodies, and glutamic acid decarboxylase autoantibodies. More than one 
of these immune markers are found in about 85-90% of individuals with high fasting 
plasma glucose. In addition, T1DM has strong associations with human leukocyte 
antigens (HLA) (Raha et al., 2009). 
Immune-mediated destruction of pancreatic β-cells usually occurs in juvenile and 
children, but it can affect any age group. The likelihood of immune destruction of 
pancreatic β-cells depends on a number of factors that include genetic predispositions 
and environmental factors (Ritchie et al., 2003). 
 
1.8.4.1.2 Idiopathic diabetes 
Some diabetic patients have regular insulin deficiency and are prone to develop 
ketoacidosis, they are classified as idiopathic T1DM because of lack of evidence of 
autoimmunity characterized by T1DM (Russell and Coustan, 2005). 
 
1.8.4.2 Type 2 diabetes mellitus (T2DM) 
Most diabetic patients have T2DM (90-95%), which is due to insulin resistance or 
reduced insulin release. T2DM was formerly called non-insulin dependent diabetes 
(NIDDM) or adult-onset diabetes.   Since this group of patients have insulin, injection 
of insulin is not neede.d for survival.  The precise origin of T2DM is not known but it is 
associated with obesity, which has been shown to be involved in insulin resistance.  
Slim patients with T2DM have also been shown to have large quantity of visceral fat 
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especially in the abdomen.  Body weight reduction and physical activity is an adjunct 
therapy in the treatment of T2DM, in addition to pharmacological treatment. 
Unfortunately, T2DM usually goes undetected for many years until the hyperglycaemia 
becomes chronic to induce diabetes complications (Hossain et al., 2007; Rydén et al., 
2007). 
 
1.8.4.3 Type 3 diabetes mellitus (T3DM) 
Glucose uptake because of brain metabolism demand is disturbed in Alzheimer‟s illness 
(Li and Holscher, 2007). Reduced glucose transporters are concurrent to disturbed 
hyperphosphorylation in Alzheimer‟s illness (Liu, et al., 2008). Consequently, 
destruction of insulin signalling leads to abnormal glucose homeostasis and several 
other deteriorating effects (Li and Holscher, 2007). Recently, a clear relationship 
linking T2DM and Alzheimer‟s illness has been established. Both Alzheimer‟s and 
T2DM have numerous similar molecular procedures, which share a related destructive 
process (Li and Holscher, 2007). Etiopathogenesis of both Alzheimer‟s and T2DM are 
multifactorial diseases and not fully identified. The aetiology of Alzheimer‟s and 
T2DM may be influenced by the co-reaction between the genetic and environmental 
elements (Wiwanitkit, 2008). The genetic role of Alzheimer‟s and T2DM illness is a 
polygenic source. Many epidemiological investigations correlate T2DM with an 
elevated hazard of Alzheimer‟s illness. Several roles may explore the relationship 
between Alzheimer‟s and T2DM such as decreased insulin secretion associated with 
insulin resistance, inflammatory factors, and oxidative toxicity (Haan, 2006). Due to the 
correlation between both of T2DM and Alzheimer‟s, a new categorization of diabetes is 
classified as T3DM (Wiwanitkit, 2008). 
 
1.8.4.4 Gestational diabetes mellitus (GDM) 
Gestational DM occurs when glucose metabolism is impaired at pregnancy. GDM 
causes complications in about 4% of examined pregnancies in the USA. However, this 
prevalence may vary from one region to the other. Impaired glucose homeostasis is 
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usually seen in pregnancy, but more common in the third trimester (Kucuka and 
Doymazb, 2009). 
 
1.8.4.5 Other specific types of diabetes mellitus 
1.8.4.5.1 Genetic defects of the β-cell 
Although several genes cause DM, some forms of diabetes are induced by monogenetic 
impairments in pancreatic β-cell action. These types of DM are usually associated with 
hyperglycaemia at a young age before maturity. They are called maturity onset diabetes 
of the young (MODY). Patients with MODY have impaired insulin release but intact 
insulin function. MODY is inherited as a dominant autosomal disease. There are at least 
defects in six genetic loci on different chromosomes with mutations on chromosome 12 
in a hepatic transcription factor called hepatocyte nuclear factor-1α (HNF-1α). 
Mutations have also been observed in the glucokinase gene on chromosome 7, leading 
to abnormal glucokinase enzyme. Glucokinase is a glucose sensor and responsible for 
the conversion of glucose to glucose-6-phosphate (G-6-P). G-6-P is important in the 
stimulation of insulin secretion from pancreatic β-cell (Manna, 2007). 
 
1.8.4.5.2 Genetic defects in insulin action 
Diabetes can also be caused by a genetically pre-determined abnormality of insulin 
action. This type of defect is associated with mutations of insulin receptor leading to 
conditions ranging from hyperinsulinemia, modest hyperglycaemia to complicated 
diabetes. Patients with insulin receptor mutations may develop acanthosis nigricans, 
virilization (in women) and polycystic ovaries (Mealey and Ocampo, 2007). Since it is 
difficult to characterize the defect in the structure and function of the insulin receptor in 
subjects with insulin resistant lipoatrophic DM, it is presumed that the lesions occur at 
the post-receptor level (Rosen et al., 2000). Hyperinsulinism in infancy (HI) is an 
infrequent disease and it leads to death at newborn and primary childhood. There are 
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several reasons of HI and they are mainly associated with impairment of ATP-sensitive 
K
+
 channel in β-cells. The disturbance may be due to gene mutation of ATP-sensitive 
K
+
 channel structure or its enzymatic cascades, which cause a deficient insulin 
secretion and eventually diabetes (Dunne et al., 2004).  
 
1.8.4.5.3 Drug- or chemical-induced diabetes 
It has been shown that several drugs such as Vacor (rodent poison) and pentamidine 
can destroy the β-cells.  Numerous drugs and hormones, including glucocorticoids and 
interferon-α can lead to diabetes establishment or even cause marked reduction in 
insulin secretion (Manna, 2007).  
 
1.9 Effect of different factors on diabetes. 
1.9.1 Gender differences in T1DM 
A study on individuals between 15-29 years showed an increased rate of T1DM in 
males relative to females. This could be due to different levels of sex hormones or 
discrepancy of environmental factors (Virk et al., 2010). 
 
1.9.2 Seasonal variation and viral infection in T1DM 
Some investigations showed that T1DM reach the uppermost frequencies in the autumn 
and winter relative to other seasons. This could be related to specific viruses, which are 
predominant in winter and autumn compared to other seasons. It may also be due to 
availability of certain kind of foods predominant in winter and autumn or because of 
weather, sunshine period, vitamin D levels or temperature variations that all induce the 
immune-mediated responses which may cause β-cell disturbance and development of 
T1DM (Svensson et al., 2009). 
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1.9.3 Immunological aspects in T1DM 
Many investigations showed that autoimmune progressions are associated with the 
aetiology of T1DM. Autoimmune illnesses, like Addison‟s disease, pernicious anaemia, 
and autoimmune thyroid disease all are implicated in T1DM. About 70% of T1DM 
have islet cell antibodies that are found in the patient‟s blood may be months or years 
prior to the real time of diabetes detection (Chatenoud and Bluestone, 2007). High titre 
of these antibodies reacts with pancreatic islet β-cells. Increased T-lymphocyte 
concentrations with elevation in insulin autoantibodies are also detected in patients of 
T1DM (Zvezdanovic et al., 2006). 
 
1.9.4 Nutritional factors and toxic agents in T1DM 
Food given throughout the neonatal and primary infancy stage, like the drinking of 
cow‟s milk containing certain protein with decreased breast-feeding in babyhood 
period, could elevate the vulnerability for T1DM. During childhood, an increased 
ingestion of nitrites and N-nitroso agents may lead to high risk of T1DM (Knip et al., 
2005). 
 
1.9.5 Gender differences in T2DM 
Many studies have indicated that the incidence of T2DM is detected in females in 
higher levels than in males especially in China (Liu et al., 2010). On the contrary, men 
are more susceptible to T2DM compared to women in India (Kaur et al., 2010a). 
 
1.9.6 Physical inactivity in T2DM 
Steady physical activity enhances insulin sensitivity and glucose balance (Kriska et al., 
2001). There are many studies, which showed that physical activities can help either to 
avoid or even to suppress the development of T2DM in subjects with impaired glucose 
tolerance. At the same time, lifestyle improvement, through diet and physical exercise, 
may lead to a reduction of about 50% in diabetes incidence. Furthermore, physical 
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training improves blood glucose tolerance in T2DM that is associated with a reduction 
of about 0.6% of glycosylated haemoglobin (HbA1c). Therefore, as a part of T2DM 
treatment, physical activity programme should be added to any therapeutic strategy to 
improve glucose tolerance and to reduce the development of diabetic complications 
(Sanz et al., 2010). 
 
1.9.7 Body weight, nutrition and obesity in T2DM 
Many recent studies have suggested a direct relationship between obesity and T2DM. 
At the same time, increased percentage of body fat showed an important association 
with T2DM. Body mass index is tightly concerned with elevated risk of T2DM. The 
intra-visceral fat mass is much more significant in predicting DM than subcutaneous fat 
(Huffman and Barzilai, 2009; Kaur et al., 2010). Ingestion of energy rich food, high 
monosaccharides and abundant with saturated fats and poor in compound carbohydrates 
and fibres could be associated with the progression of obesity and T2DM (Misra et al., 
2010). 
 
1.9.8 Severe and prolonged stress in T2DM 
Modern life style is associated with severe and sustained stress. This is also 
accompanied with disturbance of blood glucose balance and may enhance the risk of 
T2DM (Hummasti and Hotamisligil, 2010). The progress of diabetes under continuous 
stress can lead to increased secretion of either adrenaline or glucocorticoid hormones 
causing glucose disturbance (Adeghate, et al., 2006). 
 
1.9.9 Drugs and abnormal insulin secretion in T2DM 
Drugs such as corticosteroids and some contraceptive steroid pills could lead to blood 
glucose imbalance and T2DM in vulnerable persons (Livingstone and Collison, 2002). 
Mainly, in T2DM there is a decreased insulin release comparative to the blood glucose 
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concentrations. This is associated with massive β-cells destruction under the effect of 
drugs abuse (Gavin et al, 2010). 
 
1.10 Diabetes and molecular genetics 
DM is a type of disease that may be developed due to various causes, genetic and 
environmental, including physical inactivities, obesity, infection, drugs and toxic 
chemicals. T1DM is not necessarily a genetic disease while, the chances of having it 
can be inherited. However, T2DM is mainly genetically induced and at the same time, 
it may be induced by different environmental factors. It is clear that interaction between 
both the susceptible genes and the environmental factors have a critical role for the 
aetiology of DM (Adeghate et al., 2006). The exact role of genetic factors in the 
aetiology of DM is not fully established and it is multifactorial. There is a tight role of 
environmental factors and the age of onset of diabetes for the expression of the diabetic 
genotype (Al-Mutairi et al., 2007). 
Genes related to T1DM are strongly associated with disturbance in immune system. 
However, T2DM demonstrates powerful genetic effects with much contribution to 
heredity. T2DM patients demonstrate at least one-gene defect (Fajans, et al., 2001). 
These defects include two wide classes. The first class is the genes that control the 
pancreatic β-cells and their insulin secretion. These comprise glucokinase and 
hepatocyte nuclear factor-1α (HNF-1α) genes. The second class of genes, which 
manage the influence of insulin on its specific target cells, such as peroxisome 
proliferator-activated receptor- (PPAR-) and adiponectin genes (Romao and Roth, 
2008). 
 
1.10.1 Molecular genetics of T1DM 
In T1DM, the genetic vulnerability may be inherited. For example, about 30-50% 
similar susceptibility for T1DM are detected in case of identical twins (Al-Mutairi et 
al., 2007). T1DM is a multi-factorial illness induced by autoimmune damage of the β-
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cells of the pancreas, resulting in reduced synthesis of insulin (Devendra, et al., 2004). 
The damage to β-cells is triggered via infiltration of the islets of Langerhans with 
dendritic cells (DCs), macrophages and T lymphocytes (either CD4
+
 or CD8
+
). This 
damage affects only insulin-producing β-cells, but not glucagon (α) or somatostatin (δ) 
cells. T1DM is involved mainly young children in the first one and a half decades of 
their life. The detection of the disease is made mainly prior to 18 years old. The 
autoimmune disorder begins before the actual diagnosis of the disease, as indicated via 
the early discovery of autoantibodies against T1DM-specific antigens in patient serum 
(Miao et al., 2007). The three chief concerned autoantigens are insulin, glutamic acid 
decarboxylase-65 and insulin autoantigen-2. The detection of these autoantibodies is an 
indicator of β-cells damage that is mediated by T-lymphocyte. Each of CD4+ (helper) 
and CD8
+
 (cytotoxic) T-lymphocytes are vital in the progression of T1DM. The first 
step in the destruction of β-cell starts with the detection of extracellular antigens, which 
induce cytokine discharge and inflammation, while the next step is the reaction of 
inflammatory products with intracellular antigens resulting in β-cell death (Ounissi-
Benkalha and Polychronakos, 2008). At the clinical diagnosis time of T1DM, the 
majority of the β-cell insulin-release capability is completely abolished. More 
information of the genetic basis of T1DM, may significantly assist in the treatment of 
the disease (Ounissi-Benkalha and Polychronakos, 2008). 
T1DM is associated with many genes and it is linked to the human leukocyte antigens 
(HLA) gene on chromosome 6 (Devendra and Eisenbarth, 2003), which is responsible 
for around 50% of the familial clustering of T1DM via enormous changes affecting the 
normal haplotype function. Many other vital loci related to T1DM with less influence 
than HLA, include insulin gene on chromosome 11 (Undlien et al., 1995), PTPN22 on 
chromosome 1 (Ladner et al., 2005), CTLA4 on chromosome 2 (Ueda, 2003), the 
interleukin-2 receptor α (CD25, encoded by IL-2R α) locus on chromosome 10 (Lowe 
et al., 2007), IFIH1 (also known as MDA5) on chromosome 2, PTPN2 on chromosome 
1, CYP27B1 on chromosome 12 (Todd et al., 2007), and CLEC16A (KIAA0350) on 
chromosome 16 (Hakonarson et al., 2007). 
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1.10.2 Molecular genetics of T2DM 
T2DM has a significance environmental impact such as diet and lifestyles that can 
seriously be involved in the pathogenesis (or course) of the illness. Body mass index 
(BMI) of more than 30 kg/m
2
 will be defined as obesity, which leads to amplifying the 
risk factors for T2DM. Besides, there is a strong genetic involvement, which raises the 
risk of disease progress to four folds in the affected individuals. Therefore, T2DM is 
considered as a classic, polygenic, multi-factorial illness (Frayling, 2007). 
The discovery of genetic elements, which influence T2DM are important target goals to 
explore the exact relationship between T2DM and heredity (Neel, 1976). Lately, the 
investigations in several studies for genes susceptible for T2DM have established about 
52 genes with promising proofs to cause T2DM (Kaput et al., 2007). These 
investigations have detected common variants in only three specific gene loci out of 
these promising genes with greater risk of T2DM. The three variants include the 
potassium rectifying channel J 11 (KCNJ11) of β-cells, peroxisome proliferator-
activated receptor-gamma (PPAR-) and the transcription factor 2 (TCF7L2) of liver 
cells. Uncommon, but dangerous mutations in any one of these three genes may lead to 
monogenic types of T2DM (Owen and McCarthy, 2007). In addition, another 
investigation reported different variant in Zn transporter gene (SLC30A8) of β-cells. 
Furthermore, two other single nucleotide polymorphisms (SNPs) that could be of high 
risk for T2DM include insulin-degrading enzyme (IDE) and homeobox 
hematopoietically (HHEX) (Sladek et al., 2007). 
Numerous additional genes revealed a strong relationship with T2DM. Some examples 
of these genes include insulin gene polymorphism on chromosome 11, glucose 
transporter genes on chromosomes 1 and 12, human leukocyte antigens (HLA) gene on 
chromosome 6, lipoprotein gene on chromosome 6, apo-lipoprotein genes on 
chromosomes 2 and 11, haptoglobulin gene on chromosome 16, and insulin receptor 
gene on chromosome 19 (Barroso et al., 2003). 
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1.11 Diabetes and insulin resistance 
The causes of insulin resistance in T2DM and the related metabolic disorder are not 
totally known. The stress that people have on a daily basis may lead to the 
accumulation of stress factors during the course of many years. These stress elements, 
can enforce the body of the affected person to compensate by activating different 
neuro-hormonal axes. The autonomic nerves, hypothalamic-pituitary-adrenal and renin-
angiotensin pathways are collectively implicated in impaired nutrient metabolism and 
insulin function. Previous studies have revealed the possible recent mechanisms, 
pharmacological drugs and bioindicators, implicated in neurendocrine dysfunctions 
leading to insulin resistance. This has enabled scientists to understand the complicated 
and multi-factorial causes of insulin resistance (Sjostrand and Eriksson, 2009). 
 
1.11.1 Factors which can induce insulin resistance 
Insulin resistance correlates with obesity, T2DM, high blood pressure, inflammation, 
certain endocrine disturbance and polycystic ovarian disease (Reaven, 2004). In insulin 
resistance, there is a deficiency of target cell response to the regular hormonal level. 
Insulin resistance is mainly associated with glucose intolerance due to diminished 
action of insulin at glucose levels (Pessin and Saltiel, 2000). Pancreatic β-cells increase 
insulin secretion in case of decreased insulin sensitivity to overcome its reduced action. 
As a result of insulin resistance, abnormal elevation of insulin secretion will lead to 
hyper-stimulatory action of insulin on its various target cells and tissues in different 
degrees due to the distinctive action of insulin in each tissue. At the same time, the 
interaction between insulin and different hormones including epinephrine, leptin and 
growth hormone may change the ultimate effect of insulin (Muller, 2002). Elevated 
concentrations of non-esterified fatty acids are mainly associated with severe insulin 
resistance and disturbed glucose release in skeletal muscle. Saturated fatty acids 
(palmitate) and mono-unsaturated fatty acids (palmitoleate) play distinctive roles in 
insulin signalling and glucose entrance into skeletal muscle cells. High food content of 
mono-unsaturated fatty acids can enhance the influx and metabolism of glucose in 
44 
 
skeletal muscle cells under either normal or insulin resistant condition (Dimopoulos et 
al., 2006). 
Glucotoxicity has prolonged influences on both insulin secretion and the initiation of 
insulin resistance within insulin-sensitive target tissues. Insulin resistance is essentially 
established before the detection of sustained elevated blood glucose levels (Kawahito et 
al., 2009). Moreover, prolonged blood glucose levels might contribute to the 
deterioration of the diabetic condition through intensifying insulin resistance (Zhao et 
al., 2004). 
Liver: The liver is considered as one of the essential storage organs of glucose in the 
human body. Thus, the liver is an essential organ in controlling glucose balance, as 
liver uptakes glucose at hyperglycaemia and discharges glucose during hypoglycaemia 
(Brunner et al., 2009). It was reported that treatment of Zucker diabetic fatty rats with 
hypoglycaemic agent can markedly reduce insulin resistance in the rat liver (Fujimoto 
et al., 2006). In addition, other studies revealed that sustained elevated blood glucose 
levels can disturb the inhibition of glucose release from the liver during acute 
hyperglycaemia (Shao et al., 2005). 
Skeletal muscle: Skeletal muscle is an additional tissue capable for the storage of 
glucose as a glycogen. One of the main features of T2DM is the insulin resistance of 
skeletal muscle (Pratipanawatr et al., 2002). Long persistence increased blood glucose 
level in rodents can lead to insulin resistance in skeletal muscle (Kawanaka et al., 
2001). These previous reports were verified via isolated muscles (Itani et al., 2003). 
Unexpectedly, drug treatment for restoring the normal blood glucose level in Zucker 
diabetic fatty rats did not achieve an improvement of insulin resistance in skeletal 
muscle. Some studies have shown that normoglycaemia does not improve insulin 
resistance in skeletal muscle. This indicates that elevated blood glucose level is not the 
single cause of insulin resistance in skeletal muscle (Nawano et al. 2000). 
Adipose tissue: The adipose tissue is also implicated in blood glucose regulation but 
come after liver and skeletal muscle. Adipose tissue has the ability to store glucose in 
the form of triglyceride as an essential supply of energy for different body tissues 
(Rosen and Spiegelman, 2006). Severe hyperglycaemia stimulates adipose tissue to 
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release many substances like leptin and cytokines (Walker et al., 2007). Insulin 
resistance in adipose tissue may become worse under a prolonged hyperglycemia. 
Similar to skeletal muscle, insulin resistance may occur via the destruction of IRS-1 
and GLUT-4 signalling systems (Renstrom et al., 2007). 
 
1.12 Complications of DM 
DM is a chronic endocrine illness coupled with series of micro-and macrovascular 
complications. It influences the metabolic activities of carbohydrates, fat, protein, 
minerals and electrolytes, that leads to alterations in the construction of the blood 
vessels (Kumar, and Clark, 2007; Adeghate, 2001). Increased blood glucose level is the 
corner stone in diabetic patients that deteriorates most of the body organs, tissues, and 
various cells, like retinal capillary endothelial cells, renal glomerular mesangial cells, 
neuronal cells and Schwann cells in peripheral nerves. These cells are the most 
susceptible cells and they reveal many pathological illnesses under the effects of 
increased blood glucose levels (D‟Souza et al., 2009). 
Hyperglycaemia provokes oxidative toxicity and reduces antioxidant protective system, 
causes elevated free radical synthesis (D‟Souza et al., 2009). Deficient insulin 
sensitivity can lead to oxidative toxicity in diabetic patient and there is a marked 
confirmation in a reduction of antioxidant protective mechanism and in a deficiency of 
antioxidant action in diabetes. This condition has a considerable influence in the 
inhibition of insulin gene expression and insulin release (Kajimoto and Kaneto, 2004). 
 
1.13 Management and treatment of DM 
Recently, T2DM treatments begin with food control, adjustment of body weight, 
increase of physical activities, oral drugs supplementation and finally insulin injection 
(Bailes, 2002). Only food limitation and increased physical activity program could be 
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sufficient to avoid or to treat T2DM. Inductions of physical activities lead to 
enhancement of blood glucose uptake by specific tissues and reduction of blood 
glucose concentration. However, if physical exercise, as mono-therapy does not achieve 
the target of normoglycaemia, then it must be accompanied with food modification and 
drug treatments (Sato, 2000). Nevertheless, food control is considered as the essential 
primary treatment of T2DM. Diet treatment has a vital tool in avoiding DM and it also 
plays a significant effect in DM treatment. Food management must be consisting of an 
adequate mixture of carbohydrates, proteins, lipid, minerals and vegetables (Hagura, 
2000). 
Individuals suffering from T1DM are insulin dependent. Insulin are normally injected 
subcutaneously as essential therapy for T1DM (Griffen et al., 2006). Insulin is 
manufactured in different forms, like fast affecting insulin, which is vastly absorbed. 
The structural difference between normal human insulin and the synthetic form of 
insulin is the conversion or replacement of few amino acids to slow down its absorption 
or to extend its action. Rapid insulin has to be given at eating period. While, short 
effecting insulin is exerting its effect within one hour after subcutaneous injection. 
While long acting insulin may act for more than twelve hours (Dawn, et al., 2003). 
T2DM treatment depends mostly on different hypoglycaemic drugs (Moller, 2001). 
There are about five categorizes of available drugs. Sulfonylureas show their 
hypoglycaemic effect through enhancing insulin release from pancreatic β-cell. The 
mechanism of action of sulfonylureas is via its binding with ATP-sensitive potassium 
channels and thus preventing the release of potassium from the cell leading to influx of 
calcium via the voltage-dependent calcium channels. The elevated cytoplasmic calcium 
levels lead to the secretion of insulin. Meglitinide is a non-sulfonylureas drug that is 
linked to different β-cell receptors promoting a similar action to sulfonylureas in 
enhancing insulin secretion (Ganesh et al., 2010). 
Metformin is one of the biguanides anti-diabetic drug categories and it exerts its effect 
by inhibiting glucose release from the liver via suppressing gluconeogenesis and 
glycolysis. Metformin does not lead to a condition of hypoglycaemia since it has no 
effect on insulin release (Ganesh et al., 2010). Thiazolidine increases glucose entrance 
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into different tissues including skeletal muscle (Oiknine, and Mooradian, 2003). A last 
class of anti-diabetic drugs is the α-glycosidase inhibitors like miglitol and acarbose. 
Their effect is mainly through postponing carbohydrate absorption in the epithelial cells 
in the lining wall of the small intestine (Braunstein, 2003). 
 
1.14 Incretins 
The idea that secretions of the gastrointestinal tract contribute to the control of 
endocrine release was established in the 20
th
 century (Moore, 1996). The definition 
“secretin” was initially employed to denote elements that take part in regulating 
pancreatic secretion. The functional relationship between the gut and the endocrine part 
of the pancreas was noted in the mid-1960s, when it was possible to measure insulin in 
plasma. Investigators noted that the response to insulin secretion was higher when 
glucose was supplemented orally (D‟Alessio et al., 2005). 
Incretins include gastrointestinal hormones known as glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP)-1 (Drucker, 2003). Incretins may 
elevate the plasma insulin after eating via different ways defined in general as the 
incretin action. This increased insulin release is detected following oral, as compared to 
intravenous, glucose supplementation and can induce about 80% of related insulin 
release according to the dose of glucose ingested (Vetter et al., 2009). 
In healthy person, the incretin action retains the normal glucose concentrations after 
carbohydrate ingestion whatever the amount of glucose ingested, as incretins can 
increase insulin release from the β-cells of the pancreas in a dose dependent way. 
Patients with T2DM are suffering from blunting or even complete loss of the incretin 
action (Svec, 2010). Table 1.2 compares the differences between GIP and GLP-1 
incretin hormones in relation to their properties and biological effects. 
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Table 1.2: Different properties and biological actions between GIP and GLP-1. DPP-
IV, dipeptidyl peptidase-IV; GIP, glucose-dependent insulinotropic polypeptide; GLP-
1, glucagon-like peptide-1 (Modified from Holst, 2008). 
 
GIP GLP-1 
42 amino acid peptide  30/31 amino acid peptide 
Released from duodenum and jejunum 
by K-cells  
Released from jejunum and ileum by L-
cells 
NH2-terminal inactivation by DPP-IV  NH2-terminal inactivation by DPP-IV 
Potentiates glucose-induced insulin 
secretion  
Potentiates glucose-induced insulin 
secretion 
Minimal effect on gastric emptying  Inhibits gastric emptying 
No effect on glucagon secretion  Inhibits glucagon secretion 
No regulation of satiety and body weight  Inhibits food intake and weight gain 
Promotes expansion of  β-cell mass Promotes expansion of  β-cell mass 
Normal GIP release in diabetic patients 
Reduced GLP-1 release in diabetic 
patients 
Defective insulinotropic effect in T2DM  Preserved insulinotropic effect in T2DM 
 
1.14.1 Incretins synthesis and metabolism 
GIP consists of 42 amino acids while GLP-1 consists of 30/31 amino acids. Both GLP-
1 and GIP are parts of the glucagon peptide family. They are produced as a result of 
proglucagon gene expression, which produces GLP-1, GLP-2, glucagon and other 
proglucagon-derived peptides. According to the site of proglucagon gene, it is found in 
either pancreatic or intestinal cells, the differential posttranslational processing will 
produce various types of peptides according to the precursor cells as shown in figure 
1.11 (Baggio and Drucker, 2007).  
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Figure 1.11: Differential posttranslational processing of proglucagon in the pancreas, 
intestine and brain (Modified from Holst, 2007). 
 
The proglucagon gene is expressed in the pancreatic α-cells, the L-cell of the jejunum 
and ileal portions of small intestine and in a some of neurones of the brain stem (Holst, 
2007). GLP-1 is synthesized as two peptides: GLP-1 (7-36) amide and GLP-1 (7-37) 
(see Figure 1.11) (Mortensen et al., 2003). GLP-1 and GIP may be inactivated via 
splitting at the second terminal amino acid, alanine, by their inhibitory enzyme DPP-IV 
(Deacon, et al., 2000). The plasma levels of GIP and GLP-1 are reduced rapidly by 
DPP-IV (Deacon, 2005), and by kidney elimination. The plasma half-lives of GIP and 
GLP-1 are 6 and 2 minutes, respectively (Girard, 2008). 
 
1.14.2 Incretins release is affected by a number of factors 
The secretion of both GLP-1 and GIP is stimulated by food ingestion, hormonal and 
neural factors which raise their levels quickly following food intake. Remarkable 
increases in their plasma levels are prominent after about 10-15 minutes. The secretion 
of either GLP-1 or GIP is stimulated after food intake by either carbohydrates, fats or 
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proteins (Shrayyef and Gerich, 2010). Direct contact between food and the intestinal 
mucosal cells can evoke the secretion of these incretins leading to fast increase in the 
plasma insulin levels (Deacon, 2005).  Before the nutrients reach the L-cells to 
stimulate incretins release, the neural control leads to a more rapid stimulation of 
incretin release. Stimulation of cholinergic muscarinic, β-adrenergic and peptidergic 
receptors found on L-cells can enhance GLP-1 secretion (Anini and Brubaker, 2003). 
Many investigators have reported that gastrin-releasing peptide (GRP) and 
acetylcholine play an important physiological role in the initiation of GLP-1 secretion 
(Lim, and Brubaker, 2006). Laboratory studies have demonstrated that after food 
intake, GIP is released by K-cells and leads to stimulation of afferent nerves of the 
vagus, resulting in GLP-1 release through vagal efferent and gut neurones (Girard, 
2008). An increased level of GIP has an activating influence on GLP-1 secretion from 
L-cells (Hansen, and Holst, 2002). Somatostatin, released from adjacent δ-cells in the 
intestine, has a reducing effect on incretin secretion (Deacon, 2005), and somatostatin 
antagonist leads to a great increase in GLP-1 release (Hansen, et al., 2000).  
 
1.14.3 Physiological actions of incretins 
Incretins reveal their physiological actions through the stimulation of their specific G-
protein-coupled receptors (GPCRs). The G-protein receptors are expressed in 
pancreatic β- and α-cells beside numerous other tissues and organs such as intestine, 
adipose tissue, brain, nervous system, kidneys, heart and lungs. These wide distribution 
of incretins-receptors demonstrate that the physiological actions of incretins are much 
more than insulin release (Wideman and Kieffer, 2004; Girard, 2008). 
GPCRs are seven-transmembrane domain receptors (TM1-TM7) with extracellular N-
terminal domain and intracellular C-terminal domain (see Figure 1.12). "G-protein" 
represents a membrane-associated heterotrimeric G-proteins. These proteins are 
triggered via GPCRs and are formed from three subunits α, β and γ (Hurowitz et al., 
2000). Several ligands can bind to GPCRs and activate membrane, cytoplasmic and 
nuclear targets. GPCRs cooperate with heterotrimeric G-proteins in conjunction with α, 
β and γ subunits that are guanosine diphosphate (GDP) coupled in the inactive form. 
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Ligand coupling initiates a conformational change in the receptor, which activates the 
separation of GDP from α subunit, then guanosine triphosphate-binding (GTP-binding) 
to Gα and the separation of Gβγ from Gα subunits (Pierce et al., 2002). GPCR ligand 
may bind to one of four subfamilies of G-proteins α subunits; Gαs, Gαi, Gαq or Gα12 as 
seen in figure 1.12. Every G-protein binding may stimulate or inhibit numerous 
downstream cascades. Gαs activates protein kinase A (PKA) and stimulates adenylate 
cyclase (AC) which in turn changes adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP) and increases the concentrations of cAMP (Hall, 2000). 
While, Gαi supresses AC and depresses cAMP concentrations. Gαi also can activate 
phosphatases and phosphodiesterases (Billington and Penn, 2003). However, members 
of the Gαq family couple to and stimulate protein kinase A (PKA) and phospholipase C-
δ (PLC-δ). In turn, PLC-δ splits phosphatidylinositol bisphosphate (PIP2) to 
diacylglycerol (DAG) and inositol triphosphate (IP3) which elevate Ca
2+
 release (Rhee, 
2001). The Gα12 subfamily can regulate the action of GTP-binding proteins to a 
monomeric GTP binding protein family (Rho), which is a subfamily of the Ras 
superfamily and Rho is involved in cell proliferation, gene expression and apoptosis 
(Kozasa et al., 2011). The Gβ and Gγ subunits act as a dimer to stimulate several 
signalling molecules, such as, phosphinositol-3 kinase (PI-3K), phospholipases (PLs), 
ion channels and AC (Mills and Moolenaar, 2003; Marinissen and Gutkind, 2001). 
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Figure 1.12: Schematic diagram of the G proteins couple to G-protein-coupled receptor 
showing different downstream cascades regulating many cellular processes. 
Abbreviations: guanosine diphosphate (GDP); guanosine triphosphate (GTP); protein 
kinase A (PKA); protein kinase C-δ (PKC-δ); a monomeric GTP binding protein (Rho 
GTPase); diacylglycerol (DAG); inositol triphosphate (IP3); cyclic adenosine 
monophosphate (cAMP); phosphinositol-3 Kinase (PI-3K)  (Modified  from Dorsam 
and Gutkind 2007).  
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1.14.4 Effects of GLP-1 on insulin biosynthesis 
GLP-1 can activate insulin gene transcription and other steps in the translation of 
insulin and eventually insulin release. These actions are essential in the regulation of 
optimum level of insulin throughout production-secretion phases (Holst, 2006). 
 
1.14.5 Inhibitory effects of GLP-1 on glucagon secretion 
In addition to the ability of GLP-1 to stimulate insulin release, it is capable of 
suppressing glucagon release from the pancreatic α-cells. The exact way by which 
GLP-1 leads to suppression in glucagon release is not completely clear. However, there 
are the hypotheses, which suggest that this inhibition may be introduced indirectly 
through the secretion of insulin and somatostatin into the blood circulation, although a 
direct action of GLP-1 cannot be ruled out because of the presence of GLP-1 receptors 
on the glucagon-producing α-cells (Holst, 2006). 
The ability of GLP-1 to inhibit glucagon release is a key component in the regulation of 
blood glucose. For example, in patients with T1DM, GLP-1 reduces the plasma glucose 
level with associated inhibition of the action of glucagon probably via the suppression 
of glucagon-induced hepatic glucose release via reduction of either glycogenolysis or 
gluconeogenesis (Nauck et al., 2002). 
 
1.14.6 Effects of GLP-1 on the gastrointestinal tract 
GLP-1 has been shown to inhibit gut motility and secretion (Gautier et al., 2008). GLP-
1 is also capable of slowing the rate of gastric emptying and therefore reducing the 
degree at which glucose is absorbed. This in turn results in a reduction in postprandial 
blood glucose level. The ability of GLP-1 to inhibit gut motility and secretion may be 
mediated via autonomic nerves including the vago-vagal circuit (Bucinskaite et al., 
2009). This effect of GLP-1 on gastrointestinal tract motility and secretion may be 
designed to modulate the absorptive capability of the gut though inhibition of enzymes 
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production and slowing down the movement of the chyme. All of these effects can help 
in the reduction of postprandial glucose levels (Meier and Nauck, 2005). 
 
1.14.7 Effects of GLP-1 on food intake 
GLP-1 is capable of decreasing caloric intake and stimulating satiety under the control 
of central nervous system. Laboratory investigations show that intracerebroventricular 
injection (administration) of GLP-1 inhibited ingestion. This effect was abolished with 
exenatide treatment (Stanley et al., 2005). Other studies in Rhesus monkeys, db/db 
mice and Zucker diabetic fatty rats showed a significant reduction in food ingestion 
following the supplementation of GLP-1 analogues (Meier et al., 2002). 
The way by which GLP-1 suppresses food ingestion is still unclear. However, it is 
possible that GLP-1 stimulates vagal afferent fibres, which in turn regulate neuronal 
GLP-1 transmission in the central nervous system. This assumption is strengthened by 
the presence of GLP-1 in the neurones of hypothalamic region, which is involved in the 
regulation of food ingestion (Schick et al., 2003). Moreover, GLP-1 may also act via 
the area postrema and subfornical organ on the brain nuclei, which are implicated in 
food homeostasis (Baumgartner et al., 2010).  
In addition, the ability of GLP-1 to reduce food intake may be attributed to the fact that 
GLP-1 can inhibit gastric emptying. Inhibition of gastric emptying may induce the 
feeling of fullness resulting in lowering the interest for food intake (Meier et al., 2002). 
  
1.15 Therapeutic potential of incretins in the treatment 
of DM 
In healthy individuals, there is a dynamic balance between β-cell mass and body needs 
for insulin release in different body activities and under normal or pathological 
conditions. However, disturbance of this equilibrium due to insulin deficiency and/or 
insulin resistance can lead to DM. In diabetic patient, β-cell dysfunction may cause a 
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decrease in insulin release, which correlated clearly with deficiency in glucose demand 
for insulin and this contributes to glucose intolerance (Zimmet and Alberti 2006). There 
is a vital need for a new treatment of DM. This treatment is not only for preserving the 
function of the remaining β-cell but also, to induce β-cell neogenesis and to decrease β-
cell apoptosis. Using incretins could be an ideal approach to meet this target. Treatment 
of diabetic patients with incretins may improve β-cell proliferation and inhibit β-cell 
apoptosis, which may lead to enhancing insulin release and to increase the active β-cell 
mass. In this way, incretins can open a new era for advanced progress in establishing 
new drugs to meet this challenge in the next decades for treatment of T2DM. In 
addition, this can be a significant contribution to the traditional arsenal of anti-diabetic 
drugs (Karaca et al., 2009). 
Both GIP and GLP-1 are quickly destroyed by the enzyme, dipeptidyl peptidase-IV 
(DPP-IV) (Baggio and Drucker, 2007). DPP-IV breaks down the functional incretin at 
the second amino acid alanine (N-terminal) causing inactivation of the incretin (see 
Figure 1.13), (Gautier et al., 2008). DPP-IV is extensively found in different body 
tissues such as the pancreas, gut, brain, spleen, kidneys, lungs, placenta, white blood 
cells (lymphocytes), endothelial cells and adrenal glands (Gautier et al., 2008). Most of 
GLP-1 is inhibited rapidly after its release. The half-life of GLP-1 is about 2 minutes 
(Gautier et al., 2008). This reduced half-life restricts the treatment effect of GLP-1. 
Changes of the amino acids at the N-terminus of GLP-1 will increase its functional 
half-life because the new structure will be resistant to DPP-IV. In this way, the newly 
modified GLP-1 structure will significantly enhance its receptor stimulation and 
prolong its biological efficacy (Green and Flatt, 2007). 
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Figure 1.13: Structures of GLP-1 (7-36) amide, GLP-1 (7-37), exenatide, liraglutide, 
and DPP-IV inhibitor (Modified from Nauck, 2009). 
GLP-1 (7-37): 
Gly
His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Gln Met Glu Glu Glu Glu Ala
ArgLeuPheIle
Val
TrpLeuLys GluGly AsnGly
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1.15.1 Incretins-based therapy: potential use of incretin 
mimetics  
1.15.1.1 Exenatide 
Exenatide is an artificial form of the natural exendin-4 peptide (Figure 1.13). Exenatide 
was firstly extracted from the salivary juice of the lizard, gila monster (Heloderma 
suspectum) (Baggio and Drucker, 2007). The structural similarity between exenatide 
and GLP-1 is about 53% similarity of amino acid chain. Exenatide functions as an 
incretin mimetic compound via binding and stimulating the GLP-1 receptor. Exenatide 
structure has a glycine amino acid at the second location of its polypeptide chain 
instead of alanine in natural GLP-1. Therefore, it is resistant to DPP-IV inhibition and 
has a prolonged active half-life more than GLP-1 (Barnett, 2007). 
Exenatide retains pancreatic β-cell mass and activities via enhancing the expression of 
the essential β-cell genes which help in increasing β-cells propagation and neogenesis. 
Exenatide also inhibits apoptosis of β-cells (Gedulin et al., 2005). Exenatide has strong 
effects on β-cell sensitivity to glucose, which enhances insulin secretion mostly under 
increased level of glucose. Insulin release is decreased in response to reduced plasma 
glucose concentrations (Barnett, 2007). 
 
1.15.1.2 Liraglutide 
Liraglutide is a fatty acid derived GLP-1 agonist. It is formed from 16-carbon free fatty 
acid molecule linked to the amino acid lysine at position 26 as shown in figure 1.13. 
This binding covers the splitting site of liraglutide and thereby protected from DPP-IV 
action (Green and Flatt, 2007). Liraglutide reduces fasting and after-meal blood glucose 
levels in T2DM patients (Degn et al., 2004). Liraglutide therapy leads to prolongation 
of stomach evacuation time (Juhl et al., 2002) and has a glucose-dependant 
enhancement effect on insulin secretion by β-cells. Liraglutide elevates β-cell count and 
reduces apoptosis (Wajchenberg, 2007). At postprandial, liraglutide decreases glucagon 
secretion in a glucose-dependent way (Juhl et al., 2002). 
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1.15.1.3 Other incretin mimetics 
Prolonged acting exenatide LAR is supplemented as one dose weekly currently 
presenting hopeful trial results (Drucker et al., 2008). Exenatide LAR reduces 
glycosylated haemoglobin (HbA1c), fasting blood glucose and body weight (Kim et al., 
2007).  
Taspoglutide is a GLP-1 mimetic drug given as a single dose per week, which 
decreases the HbA1c and reduces body weight (Nauck et al., 2009).  
Albiglutide is an albumin-linked peptide drug of GLP-1 similar action (Tomkin, 2009). 
It has a 7 days prolonged effective period (Bush et al., 2009). The action of albiglutide 
can lead to a decrease in the average fasting and postprandial blood glucose 
concentrations per day with minimal hazard of hypoglycaemia (Matthews et al., 2008). 
Albiglutide also enhances GLP-1 receptor-dependent, which is accompanied with blood 
glucose normalization and suppression of gut movement. In addition, it increases 
insulin release and decreases plasma glucose concentration (Baggio et al., 2004). 
 
1.15.2 DPP-IV and DPP-IV inhibitors therapy 
DPP-IV enzyme is formed from 766 amino acid. It is a serine-type protease enzyme, 
which inhibits GLP-1 action (Lambeir et al., 2003). DPP-IV antagonists exert their 
action in reduction of blood glucose levels in T2DM via prolongation of incretin 
activity (Flatt et al., 2008). 
The effective oral DPP-IV antagonists inactivate more than 90% of blood DPP-IV 
action for more than a day in vivo study (Pratley and Gilbert, 2008). These drugs 
enhance incretin action through inhibiting its fast degradation. Therefore, DPP-IV 
antagonists can be used to treat T2DM patients (Pratley, 2008). 
DPP-IV suppression leads to improving glucose tolerance by multiple effects. The main 
action is to enhance pancreatic islet-cells activities. DPP-IV suppression is conducted 
through the subsequent steps: (1) elevation of fasting and after meal GLP-1 
concentrations, (2) reduction of fasting and after meal blood glucose levels, (3) 
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enhancement of β- and α-cells activities in T2DM, (4) elevation of β-cells occupation 
area, as confirmed in rodent's studies and (5) improvement of insulin efficiency (Ahren, 
2009). 
Numerous drugs of DPP-IV suppression are available for use nowadays (Ahren, 2007), 
including sitagliptin, vildagliptin, alogliptin and saxagliptin (Karasik et al., 2008). 
These drugs are administered orally and are absorbed quickly via the gastrointestinal 
tract to exert their actions (Bergman et. al., 2007). 
 
1.15.2.1 Sitagliptin 
Sitagliptin is a powerful reversible competitive suppressor of DPP-IV and it is orally 
administered (see Figure 1.14), (Lotfy et al., 2011). In a previous study, STZ-induced 
diabetic rats under fat-enriched food were treated by sitagliptin and the results showed 
an elevation of the β-cells area and correction of β- to α-cells ratio. Sitagliptin also 
normalizes the levels of fasting and after meal blood glucose, HbA1c, blood 
triglycerides and free fatty acids (Mu et al., 2006). Administration of sitagliptin to 
T2DM patients once a day revealed marked reduction of DPP-IV action, improvement 
of glucose tolerance, elevation in insulin levels and reduction in glucagon secretion 
(Herman et al., 2006). 
 
1.15.2.2 Vildagliptin  
Vildagliptin is a DPP-IV suppressor (see Figure 1.14). Sitagliptin and vildagliptin have 
different inhibitory effects. Sitagliptin is a competitive inhibitor of DPP-VI, while 
vildagliptin and saxagliptin are DPP-IV substrate suppressors (Lotfy et al., 2011). 
These DPP-IV inhibitors reduce blood glucose levels in T2DM patients and they 
improve HbA1c levels (Rosenstock et al., 2007). Investigations on T2DM have shown 
that vildagliptin elevates fasting and after meal GLP-1 concentrations, increase β-cell 
glucose responsiveness and insulin efficiency and decreasing after meal plasma lipids. 
In addition, vildagliptin enhances glucose homeostasis and decreases fasting blood 
glucose concentrations (Garber et al., 2006). Vildagliptin also shows an elevation in 
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insulin release (Balas et al. 2007). Vildagliptin reduces the α-cell glucagon secretion 
after mealtime in glucose-dependent manner (Azuma et al., 2008). The correction in 
glucagon/insulin ratio correlates with increased insulin secretion that reduces blood 
glucose levels and with inhibition of liver glucose release via inhibition of glucagon 
release (Balas et al. 2007).  
 
1.15.2.3 Saxagliptin 
Saxagliptin is a DPP-IV suppressor for T2DM treatment (see Figure 1.14). Saxagliptin 
is a specific and reversible substrate suppressor of DPP-IV enzyme (Lotfy et al., 2011). 
Saxagliptin has 10-fold extra effect than both vildagliptin and sitagliptin (Kirby et al., 
2008). In a previous investigation, saxagliptin was administered as single dose per day 
in diabetic patients and the results showed a decrease in HbA1c levels (Rosenstock, et 
al., 2008). As a result, saxagliptin has a significant inhibitory action on DPP-IV and it 
can enhance the glucose tolerance (Pratley et al., 2007). Treatment of diabetic patients 
with saxagliptin has shown a strong decrease in fasting and after meal, blood glucose 
concentrations. Treatment with saxagliptin has also revealed an increase in β-cell 
activities (Rosenstock, et al., 2008). 
 
1.15.2.4 Alogliptin 
Alogliptin is an oral potent and highly selective quinazolinone-based DPP-IV 
suppressor (see Figure 1.14) (Lotfy et al., 2011). Alogliptin has an enhancing effect on 
the blood glucose tolerance in patients with T2DM (Fleck et al., 2008). A single daily 
dose of alogliptin improves insulin secretion after glucose load in fatty rats. (Feng et al., 
2007). In addition, administration of alogliptin reduces HbA1c concentrations 
(Takeuchi et al., 2006). Treatment by alogliptin also reduces triglycerides and enhances 
β-cell function in ob/ob mice (Moritoh et al., 2008). 
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Figure 1.14: The chemical structure of sitagliptin, vildagliptin, saxagliptin and 
alogliptin (Modified from Thornberry and Gallwitz, 2009). 
 
1.16 Gene therapy and GLP-1 
Single injection of STZ-induced diabetic non-obese immunodeficient mice with  
recombinant adenoviral vector expressing GLP-1 (rAd-GLP-1), leads to a reduction and 
normalization of blood glucose levels during the 10 days of the study (Liu et al., 2007). 
GLP-1/Fc gene introduction to db/db mice has shown that the transcription of GLP-
1/Fc gene improves blood glucose levels through increasing insulin release and 
decreasing glucagon secretion. Therefore, induction of this GLP-1 gene elevates the 
expression of GLP-1 with its prospective role in the treatment of DM (Kumar et al., 
2007). 
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1.17 Working hypothesis 
Newly developed incretin-like peptides may be effective in both the synthesis and the 
release of insulin from the endocrine pancreas in T1DM and exert their secretagogue 
effects on the endocrine pancreas via similar or different mechanisms.    
 
1.17.1 Main aim 
The main aim of this study was to investigate the effects of new peptides on insulin and 
glucagon release in age-matched control and STZ-induced diabetic rats. 
 
1.17.2 Specific aims 
1. To determine the pattern of distribution of GLP-1 and exenatide in the endocrine 
pancreas of normal and diabetic rats. 
2. To determine the mechanism of GLP-1 and exenatide induced insulin release. 
3. To investigate the subcellular localization of GLP-1 and exenatide in the endocrine 
pancreas of normal and diabetic rats. 
4. To determine the effect GLP-1 and exenatide on liver and kidney function tests. 
5. To investigate the role of GLP-1 and exenatide on distribution of endogenous 
antioxidants. 
6. To determine whether GLP-1 and exenatide can ameliorate the impaired metabolic 
parameters (body weight, blood glucose, GTT and lipid profile) observed in 
diabetes.  
7. To investigate the effects of the expression of genes related to β-cell function. 
8. To analyse the data and write up the PhD thesis. 
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2. Materials and Methods 
2.1 Experimental animals 
This study employed young male Wistar rats weighing approximately 250 grams (10 
weeks old) at the beginning of the experimental period. The animals were obtained 
from the Faculty of Medicine and Health Sciences (FMHS), United Arab Emirates 
University, (UAEU) breeding colony and the Animal Research Group‟s guidelines for 
the care and use of laboratory animals were followed. All the rats were housed in 
temperature (25°C) and humidity controlled rooms and 12 hours light and dark periods. 
The animals were fed on a standard rat chow and tap water ad libitum. This project had 
the ethical clearance from the ethics committees from University of Central Lancashire 
(UCLAN) and UAEU to carry out the experiments. 
 
2.2 Induction of experimental diabetes 
Diabetes was induced in the rats by a single intraperitoneal injection (ip) of (0.3 ml) 
streptozotocin, (STZ) (Sigma, Poole, UK) at a dose of 60 mg/kg body weight 
(Adeghate, 1999). The STZ was freshly dissolved in citrate buffer (0.5 M, pH 4.5) (see 
appendix). Age-matched healthy control rats received the same volume (0.3 ml) of the 
citrate buffer only. Following five days after either STZ or citrate buffer injection, the 
rats were tested for diabetes by using a drop of blood from the tail end of each rat. The 
blood glucose estimations were made by Optium Xceed Glucometer (Abbott, Park, 
llinois, USA) for each individual rat. The rats were considered diabetic if the fasting 
blood glucose levels were equal to or more than 280 mg/dl. 
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2.3 Experimental design 
Following the diagnosis of diabetes, both age-matched healthy control and STZ-
induced diabetic rats were divided into six groups each containing ten rats. The diabetic 
rats were intraperitoneally injected daily with either GLP-1 (50 nmol/kg) or exenatide 
(1 µg/kg) for ten weeks. GLP-1 and exenatide were purchased from Phoenix 
Pharmaceuticals, Burlingame, California, USA. The age-matched control rats received 
the vehicle for over the same period of ten weeks. The six treated groups were: 
A. Group 1, served as untreated normal healthy control. 
B. Group 2, served as untreated diabetic control. 
C. Group 3, served as normal-treated with glucagon like peptide-1 (50 nmol/kg). 
D. Group 4, served as diabetic-treated with glucagon like peptide-1 (50 nmol/kg). 
E. Group 5, served as normal-treated with exenatide (1 µg/kg). 
F. Group 6, served as diabetic-treated with exenatide (1 µg/kg). 
Each group in this study contained 10 rats (n=10). 
All rats were 10 weeks old at the beginning of the experiment (zero week) and were 20 
weeks old at the end of the study period. All measurements were performed at the end 
of the experiment except the measurement of body weight and the fasting blood glucose 
levels, which were estimated every two weeks from zero week till week number 10. 
  
2.4 Weight measurement 
The weights of normal and diabetic rats were recorded every two weeks using a 9001 
Scale (Satorius, Hertfordshire, UK). The mean ± standard error of the mean (SEM) of 
the body weight for each rat within each experimental group was calculated for each 
two weeks of the experiment period. 
 
66 
 
2.5 Fasting blood glucose measurement 
The fasting blood glucose level was measured every two weeks for each individual rat 
of all groups. The blood samples were drawn from the rat‟s tail end for blood glucose 
measurement. The mean ± standard error of the mean (SEM) of the blood glucose for 
each experimental group was calculated every two weeks during the experiment period. 
 
2.6 Intraperitoneal glucose tolerance test (IPGTT) 
At the end of the ten weeks of the treatment, age-matched healthy control and STZ-
induced diabetic rats were subjected to intraperitoneal glucose tolerance test, after an 
overnight fasting for 18 hours. Each rat was given an intraperitoneal glucose load of 2 
g/kg body weight according to the method of Caluwaerts et al., (2007). The blood 
glucose measurements were made at fasting zero time (before glucose load), 30, 60, 
120 and 180 minutes after the glucose load. 
 
2.7 Biochemical analysis 
Serum aspartate aminotransferase, serum alanine aminotransferase, blood urea nitrogen, 
serum creatinine, serum uric acid, serum cholesterol and serum triglyceride were 
performed in Al-Ain Hospital Clinical Laboratory using the Beckman Coulter 
(Synchron UniCel, DxC, 800 Synchron, Clinical System, California, USA). 
 
2.8 Tissue collection and tissue processing 
After the end of the experiments, all the rats from each group were killed humanely 
under general anesthesia by diethyl ether. A mid-line abdominal incision was made and 
the pancreas was rapidly removed. Representative pancreatic fragments were taken 
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from different parts of the body of the pancreas and they were used for both 
morphological, in vitro study and molecular biological studies. 
 
2.9 Serum insulin estimation by enzyme-linked 
immunosorbent assay 
Serum insulin level was determined by using DakoCytomation Kit, Glostrup, Denmark, 
which was an enzyme-linked immunosorbent assay (ELISA) method based on two 
monoclonal antibodies. Simultaneous incubation of sample and enzyme-labelled 
antibody in a microplate microwell coated with a specific anti-insulin antibody formed 
a complex. A simple washing step removed unbound enzyme-labelled antibody. The 
bound conjugate was detected by reaction with the substrate tetramethylbenzidine 
(TMB). The reaction was stopped by adding sulphuric acid to give a colorimetric 
endpoint absorbance that was measured spectrophotometrically using Biochrom Anthos 
2010, Microplate Reader (Cambridge, England). The inclusion of calibrators of known 
insulin concentrations in the assay allowed a calibration curve to be constructed from 
which the level of insulin in the samples could be calculated.  
 
2.10 Estimation of in vitro pancreatic insulin release 
In these experiments, ten rats from each group were used. The pancreas was removed 
and placed in ice-cold phosphate buffer saline (PBS) (see appendix). The pancreas was 
trimmed free of adherent fat and connective tissue and cut into small fragments (1-2 
mm
3
). Thereafter, the pancreatic fragments were then placed in glass tubes containing 1 
ml of PBS and the tubes were weighed before and after addition of pancreatic 
fragments. Each tube was preincubated for 30 minutes in a shaking water bath at 37°C, 
in order to wash away any enzymes and hormones due to cutting of the tissues. The 
tissues were gassed with 5% CO2 and 95% O2.. After the preincubation period, the PBS 
solution was drained and the fragments were subsequently incubated for 1 hour with 1 
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ml of PBS containing different concentrations of the following solutions. Before the 
incubation, all the tubes were weighed again to estimate the tissue net weight in each 
tube. 
This study employed either GLP-1 or exenatide. The different concentrations employed 
in this study included either GLP-1 (10
-12
, 10
-9
 and 10
-6
M) or exenatide (10
-12
, 10
-9
 and 
10
-6
M). In control experiments, the fragments were incubated in PBS solution alone for 
the same period at 37°C in a shaking water bath. During the incubation period, each 
vial was gassed with 95% oxygen and 5% carbon dioxide every 10 minutes.  At the end 
of each experiment, the tissues were removed and incubation solutions were stored at    
-20°C for ELISA estimation of insulin concentrations. All values for insulin secretion 
levels were expressed as µIU/ml/100 mg tissue. 
  
 2.11 Immunohistochemical studies 
Ten rats from each group (either control or diabetic) were used for the experiments. The 
isolated pancreas was trimmed free of adherent fat and connective tissues and cut into 
small pieces (2 mm
3) and fixed overnight in freshly prepared Zamboni‟s fixative 
(Zamboni and de Martino, 1967) (see appendix). The tissues were later dehydrated in 
graded concentrations of ethanol. The specimens were changed every 2 hours in 70% 
and 95% and 3 changes in absolute ethanol for 2 h. After dehydration, the specimens 
were cleared in xylene and subsequently embedded in paraffin wax at 55°C. Sections of 
6 µm thickness were cut on a microtome (Shandon AS325, Michigan, USA), and 
placed in water bath at 48°C. Thereafter, they were transferred onto prewashed 
microscopic slides, which were dried in an oven at 55°C for 30 minutes to enhance 
attachment of sections. 
The slides were deparaffinized with xylene (twice, 5 minutes each) and then transferred 
into absolute ethanol (twice, 5 minutes each). The sections were then incubated for 30 
minutes in 0.3% hydrogen peroxide solution in methanol to block endogenous 
peroxidase activity. The sections were hydrated in decreasing concentrations of ethanol 
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and brought to phosphate buffered saline (PBS) (see appendix). The slides were washed 
three times (5 minutes each) in PBS. After washing in PBS, the tissues were marked 
around with a Dako pen (DakoCytomation, Glostrup, Denmark) to prevent solutions 
draining away from the tissue sections. The staining procedure started by incubating the 
sections with blocking reagent. After 30 minutes the blocking reagent was drained off 
and appropriate dilution of primary antibodies and negative control reagents were 
applied. The sections were then incubated in primary antibodies for 1 h at room 
temperature. The slides were then washed (3 times, 5 minutes each) with PBS and 
incubated for 30 minutes with prediluted biotinylated anti-rabbit or anti-mouse IgG for 
30 minutes. They were washed again in PBS (3 times, 5 minutes each) and 
subsequently incubated in streptavidin peroxidase conjugate for 45 minutes. After a 
final wash in PBS (3 times, 5 minutes each), the peroxidase activity was revealed by 
incubating the specimens for 3 minutes in 3,3-diaminobenzidine tetrahydrochloride 
containing 0.03% hydrogen peroxide in PBS. The slides were later washed for 1 minute 
under running tap water and counterstained with haematoxylin for 30 seconds. They 
were then differentiated in acid ethanol and washed for 1 minute under running tap 
water, dehydrated in ascending grades of ethanol and subsequently cleared in xylene for 
longer time to dissolve the Dako pen mark. The tissues were subsequently mounted in 
Cytoseal 60 (Stephens Scientific, Riverdale, New Jersey, USA). Slides were examined 
under Ziess Axiophot microscope (Carl Zeiss, Jena, Germany) and immunopositive 
cells of the tissue sections were photographed.  
The number of insulin, glucagon, GLP-1, exenatide, glutathione reductase and catalase-
positive cells were counted and estimated semi-quantitatively in normal and diabetic 
pancreatic tissues. The antibodies for insulin, glucagon, GLP-1, exenatide, glutathione 
reductase and catalase were purchased from commercial suppliers (see appendix). They 
were used at appropriate dilutions (see appendix). No specific immunostaining was 
observed in pancreatic tissue when primary antibodies were omitted. (The 
immunohistochemical staining was performed by the Labelled Streptavidin Biotin 
method using a Dako LSAB
®
 peroxidase kit, California, USA). 
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2.12 Immunofluorescence studies 
Isolated pancreatic tissues were retrieved, fixed and embedded in paraffin. Sections of  
6 µm thickness were deparaffinized in xylene, hydrated in descending concentration of 
ethanol (5 minutes each) and washed 3 times in PBS for (5 minutes each). After 
washing in PBS, the tissue was marked around with a Dako pen to prevent solutions 
draining away from the tissue section. The staining procedure started by incubating the 
sections with blocking reagent for 30 minutes.  Thereafter, the blocking reagent was 
drained off and appropriate dilution of primary antibodies were applied and incubated 
at 4°C for 24 hours. On the following day, the sections were incubated at room 
temperature for 1 hour. The slides were then washed 3 times in PBS (5 minutes each) 
and incubated with secondary antibodies conjugated with FITC or TRITC (Jackson 
Laboratory, West Grove, Pennsylvania, USA) for 1 hour and washed in PBS (3 times 5 
minutes each). Sections were then mounted in CITI-Floure mounting media and viewed 
and photographed with Ziess Axiophot Fluorescence Microscope, (Carl Zeiss, Jena, 
Germany). 
 
2.13 Electron microscopic studies 
The pancreas was trimmed free of adherent fat and connective tissue and cut into small 
pieces of 2 mm
3
 and fixed overnight in freshly prepared Karnovsky fixative (see 
appendix) (Karnovsky, 1965). Thereafter, they were washed 3 times in sodium 
cacodylate buffer (see appendix) and post-fixed in 1% osmium tetroxide for 1 hour. 
After post-fixation, they were washed 5 times in the same buffer and dehydrated. 
Dehydration of tissues were done in ethanol series with single change of 15 minutes in 
30%, 50%, 70%, 95% and 4 changes in absolute ethanol for 15 minutes each. After the 
dehydration, they were cleared in propylene oxide (2 changes of 15 minutes each) and 
transferred to 1:1 mixture of propylene oxide and resin (see appendix) for 1 hour and 
later transferred to 1:2 mixtures of propylene oxide and resin. After one hour in the 1:2 
mixtures, they were infiltrated with resin overnight. The samples were later embedded 
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in resin using moulds; polymerization of the resin block was completed in 24 hours at 
55°C. The blocks were trimmed and 1µm semi-thin sections were cut with glass knives 
on an ultra-microtome (Reichert Ultracut 5, Massachusetts, USA) and sections were 
transferred onto drops of water on a microscope slide using watchmaker‟s forceps. The 
slides were stained with toludine blue and observed under microscope to locate the 
islets of Langerhans. The tissue blocks were later trimmed for ultra-thin sectioning. 
Ultra-thin sections were cut at a thickness of 80 nm by a diamond knife. The sections 
were then transferred onto 300 mesh copper grid by a wire loop. The grids were dried 
on a filter paper and stained with uranyl acetate for 30 minutes and washed 5 times in 
filtrated distilled water. To further enhance the contrast, the sections were stained in 
lead citrate for 3 minutes and washed 3 times in filtrated distilled water. The dried grids 
were observed on transmission electron microscope (Philips CMIO, Eindhoven, 
Holland) and photographed.  
 
2.14 Immunoelectron microscopic studies 
Nickel grids with sections of pancreas were immerse in 0.01 M sodium citrate buffer at 
90°C for 5 minutes and cooled at room temperature in the citrate buffer for 20 minutes.  
Then the grids were Jet-washed with deionized water. Grids were placed in 10% H2O2 
for 10 minutes.  Washed in deionized water then immersed in 0.5 M NH4Cl in 0.01 M 
PBS for 20 minutes.  Grids were washed in PBS containing 1% bovine serum albumin 
(BSA) and 0.1% Tween-20 (washing buffer) for 5 minutes.  Grids were blocked in 20% 
normal goat serum (NGS) diluted in washing buffer (blocking buffer) for 10 minutes 
and  then incubated overnight at 4°C in primary antibody. After that, grids were placed 
in room temperature for 1 hour and washed in washing buffer for 5 minutes three times. 
The grids were incubated in blocking buffer for 20 minutes at room temperature and 
later in goat anti-mouse IgG conjugated to 20 nm gold particles (TAAB, Berkshire, 
UK) at room temperature for 2 hours. Grids were then washed (washing buffer) for 3 
minutes five times and later incubated overnight at 4°C in secondary antibody. After 
that, the grids were placed in room temperature for 1 hour and washed in washing 
72 
 
buffer for 5 minutes three times. They were later incubated in blocking buffer for 20 
minutes at room temperature. Grids were incubated in goat anti-mouse IgG conjugated 
to 15 nm gold particles (TAAB, Berkshire, UK) at room temperature for 2 hours. After 
that, the grids were washed (washing buffer) for 3 minutes (five times) and later fixed 
in glutaraldehyde (2.5% aqueous) for 5 minutes.  Grids were then washed in deionized 
water for 3 minutes 5 times. Finally, the grids were placed on filter paper to dry for 1 
hour and were contrasted with uranyl acetate and lead citrate for 15 minutes and 7 
minutes, respectively. The dried grids were observed on transmission electron 
microscope (Philips CMIO, Eindhoven, Holland) and photographed. 
 
2.15 Molecular biology studies by relative quantification 
assay using real-time PCR 
This study investigated the effect of certain transcription factors on insulin gene 
expression. These included pancreatic duodenal homeobox-1, heat shock protein-70, 
glutathione peroxidase, glucagon, insulin receptor and glucagon-like peptide-1 receptor. 
Estimation the levels of these transcription factors was done using relative 
quantification assay by real-time polymerase chain reaction (PCR) technique. Relative 
quantification was used to compare expression levels of the gene expression in different 
tissues or in differently treated and untreated samples. Relative quantification can 
match the expression values of the gene expression in treated and untreated pancreatic 
rat tissues. Relative quantification method estimates precisely the values of gene 
expression in each treatment with no need for absolute determination of either gene 
expression copy number or even standard curves estimation.   
Relative quantification assay using real-time PCR technique was used to determine 
whether GLP-1 and exenatide could stimulate any changes in the levels of pancreatic 
duodenal homeobox-1, heat shock protein-70, glutathione peroxidase, glucagon, insulin 
receptor and glucagon like peptide-1 receptor genes, which are implicated in the 
differentiation, maturation of pancreatic islet cells and their relation to insulin 
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secretions. The relative estimation was to find out if it could contribute to the 
amelioration of the signs and symptoms of DM. 
 
2.15.1 Total RNA extraction 
Total RNA was extracted from rat pancreatic tissues using RiboPure Extraction kit (Cat 
No. 1924, AMBION-Applied Biosystems, California, USA) according to the 
manufacturer`s recommendations.  
 
2.15.2 RNA yield and quality 
The concentrations and the purity of the RNA samples were determined by measuring 
their absorbance at 260 nm and 280 nm using the Spectrophotometer NanoDrop 1000A, 
Wilmington, USA. 
 
2.15.3 cDNA synthesis 
Complementary deoxyribonucleic acid (cDNA) was synthesized using high capacity 
cDNA reverse transcription kit with RNAase inhibitor (Applied Biosystems, California, 
USA).  
 
2.15.4 Gene expression assay using real-time PCR  
Gene expression assays using TaqMan labelled primers and probes (for the target genes 
[pancreatic duodenal homeobox-1 (Gene Bank ID: 29535), heat shock protein-70 (Gene 
Bank ID: 266759), glutathione peroxidase (Gene Bank ID: 24404), glucagon (Gene 
Bank ID: 24952), insulin receptor (Gene Bank ID: 24954) and glucagon like peptide-1 
receptor (Gene Bank ID: 25051) were undertaken using relative real time PCR. The 
endogenous control was β-actin (Gene Bank ID: 81822). All primers and probes were 
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purchased from Applied Biosystems, California, USA. By using the endogenous 
control as an active reference, the target mRNA was normalized and quantified by 
measuring the differences in the amounts of total RNA added to each reaction. PCR 
reactions were carried out using the following cycling conditions as one cycle at 50°C 
for 2 minutes then 1 cycle at 95°C for 10 minutes followed by 40 cycles at 95°C for 15 
second and 60°C for 1 minute. Relative quantification method was accomplished by 
relative real-time PCR. The technique of real-time PCR estimates directly the levels of 
the gene expression simultaneously during the real-time PCR amplification and finally 
when the experiment is completed using Applied Biosystems 7500 Real-time PCR 
System (California, USA). 
 
2.15.5 Analysing the results 
Data were analyzed by creating a relative quantification (RQ) study document using the 
sequence detection systems (SDS) software of 7500 ABI instrument (Applied 
Biosystems, California, USA). Relative quantification technique was employed to 
determine the change in expression of the target gene in treated sample relative to the 
untreated sample. The results are calculated as a fold-difference of the gene 
amplification values after their normalization to the levels of the housekeeping 
endogenous β-actin gene expression.  
 
2.16 Statistical analysis 
All values were calculated as mean ± standard error of the mean (SEM). Student's t-test 
and ANOVA test were used to analyze the significance of differences between mean 
values and different groups were assessed using SPSS statistical analysis software. 
Values with (P < 0.05) were accepted as significant comparing control and treated 
samples. Values with either (P < 0.01) or (P < 0.001) were accepted as moderate or 
highly significant, respectively. 
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In vivo studies  
3.1 Effect of GLP-1 and exenatide treatment on metabolic 
parameters of normal and diabetic rats 
3.1.1 Effect of GLP-1 and exenatide treatment on body weight of normal rats 
Treatment with either GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body 
weight), did not result in significant weight gain compared to control (Figure 3.1). The 
weight gain observed in normal rats treated with either GLP-1 or exenatide was more or 
less similar to that of untreated normal rats. The weight gain in exenatide treated 
normal rats was slightly less than in case of GLP-1 treated normal rats compared with 
the weight gain in untreated normal rats. All the three groups of rats gained mild weight 
increases over the experimental period compared to the start of experiment period at 0 
week. 
 
Figure 3.1: Time course effect of 10 weeks of treatment with either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on body weight of normal treated rats 
compared to untreated normal control rats. Data are mean ± SEM, n = 10 rats for each 
point. Note that there was no significant difference in the body weight between all 
normal groups. 
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3.1.2 Effect of GLP-1 and exenatide treatment on body weight of diabetic rats 
Treatment with either GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body 
weight), to STZ-induced diabetic rats over the experimental period resulted in a slight 
but not significant weight loss compared to the weight of diabetic rats prior to treatment 
(time 0 week) (Figure 3.2). Untreated diabetic rats lost weight gradually from week to 
week until the end of the experiment. However, diabetic rats treated with either GLP-1 
or exenatide had a significantly (p < 0.05) higher weight profile compared to untreated 
diabetic rats at weeks 6 and 8. Generally, the results show that the total body weight 
loss in either GLP-1 or exenatide treated rats was lower compared to untreated rats 
throughout the entire 10-week period of the study. 
 
 
Figure 3.2: Time course effect of 10 weeks of treatment of either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on body weight of diabetic treated 
rats compared to diabetic untreated rats. Data are mean ± SEM, n = 10 rats for each 
point rats. *P < 0.05 significant increase in body weight of diabetic treated rats with 
either GLP-1 or exenatie compared to untreated diabetic rats at 6 and 8 weeks. Note 
that the higher change detected in either GLP-1 or exenatide treated diabetic rats was 
between weeks 6-10.  
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3.1.3 Effect of GLP-1 and exenatide treatment on blood glucose levels of normal rats 
Figure 3.3 shows the time course for fasting blood glucose (FBG) levels of normal rats 
after treatment with either GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body 
weight) compared to untreated normal rats. A slight but not significant reduction in 
FBG was detected in normal rats at the end of the 10 weeks of the experiment period 
compared to the start of the experimental period in week zero mainly due to the effect 
of treatment with either GLP-1 or exenatide. Almost similar but not significant changes 
of FBG levels were detected in both normal groups treated with either GLP-1 or 
exenatide at the end of the 10 weeks of the experiment compared to untreated normal 
rats. 
 
Figure 3.3: Time course effect of 10 weeks of treatment with either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on blood glucose levels of normal 
treated rats compared to untreated normal control rats. Data are mean ± SEM, n = 10 
rats for each time point.  
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3.1.4 Effect of GLP-1 and exenatide treatment on blood glucose levels of diabetic rats 
Figure 3.4 has shown that all the fasting blood glucose (FBG) levels of diabetic rats 
were markedly higher than the FBG levels of all normal rats detected in figure 3.3. The 
results of figure 3.4 also revealed a reduction in fasting blood glucose (FBG) levels 
during and at the end of the experiment period in diabetic rats treated with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/Kg body weight) diabetic treated rats 
compared to untreated diabetic rats. A significant reduction was detected in diabetic 
rats treated with GLP-1 starting from weeks 4-8 (p < 0.05) to the week 10 (p < 0.01) 
compared to untreated diabetic rats. In addition, a significant reduction of FBG levels 
were detected in exenatide treatment diabetic rats in weeks 4 and 10 (p < 0.05) 
compared to untreated diabetic rats.  
 
Figure 3.4: Time course effect of 10 weeks of treatment with either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on blood glucose levels of diabetic 
rats compared to untreated diabetic control rats. Data are mean ± SEM, n = 10 rats for 
each time point. * P < 0.05;  and ** P < 0.01 significant decreases in fasting blood 
glucose levels of diabetic treated rats with either GLP-1 or exenatie compared to 
untreated diabetic rats. The results also show that the diabetic rats treated with GLP-1 
showed mild significant (p < 0.05) reduction in FBG levels when compared to 
untreated diabetic rats starting from the fourth week and continued until the eight week 
and the difference reached to moderate significant (p < 0.01) reduction detected at the 
tenth week. However, the results show that exenatide diabetic treated rats have mild 
significant (p < 0.05) reduction detected at weeks four and ten.  
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3.1.5 Intraperitoneal glucose tolerance test (IGTT) in GLP-1- and exenatide treated 
normal rats. 
The results for the IGTT of normal rats are shown in Figure 3.5. The data show that rats 
treated with either GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body 
weight) have a better IGTT values compared to untreated normal rats. However, it 
appeared that the IGTT results of normal treated GLP-1 rats was better than that the 
exenatide treated normal rats. There was a significant (p < 0.05) decrease in blood 
glucose levels of rats treated with GLP-1 compared to normal, untreated rats at 30 and 
120 minutes following glucose load, while, a small significant (p < 0.05) decrease was 
detected in blood glucose levels of rats treated with exenatide compared to normal 
untreated rats at 120 minutes following glucose load. The results also show that after 
180 minutes, blood glucose level for all rats returned to almost normal level. 
 
Figure 3.5: Time course effect of 10 weeks of treatment with either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on IGTT of normal rats compared to 
untreated normal control rats. * P < 0.05 for glucose levels of normal treated rats 
compared to untreated normal control rats. Data are mean ± SEM, n = 10 rats in each 
data point. 
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3.1.6 Intraperitoneal glucose tolerance test (IGTT) in GLP-1- and exenatide treated 
diabetic rats. 
Figure 3.6 shows the time course of IGTT in diabetic rats that were treated with either 
GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body weight) compared to 
untreated diabetic rats. At the start of the experiments all the diabetic rats had high 
blood glucose level compared to normal rats (see Figure 3.5). The IGTT values of 
diabetic rats treated with exenatide was lower than that of the untreated diabetic rats, 
the difference was significant (p < 0.05) at both 0 minutes and 120 minutes. Moreover, 
rats that were treated with GLP-1 had significantly (p < 0.05; p < 0.01) lower IGTT 
values at 0, 30, 60, 120 and 180 minutes after the glucose load as compared to untreated 
diabetic rats. These results demonstrated that GLP-1 was more effective in reducing 
blood glucose in diabetic rats compared to exenatide. 
 
Figure 3.6: Time course effect of 10 weeks of treatment with either GLP-1 (50 nmol/kg 
body weight) or exenatide (1 μg/kg body weight) on IGTT of diabetic rats compared to 
untreated diabetic rats. * P < 0.05 and ** P < 0.01 for glucose levels of diabetic treated 
rats compared to untreated diabetic rats. Data are mean ± SEM, n = 10 rats for each 
data point. 
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3.2 Effect of GLP-1 and exenatide treatment on biochemical 
parameters of normal and diabetic rats 
3.2.1 Serum aspartate transferase (AST) 
Figures 3.7 and 3.8, respectively show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight) on serum AST in normal and diabetic 
treated rats. Treatments of normal rats with either GLP-1 or exenatide resulted in a 
significant (p < 0.001) reduction in serum AST levels compared to untreated rats 
(Figure 3.7). On the other hand, diabetic rats treated with either GLP-1 or exenatide 
have a more pronounced and significant reduction in serum AST levels (p < 0.001) 
compared to untreated diabetic rats (Figure 3.8). 
 
 
Figure 3.7: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum AST levels of 
normal rats. *** P < 0.001 for normal GLP-1 and exenatide treated rats compared to 
untreated normal rats. Data are mean ± SEM, n = 10 rats for each time point. 
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Figure 3.8: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum AST levels of 
diabetic rats. *** P < 0.001 for diabetic GLP-1 and exenatide treated rats compared to 
untreated diabetic rats. Data are mean ± SEM, n = 10 rats for each time point. 
 
3.2.2 Serum alanine transferase (ALT) 
Figures 3.9 and 3.10 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight) on serum ALT in normal and diabetic treated rats, 
respectively, compared to untreated rats. Treatments of normal rats with GLP-1 resulted 
in a slight reduction in serum ALT levels and a significant reduction in serum ALT 
levels (p < 0.01) of normal rats treated with exenatide, compared to normal untreated 
rats (Figure 3.9). On the other hand, treatment of diabetic rats with either GLP-1 or 
exenatide resulted in a significant reduction in serum ALT levels (p < 0.001; p < 0.01), 
respectively, compared to diabetic untreated rats (Figure 3.10). These results also reveal 
that both GLP-1 and exenatide were more effective in reducing serum ALT levels in 
diabetic rats compared to normal treated rats. 
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Figure 3.9: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum ALT levels of 
normal rats compared to normal untreated rats. ** P < 0.01 for exenatide treated normal 
rats compared to normal untreated rats. Data are mean ± SEM, n = 10 rats for each 
group. 
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Figure 3.10: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum ALT levels of 
diabetic rats. ** P < 0.01; *** P < 0.001 for diabetic GLP-1 and exenatide treated rats 
compared to untreated diabetic rats. Data are mean ± SEM, n = 10 rats for each group. 
 
3.2.3 Blood urea nitrogen (BUN) 
Figures 3.11 and 3.12 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight) on BUN levels in normal and diabetic treated rats, 
respectively, compared to their untreated controls. The results show that treatment of 
either normal or diabetic rats with either GLP-1 or exenatide resulted in only a small 
but not significant reduction in BUN levels compared to their respective untreated 
controls. However, the inhibitory effect on BUN levels in GLP-1 treated diabetic rats 
was significant (p < 0.05) compared to untreated diabetic rats. The inhibitory effect of 
both GLP-1 and exenatide on BUN levels was more pronounced in the diabetic rats 
compared to normal.  
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Figure 3.11: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on blood urea nitrogen 
levels of normal rats compared to normal untreated rats. Data are mean ± SEM, n = 10 
rats for each point. 
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Figure 3.12: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on blood urea nitrogen 
levels of diabetic rats compared to diabetic untreated rats. Note that, the effect of GLP-
1 was more prominent compared to exenatide. * P < 0.05 for   compared to untreated 
diabetic rats. Data are mean ± SEM, n = 10 rats for each point. 
 
3.2.4 Serum creatinine 
Figures 3.13 and 3.14 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight), on serum creatinine levels in normal and diabetic 
treated rats, respectively, compared to their respective controls. The results show that 
treatment of normal and diabetic rats with GLP-1 and exenatide resulted in small 
reductions in serum creatinine levels compared to their respective untreated controls. 
The reduction of serum creatinine levels was only significant (p < 0.05) in the case of 
normal and diabetic rats treated with exenatide compared to their respective untreated 
normal and diabetic controls. 
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Figure 3.13: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum creatinine 
levels of normal rats compared to normal untreated rats. * P < 0.05 for exenatide 
treated normal rats compared to normal untreated rats. Data are mean ± SEM, n = 10 
rats for each point. 
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Figure 3.14: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum creatinine 
levels of diabetic rats compared to diabetic untreated rats. * P < 0.05 for exenatide 
treated diabetic rats compared to untreated diabetic rats. Data are mean ± SEM, n = 10 
rats for each point rats for each point. 
 
3.2.5 Serum uric acid 
Figures 3.15 and 3.16 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight), on serum uric acid levels in normal and diabetic 
treated rats, respectively, compared to the untreated control rats. The results show a 
small reduction in serum uric acid levels of GLP-1 treated normal rats compared to 
normal untreated rat. However, a significant reduction (p < 0.05) was obtained in 
exenatide treated normal rats compared to normal untreated rats. Similarly, treatment of 
diabetic rats with either GLP-1 or exenatide resulted in significant reduction (p < 0.05; 
p < 0.01) in serum uric acid levels, respectively, compared to untreated diabetic rats. 
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Figure 3.15: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum uric acid levels 
of normal rats compared to untreated normal rats. * P < 0.05 for exenatide treated 
normal rats compared to untreated normal rats. Data are mean ± SEM, n = 10 rats for 
each point. 
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Figure 3.16: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum uric acid levels 
of diabetic rats compared to untreated diabetic rats. * P < 0.05 for GLP-1 treated 
diabetic and ** P < 0.01 for exenatide treated diabetic rats compared to untreated 
diabetic rats. Data are mean ± SEM, n = 10 rats for each point.  
 
3.2.6 Serum cholesterol 
Figures 3.17 and 3.18 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight) on serum cholesterol levels in normal and diabetic 
treated rats, respectively, compared to their respective controls. The results showed no 
detectable effect of normal, GLP-1 treated rats on serum cholesterol levels compared to 
normal untreated rats. However, exenatide treated normal rats showed significant (p < 
0.05) reduction in serum cholesterol levels compared to normal untreated rats. On the 
other hand, GLP-1 evoked a significant (p < 0.05) reduction in serum cholesterol levels 
diabetic rats compared to untreated diabetic rats. A small reduction in serum cholesterol 
levels was detected in exenatide-treated diabetic rats compared to untreated diabetic 
rats. 
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Figure 3.17: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum cholesterol 
levels of normal rats compared to normal untreated rats. * P < 0.05 for exenatide 
treated normal rats compared to normal untreated rats. Data are mean ± SEM, n = 10 
rats for each point. 
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Figure 3.18: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum cholesterol 
levels of diabetic rats compared to diabetic untreated rats. * P < 0.05 for diabetic   
GLP-1 treated rats compared to diabetic untreated rats. Data are mean ± SEM, n = 10 
rats for each point.  
 
3.2.7 Serum triglyceride 
Figures 3.19 and 3.20 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight) on serum triglyceride levels in normal and diabetic 
treated rats, respectively, compared to their respective control. The results showed that 
GLP-1 reduced, but not significantly, serum triglyceride levels in GLP-1-treated normal 
rats compared to normal untreated rats. However, exenatide evoked more and 
significant (p < 0.001) decrease in serum triglyceride levels compared to normal 
untreated rats. The results also showed that treatment of diabetic rats with either GLP-1 
or exenatide resulted in marked and significant reductions in serum triglyceride levels 
(p < 0.001 and p < 0.01), respectively, compared to diabetic untreated rats. 
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Figure 3.19: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum triglyceride 
levels of normal rats compared to normal untreated rats. *** P < 0.001 for exenatide 
treated normal rats compared to normal untreated rats. Data are mean ± SEM, n = 10 
rats for each point. Note that exenatide but not GLP-1 has evoked significant decrease 
in serum triglyceride levels compared to normal untreated rats. 
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Figure 3.20: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum triglyceride 
levels of diabetic rats compared to untreated diabetic rats. *** P < 0.001 for GLP-1 and 
** P < 0.01 for exenatide in diabetic treated rats compared to diabetic untreated rats. 
Data are mean ± SEM, n = 10 rats for each point. 
 
3.3 Effect of either GLP-1 or exenatide treatment on serum 
insulin secretion from diabetic and normal rats 
Figures 3.21 and 3.22 show the effect of either GLP-1 (50 nmol/kg body weight) or 
exenatide (1 μg/kg body weight) on serum insulin levels in normal and diabetic treated 
rats, respectively, compared to their respective controls. The results show that treatment 
of both normal and diabetic rats with either GLP-1 or exenatide resulted in significant 
increases in serum insulin levels compared to their respective untreated controls. 
Significant (p < 0.05) increase in serum insulin level was detected in normal rats treated 
with either GLP-1 or exenatide compared to normal untreated rats. Similarly, a 
moderately significant (p < 0.01) increase in serum insulin level was obtained in 
diabetic rats treated with either GLP-1 or exenatide compared to untreated diabetic rats.  
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Figure 3.21: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum insulin levels 
of normal rats compared to untreated normal rats. * P < 0.05 for either GLP-1 or 
exenatide normal treated rats compared to normal untreated rats. Data are mean ± SEM, 
n = 10 rats for each point. 
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Figure 3.22: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on serum insulin levels 
of diabetic rats compared to untreated diabetic rats. ** P < 0.01 for either GLP-1 or 
exenatide treated diabetic rats compared to untreated diabetic rats. Data are mean ± 
SEM, n = 10 rats for each point. 
 
3.4 In vitro study of either GLP-1 or exenatide effect on 
insulin secretion from pancreatic tissue fragments 
3.4.1 Effect of GLP-1 on insulin secretion from normal pancreatic fragments  
The in vitro study shows that the basal level of insulin secretion (release) was (1.0 ± 
0.04) µIU/ml/100 mg tissue from normal pancreatic fragments compared to (0.6 ± 0.03) 
µIU/ml/100 mg tissue from diabetic pancreatic fragments. These results reveal that the 
basal insulin release level estimated from normal rat pancreatic fragments is two-fold of 
that retrieved from pancreatic fragments of diabetic rats. Figure 3.23 shows insulin 
release after incubation of normal pancreatic tissue fragments with different 
concentrations (10
-12
, 10
-9
 or 10
-6
 M) of GLP-1. The results show that 10
-12
 or 10
-9
 M of 
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GLP-1 can evoke a significant (p < 0.01) and dose dependent increase in insulin 
secretion from normal pancreatic fragments compared to the basal. The maximal 
significant elevation (p < 0.001) of insulin secretion from normal pancreatic fragments 
was obtained with 10
-6
 M of GLP-1 compared to basal insulin secretion.  
 
Figure 3.23:  Histograms showing in vitro insulin secretion levels from pancreatic 
tissues of normal rats incubated with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of 
GLP-1.  ** P < 0.01 and *** P < 0.001 showing significant increase in insulin secretion 
levels at concentrations (10
-12
, 10
-9
 and 10
-6
 M) of GLP-1 compared to basal insulin 
secretion. Data are mean ± SEM, n = 10 rats for each point. 
 
3.4.2 Effect of GLP-1 on insulin secretion from pancreatic fragments of diabetic rats 
Figure 3.24 shows insulin release after incubation of pancreatic tissue fragments of 
diabetic rats with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of GLP-1. The results 
show that 10
-12
 M of GLP-1 can evoke a significant (p < 0.05) increase in the secretion 
of insulin from diabetic rat tissue compared basal. GLP-1 at concentrations of 10
-9
 and 
10
-6
 M evoked highly significant (P < 0.001) increases in insulin release compared to 
basal. These effects were dose-dependent with maximal secretion occurring with 10
-6
 
M of GLP-1.  
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Figure 3.24: Histograms showing in vitro insulin secretion levels from pancreatic 
tissues of diabetic rat incubated with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of 
GLP-1 compared to the basal. ** P < 0.01 and *** P < 0.001 showing significant 
increase in insulin secretion at 10
-12
, 10
-9
 and 10
-6
 M of GLP-1 compared to basal 
insulin secretion. Data are mean ± SEM, n = 10 rats for each point. 
 
3.4.3 Effect of exenatide on insulin secretion from pancreatic tissue fragments of 
normal rats untreated tissue 
Figure 3.25 shows insulin release after incubation of pancreatic tissue fragments of 
normal rats with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of exenatide. The result 
is compared to that of basal secretion. The results show that exenatide can evoke a 
markedly significant (p < 0.001) increase in insulin secretion from pancreatic fragments 
of normal rats at all concentrations (10
-12
, 10
-9
 and 10
-6
 M) of exenatide compared to 
basal. The maximal effect was obtained with 10
-6
 M of exenatide. 
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Figure 3.25: Histograms showing in vitro insulin secretion levels from pancreatic 
tissues of normal rats incubated with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of 
exenatide. *** P < 0.001 showing significant increase in insulin secretion levels at all 
concentrations (10
-12
, 10
-9
 and 10
-6
 M) of exenatide compared to basal insulin secretion. 
Data are mean ± SEM, n = 10 rats for each point. 
 
3.4.4 Effect of exenatide on insulin secretion from pancreatic fragments of diabetic 
rats 
Figure 3.26 shows insulin release after incubation of pancreatic tissue fragments of 
diabetic rats with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of exenatide. The result 
is compared to that of basal secretion. The results show that exenatide can evoke 
markedly significant increase (p < 0.001) in insulin secretion from pancreatic fragments 
of diabetic rats at all concentrations (10
-12
, 10
-9
 and 10
-6
 M) of exenatide compared to 
basal insulin secretion. The maximal effect was obtained with 10
-6
 M of exenatide. Data 
are mean ± SEM, n = 10 rats for each point. 
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Figure 3.26: Histograms showing in vitro insulin secretion levels from pancreatic 
tissues of diabetic rats incubated with different concentrations (10
-12
, 10
-9
 or 10
-6
 M) of 
exenatide compared to the basal. *** P < 0.001 showing significant increase in insulin 
secretion at all concentrations (10
-12
, 10
-9
 and 10
-6
 M) of exenatide compared to basal 
insulin secretion. Data are mean ± SEM, n = 10 rats for each point. 
 
3.5 Effect of GLP-1 and exenatide treatment on the 
distribution of insulin, glucagon, GLP-1, exenatide, 
catalase and glutathione reductase immunoreactive cells 
in the pancreas of normal and diabetic rats 
3.5.1 Insulin immunoreactive cells in the pancreas of normal and diabetic rats 
Figures 3.27, 3.28, 3.29 and 3.30 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight) on the pattern of distribution of insulin 
immunoreactive cells in normal and diabetic rats. Figures 3.27 and 3.28 show the 
percentages of insulin-positive cells in normal and diabetic rats, respectively, following 
treatment with either GLP-1 or exenatide. Similarly, figures 3.29 and 3.30 show 
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micrographs of insulin immunoreactive cells of normal and diabetic rats following 
treatment with either GLP-1 or exenatide, respectively. The results show that the 
insulin-positive cells in the pancreatic islets of normal rats are distributed mainly in the 
region position compared to the peripheral portions. In contrast, the distribution of 
insulin-positive cells in diabetic rats were much fewer compared to the islets of normal 
pancreas. Treatments of normal and diabetic rats with either GLP-1 or exenatide can 
result in small significant (p < 0.05) increases in the percentage of insulin-positive cells 
in normal treated rats. Similarly, diabetic rats treated with either GLP-1 or exenatide 
show marked significant increases in insulin-positive cells (p < 0.001) and (p < 0.01), 
respectively, compared to diabetic untreated rats. GLP-1 has (3-fold) higher effect than 
exenatide on increasing the percentage of insulin immunopositive cells in diabetic rats. 
The results also show that islets from normal treated rats contain more insulin 
immunopositive cells compared to both treated and untreated diabetic rats. 
 
Figure 3.27: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
insulin-positive cells in pancreatic islets of normal rats. The data show significant 
increases * P < 0.05 in both GLP-1 and exenatide treated rats compared to normal 
untreated rats. Data are mean ± SEM, n = 10 islet/10 rats for each point. 
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Figure 3.28: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage 
distribution of insulin-positive cells in pancreatic islets of diabetic rats. The data show 
significant increases. *** P < 0.001 and ** P < 0.01 in both GLP-1 and exenatide 
treated diabetic rats, respectively compared to untreated diabetic rats. GLP-1 was about 
3-fold more effective than exenatide in increasing the number of insulin 
immunopositive cells in the treated diabetic rat pancreas. Data are mean ± SEM, n = 10 
islets/10 rats for each point. 
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Figure 3.29: Micrographs showing the distribution of insulin-positive cells in the 
pancreatic islet of normal rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Insulin-positive cells in normal 
untreated rat pancreas, (B) insulin-positive cells in normal GLP-1-treated rats and (C) 
insulin-positive cells in normal exenatide-treated rats. Magnification: X 400. 
105 
 
 
 
Figure 3.30: Micrographs showing the distribution of insulin-positive cells in the 
pancreatic islet of diabetic rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Insulin-positive cells in untreated 
diabetic rat pancreas, (B) insulin-positive cells in GLP-1-treated diabetic rats and (C) 
insulin-positive cells in exenatide-treated diabetic rats. Magnification: X 400. Note the 
decreased distribution of insulin-positive cells in the islets of diabetic rats compared to 
islets of normal control rats in both treated and untreated conditions (see Figure 3.33). 
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3.5.2 Glucagon immunoreactive cells in the pancreas of normal and diabetic rats 
Figures 3.31, 3.32, 3.33 and 3.34 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight), on the distribution of glucagon 
immunoreactive cells in islets of normal and diabetic rats. The percentages of glucagon-
positive cells of treated and untreated normal and diabetic rats are shown in figures 3.31 
and 3.32, respectively. In addition, figures 3.33 and 3.34 show the micrographs of 
normal and diabetic rats. The results showed that glucagon-positive cells were the 
second most commonly occurring cells in the normal endocrine pancreas and were 
located mainly in the peripheral part of the islet of Langerhans. Solitary glucagon-
positive cells were found scattered throughout normal islets. In the diabetic pancreas, 
the number of glucagon immunoreactive cells increased with abnormal pattern of 
distribution when compared to the normal islets. Moreover, glucagon-positive cells 
were located in both the peripheral and the central regions of the diabetic rat islets. 
There was a marked significant increase in the number of glucagon-positive cells in the 
diabetic rat pancreas compared to normal rats. Both GLP-1 and exenatide-treated 
normal rats showed significant (p < 0.05; p < 0.01) reduction in the percentage of 
glucagon-positive cells, respectively, compared to untreated normal rats. In addition, 
GLP-1 and exenatide treated diabetic rats showed significant (p < 0.001) reduction in 
the percentage of glucagon-positive cells compared to untreated diabetic rats.  
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Figure 3.31: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
glucagon-positive cells in pancreatic islets of normal rats. * P < 0.05 and ** P < 0.01 
for treated rats compared to untreated rats. Data are mean ± SEM, n = 10 islets/10 rats 
for each point. 
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Figure 3.32: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
glucagon-positive cells in pancreatic islets of diabetic rats. *** P < 0.001 for treated 
rats compared to untreated diabetic rats. Note the significant reductions in glucagon-
positive cells in diabetic rats following either GLP-1 or exenatide treatment compared 
to untreated rats. Data are mean ± SEM, n = 10 islets/10 rats for each point. 
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Figure 3.33: Micrographs showing the distribution of glucagon-positive cells in the 
pancreatic islet of normal rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Glucagon-positive cells in untreated 
normal rat pancreas, (B) glucagon-positive cells in normal GLP-1-treated rats and (C) 
glucagon-positive cells in normal exenatide-treated rats.  Magnification: X 400. 
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Figure 3.34: Micrographs showing the distribution of glucagon-positive cells in the 
pancreatic islet of diabetic rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Glucagon-positive cells in untreated 
diabetic rat pancreas, (B) glucagon-positive cells in GLP-1-treated diabetic rats and (C) 
glucagon-positive cells in exenatide-treated diabetic rats.  Magnification: X 400. 
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3.5.3 GLP-1 immunoreactive cells in the pancreas of normal and diabetic rats 
Figures 3.35, 3.36, 3.37 and 3.38 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight), on percentage distribution of GLP-1 
immunoreactive cells in normal and diabetic rats. The percentages of GLP-1-positive 
cells are shown in figures 3.35 and 3.36 while the micrographs are shown in figures 
3.41 and 3.42 for treated and untreated normal and diabetic rats, respectively. The 
results presented in figures 3.37 and 3.38 show that treatment of normal and diabetic 
rats with either GLP-1 or exenatide caused significant (P < 0.01) increases in the 
percentage of GLP-1-positive cells in treated normal and diabetic rats compared to 
untreated rats. In relation to the morphology, the results show that GLP-1-positive cells 
are more prominent in the peripheral edges of the islets. The pancreatic islets of 
diabetic rats contain more GLP-1-positive cells than the pancreatic islets of normal rats 
(see figures 3.37 and 3.38).  
 
 
Figure 3.35: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
GLP-1-positive cells in pancreatic islets of normal rats. ** P < 0.01 for treated normal 
rats compared to normal untreated rats. Data are mean ± SEM, n = 10 islets/10 rats for 
each point. 
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Figure 3.36: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
GLP-1-positive cells in pancreatic islets of diabetic rats. ** P < 0.01 for treated diabetic 
rats compared to diabetic untreated rats. Data are mean ± SEM, n = 10 islets/10 rats for 
each point.  
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Figure 3.37: Micrographs showing the distribution of GLP-1-positive cells in the 
pancreatic islet of normal rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) GLP-1-positive cells in normal untreated 
rat pancreas, (B) GLP-1-positive cells in normal GLP-1-treated rats and (C) GLP-1-
positive cells in normal exenatide-treated rats. Magnification: X 400. 
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Figure 3.38: Micrographs showing the distribution of GLP-1-positive cells in the 
pancreatic islet of diabetic rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) GLP-1-positive cells in diabetic 
untreated rat pancreas, (B) GLP-1-positive cells in diabetic GLP-1-treated rats and (C) 
GLP-1-positive cells in diabetic exenatide-treated rats. Magnification: X 400.  
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3.5.4 Exenatide immunoreactive cells in the pancreas of normal and diabetic rats 
Figures 3.39, 3.40, 3.41 and 3.42 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight), on the percentage distribution of 
exenatide-positive cells in normal and diabetic rats. The percentage changes in 
exenatide immunoreactive-positive cells are shown in figurers 3.39 and 3.40 while the 
micrographs of exenatide immunoreactive cells for normal and diabetic rats, 
respectively, are shown in figures 3.41 and 3.42. The results show that in normal rats, 
neither GLP-1 nor exenatide can evoke any detectable changes in the percentage of 
exenatide-positive cells compared to untreated normal rats. However, in diabetic rats, 
either GLP-1 or exenatide produces significant (p < 0.05 and p < 0.01) increase, 
respectively, in the percentage of exenatide immunoreactive cells compared to 
untreated diabetic rats. The results of this study also show that islet from untreated and 
treated diabetic rats contain more exenatide immunoreactive cells compared to 
pancreatic islets from untreated normal rats. The results from the micrographs show 
that the exenatide immunoreactive cells were more pronounced in the peripheral parts 
of the pancreatic islets in normal treated rats. On the other hand, in the islets of diabetic 
rats, the exenatide immunoreactive cells were localized randomly in the islets of both 
untreated and treated diabetic rats.  
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Figure 3.39: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
exenatide immunoreactive cells in pancreatic islets of normal rats. Note that there was 
no significant change in the exenatide-positive cells when comparing treated with 
untreated normal rats. Data are mean ± SEM, n = 10 islets/10 rats for each point. 
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Figure 3.40: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
exenatide-positive cells in pancreatic islets of diabetic rats. * P < 0.05 and ** P < 0.01 
for both GLP-1 and exenatide treated rats compared to untreated diabetic rats. Note that 
the islets of diabetic rats have more exenatide immunoreactive cells compared to the 
pancreatic islets of normal rats in both treated and untreated conditions. Data are mean 
± SEM, n = 10 islets/10 rats for each point. 
 
 
 
* 
** 
0
10
20
30
40
50
60
70
80
90
Diabetic Untreated Diabetic GLP-1
Treated
Diabetic Exenatide
Treated
%
  o
f 
Ex
e
n
at
id
e
-P
o
si
ti
ve
 C
e
lls
 
118 
 
 
 
Figure 3.41: Micrographs showing the distribution of exenatide-positive cells in the 
pancreatic islet of normal rats. The micrographs are typical of different experiments 
taken from 10 rats in each group. (A) Exenatide-positive cells in untreated diabetic rat 
pancreas, (B) exenatide-positive cells in GLP-1-treated diabetic rats and (C) exenatide-
positive cells in exenatide-treated diabetic rats. Magnification: X 400. Note that the 
exenatide immunoreactive cells are more pronounced in the peripheral parts of the 
islets.  
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Figure 3.42: Micrographs showing the distribution of exenatide-positive cells in the 
pancreatic islet of diabetic rats. Micrographs are typical of 10 such different 
experiments taken from 10 rats. (A) Exenatide-positive cells in untreated diabetic rat 
pancreas, (B) exenatide-positive cells in GLP-1-treated diabetic rats and (C) exenatide-
positive cells in exenatide-treated diabetic rats. Magnification: X 400. Note that the 
exenatide immunoreactive cells are localised all over the pancreatic islets of the 
diabetic rats. 
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3.5.5 Catalase immunoreactive cells in the pancreas of normal and diabetic rats 
Figures 3.43, 3.44, 3.45 and 3.46 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight), on catalase immunoreactive cells in 
normal and diabetic rats. The percentage of immunoreactive catalase-positive cells are 
shown in figures 3.43 and 3.44 while the micrographs of immunoreactive catalase-
positive cells are shown in figures 3.45 and 3.46 for normal and diabetic rats. The 
results for normal rats show that neither GLP-1 nor exenatide had any significant effect 
on the number of catalase-positive cells. However, diabetic rats treated with either 
GLP-1 or exenatide showed significant (p < 0.001) increases in the percentage of 
catalase-positive cells compared to untreated diabetic rats. The results presented in 
figures 3.43 and 3.44 show that the islets of normal rats contain more immunoreactive 
catalase-positive cells compared to the islet of diabetic rats in both treated and untreated 
conditions. Moreover, in the islets of treated and untreated normal rats, the number of 
immunoreactive catalase-poistive cells was more prominent at the periphery of the 
islets. In contrast, in the islets of the diabetic pancreas, the immunoreactive catalase-
positive cells were distributed randomly in the islets of both untreated and treated 
diabetic rats. 
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Figure 3.43: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
catalase-positive cells in pancreatic islets of normal rats. Note that both GLP-1 and 
exenatide had no significant effect on the percentage of catalase-positive cells in 
normal treated rats compared to normal untreated rats. Data are mean ± SEM, n = 10 
islets/10 rats for each point. 
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Figure 3.44: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the percentage of 
catalase-positive cells in pancreatic islets of diabetic rats. *** P < 0.001 for GLP-1 and 
exenatide treated rats compared to untreated diabetic rats. Data are mean ± SEM. Note 
that both GLP-1 and exenatide can evoke significant increases in the percentage of 
catalase-positive cells in diabetic treated rats compared to diabetic untreated rats. n = 10 
islets/10 rats for each point. 
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Figure 3.45: Micrographs showing the distribution of catalase-positive cells in the 
pancreatic islet of normal rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Catalase-positive cells in normal 
untreated rat pancreas, (B) catalase-positive cells in normal GLP-1-treated rats and (C) 
catalase-positive cells in normal exenatide-treated rats; Magnification: X 400. Note the 
increase in catalase-positive cells in B and C compared to A and these cells are more 
prominent at the periphery of the islets. 
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Figure 3.46: Micrographs showing the distribution of catalase-positive cells in the 
pancreatic islet of diabetic rats. The micrographs are typical of similar micrographs 
taken from 10 different rats in each group. (A) Catalase-positive cells in untreated 
diabetic rat pancreas, (B) catalase-positive cells in GLP-1-treated diabetic rats and (C) 
catalase-positive cells in exenatide-treated diabetic rats. Magnification: X 400. Note the 
increase in catalase-positive cells in B and C compared to A and these cells are 
distributed randomly throughout the islets. 
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3.5.6 Glutathione reductase immunoreactive cells in the pancreas of normal and 
diabetic rats 
Figures 3.47, 3.48, 3.49 and 3.50 show the effect of either GLP-1 (50 nmol/kg body 
weight) or exenatide (1 μg/kg body weight), on glutathione reductase (GSH) 
immunoreactive cells in normal and diabetic rats. The percentage of changes in 
glutathione reductase-positive cells are shown in figures 3.47 and 3.48 for normal and 
diabetic rats while the micrographs are shown in figures 3.49 and 3.50, respectively. 
Both GLP-1 and exenatide treated normal rats showed no significant increase in the 
percentage of glutathione reductase-positive cells compared to untreated control rats. In 
contrast, in the islets of diabetic rat treated with either GLP-1 or exenatide, there were 
significant (P < 0.001 and P < 0.01) increases, respectively, in the number of GSH 
immunoreactive cells compared to normal untreated rats. The results also show that 
pancreatic islets of normal rats contain more GSH immunoreactive cells compared to 
pancreatic islets of diabetic rats in both treated and untreated conditions. The results 
presented in figures 3.49 and 3.50 also show that GSH immunoreactive cells were 
distributed more prominently at the peripheral parts of the islets of normal rats. In 
contrast, in the pancreatic islets of diabetic rats, GSH immunoreactive cells were 
distributed randomly.  
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Figure 3.47: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on percentage of 
glutathione reductase (GSH)-positive cells in pancreatic islets of normal rats. Note the 
small increases in the percentage of GSH cells in GLP-1 and exenatide treated normal 
rats compared to normal untreated rats. Data are mean ± SEM, n = 10 islets/10 rats for 
each point. 
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Figure 3.48: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on percentage of 
glutathione reductase (GSH)-positive cells in pancreatic islets of diabetic rats. *** P < 
0.001 and ** P < 0.01 for treated diabetic rats with both GLP-1 and exenatide, 
respectively, compared to diabetic untreated rats. Data are mean ± SEM, n = 10 
islets/10 rats for each point. 
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Figure 3.49: Micrographs showing the distribution of glutathione reductase (GSH)-
positive cells in the pancreatic islet of normal rats. The micrographs are typical of 
similar micrographs taken from 10 different rats in each group. (A) GSH-positive cells 
in untreated normal rat pancreas, (B) GSH-positive cells in normal, GLP-1-treated rats 
and (C) GSH-positive cells in normal, exenatide-treated rats; Magnification: X 400.  
Note the distribution and increases in GSH-positive cells in B and C compared to A. 
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Figure 3.50: Micrographs showing the distribution of glutathione reductase (GSH)-
positive cells in the pancreatic islet of diabetic rats. The micrographs are typical of 
similar micrographs taken from 10 different rats in each group. (A) GSH-positive cells 
in untreated diabetic rat pancreas, (B) GSH-positive cells in GLP-1-treated diabetic rats 
and (C) GSH-positive cells in exenatide-treated diabetic rats. Magnification: X 400. 
Note the distributions and increases in GSH-positive cells in B and C compared to A. 
GSH immunoreactive cells seem to be distributed randomly all over the islets in the 
diabetes rats compared to the islet normal rat, where they were localised more 
prominent at the periphery.   
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3.6 Co-localization of insulin and GLP-1 cells in the 
pancreatic islet of normal and diabetic rats 
3.6.1 The distribution of insulin and GLP-1 cells in the pancreatic islet of normal 
rats 
Figure 3.51 shows the immunofluorescence double labelling method for the co-
localization of insulin (green) cells (A) and GLP-1 (red) cells (B) and (C) shows the  
merging of the two cell types in normal rats in (1) untreated normal rat, (2) GLP-1 
treated normal rat and (3) exenatide treated normal rat. This figure shows that GLP-1 is 
randomly localized in the islet cells with both insulin and glucagon. The islets of 
untreated normal rats contained fewer either insulin-positive cells in (A1) or GLP-1-
positive cells (B1) compared to treated rats. The number of insulin cells increased in 
normal rats treated with either GLP-1 (A2) or exenatide (A3). A similar increase in 
GLP-1 stained cells was detected in normal rats treated with either GLP-1 (B2) or 
exenatide (B3). 
 
3.6.2 The distribution of insulin with GLP-1 cells in the pancreatic islet of diabetic 
rats 
Figure 3.52 shows the immunofluorescence double labelling method for the co-
localization of insulin (green) cells (A) with GLP-1 (red) cells (B) and (C) the merging 
of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 treated 
diabetic rat (3) exenatide treated diabetic rat. This figure shows that GLP-1 is randomly 
co-localized with insulin and glucagon in pancreatic islets. The islets of untreated 
diabetic rats contained fewer either insulin-positive cells in (A1) or GLP-1-positive 
cells in (B1) compared to treated rats. The number of insulin cells increased in diabetic 
rats treated with either GLP-1 (A2) or exenatide (A3). Similar increase in GLP-1 
stained cells was detected in diabetic rats treated with either GLP-1 (B2) or exenatide 
(B3).  
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Figure 3.51: Micrographs of immunofluorescence double labelling showing the 
distribution of (A) insulin cells (green) and (B) glucagon like peptide-1 cells  (red) in 
the pancreatic islet of normal rats while (C) shows the merging of the two cell types. 
The micrographs are typical of 10 different experiments taken from 10 different rats in 
each group. Magnification: X 400. N (normal rats), insulin (INS), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated normal rat (1), 
GLP-1 treated normal rats (2) and exenatide normal treated rats (3).  
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Figure 3.52: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) glucagon like peptide-1 cells (red) in 
the pancreatic islet of diabetic rats while (C) shows the merging of the two cell types. 
The micrographs are typical of 10 different experiments taken from 10 different rats in 
each group. Magnification: X 400. Diabetic rats (D), insulin (INS), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated diabetic rat (1), 
GLP-1 treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.3 The distribution of insulin with exenatide cells in the pancreatic islet of normal 
rats 
Figure 3.53 shows the immunofluorescence double labelling method for the co-
localization of insulin (green) cells (A) and exenatide (red) cells (B) and (C) the 
merging of the two cell types in normal rats in (1) untreated normal rat (2) GLP-1 
treated normal rat (3) exenatide treated normal rat. This figure shows that exenatide is 
randomly co-localized with both insulin and glucagon in pancreatic islets. The islets of 
untreated normal rats contained fewer either insulin-positive cells in (A1) or exenatide-
positive cells (B1) compared to treated rats. The number of insulin cells increased in 
normal rats treated with either GLP-1 (A2) or exenatide (A3). Similar increase in 
exenatide stained cells was detected in normal rats treated with either GLP-1 (B2) or 
exenatide (B3). 
 
3.6.4 The distribution of insulin with exenatide cells in the pancreatic islet of diabetic 
rats 
Figure 3.54 shows the immunofluorescence double labelling  method for the co-
localization of insulin (green) cells (A) and exenatide (red) cells (B) and (C) the 
merging of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 
treated diabetic rat (3) exenatide treated diabetic rat. This figure shows that exenatide is 
randomly co-localized with insulin islet cells. The islets of untreated diabetic rats 
contained fewer either insulin-positive cells in (A1) or exenatide-positive cells in (B1) 
compared to treated rats. The number of insulin cells increased in diabetic rats treated 
with either GLP-1 (A2) or exenatide (A3). Similar increase in exenatide stained cells 
was detected in diabetic rats treated with either GLP-1 (B2) or exenatide (B3). 
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Figure 3.53: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) exenatide cells (red) in the pancreatic 
islet of normal rats while (C) shows the merging of the two cell types. The micrographs 
are typical of similar micrographs taken from 10 different rats in each group. 
Magnification: X 400. Normal rats (N), insulin (INS), glucagon like peptide-1 (GLP-1), 
exenatide (EXN), merged cells (Merg), untreated normal rat (1), GLP-1 treated normal 
rats (2) and exenatide normal treated rats (3). 
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Figure 3.54: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) exenatide cells (red) in the pancreatic 
islet of diabetic rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), insulin (INS), glucagon like peptide-1 
(GLP-1), exenatide (EXN), merged cells (Merg), untreated diabetic rat (1), GLP-1 
treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.5 The distribution of glucagon with GLP-1 cells in the pancreatic islet of normal 
rats 
 
Figure 3.55 shows the immunofluorescence double labelling method for the co-
localization of glucagon (green) cells (A) GLP-1 (red) cells (B) and (C) the merging of 
the two cell types in normal rats in (1) untreated normal rat (2) GLP-1 treated normal 
rat (3) exenatide treated normal rat. This figure shows that GLP-1 is randomly co-
localized with both insulin and glucagon in pancreatic islets. The number of glucagon-
positive cells decreased in normal rats treated with either GLP-1 (A2) or exenatide 
(A3). An increase in GLP-1 stained cells was detected in normal rats treated with either 
GLP-1 (B2) or exenatide (B3). 
 
3.6.6 The distribution of glucagon with GLP-1 cells in the pancreatic islet of diabetic 
rats 
Figure 3.56 shows the immunofluorescence double labelling method for the co-
localization of glucagon (green) cells (A) and GLP-1 (red) cells (B) and (C) the 
merging of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 
treated diabetic rat (3) exenatide treated diabetic rat. This figure shows that GLP-1 is 
randomly co-localized with both insulin and glucagon in pancreatic islets. The number 
of glucagon cells decreased in diabetic rats treated with either GLP-1 (A2) or exenatide 
(A3). An increase in GLP-1 stained cells was detected in diabetic rats treated with 
either GLP-1 (B2) or exenatide (B3). 
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Figure 3.55: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) glucagon like peptide-1 cells (red) in 
the pancreatic islet of normal rats while (C) shows the merging of the two cell types. 
The micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Normal rats (N), glucagon (GLCG), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated normal rat (1), 
GLP-1 treated normal rats (2) and exenatide normal treated rats (3). 
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Figure 3.56: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) glucagon like peptide-1 cells  (red) in 
the pancreatic islet of diabetic rats while (C) shows the merging of the two cell types. 
The micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), glucagon (GLCG), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated diabetic rat (1), 
GLP-1 treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.7 The distribution of glucagon with exenatide cells in the pancreatic islet of 
normal rats 
Figure 3.57 shows the immunofluorescence double labelling method for the co-
localization of glucagon (green) cells (A) and exenatide (red) cells (B) and (C) the 
merging of the two cell types in normal rats in (1) untreated normal rat (2) GLP-1 
treated normal rat (3) exenatide treated normal rat. This figure shows that exenatide is 
co-localized with both insulin and glucagon in pancreatic islets. The number of 
glucagon cells decreased in normal rats treated with either GLP-1 (A2) or exenatide 
(A3). An increase of exenatide stained cells was detected in normal rats treated with 
either GLP-1 (B2) or exenatide (B3). 
 
3.6.8 The distribution of glucagon with exenatide cells in the pancreatic islet of 
diabetic rats 
Figure 3.58 shows the immunofluorescence double labelling method for the co-
localization of glucagon (green) cells (A) and exenatide (red) cells (B) and (C) the 
merging of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 
treated diabetic rat (3) exenatide treated diabetic rat. This figure shows that exenatide 
randomly co-localized with both insulin and glucagon in pancreatic islets. The number 
of glucagon cells decreased in diabetic rats treated with either GLP-1 (A2) or exenatide 
(A3). An increase in exenatide stained cells was detected in diabetic rats treated with 
either GLP-1 (B2) or exenatide (B3). 
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Figure 3.57: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) exenatide cells (red) in the pancreatic 
islet of normal rats while (C) shows the merging of the two cell types. The micrographs 
are typical of similar micrographs taken from 10 different rats in each group. 
Magnification: X 400. Normal rats (N), glucagon (GLCG), glucagon like peptide-1 
(GLP-1), exenatide (EXN), merged cells (Merg), untreated normal rat (1), GLP-1 
treated normal rats (2) and exenatide normal treated rats (3). 
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Figure 3.58: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B)  exenatide cells (red) in the pancreatic 
islet of diabetic rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), glucagon (GLGC), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated diabetic rat (1), 
GLP-1 treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.9 The distribution of insulin with catalase in the pancreatic islet of normal rats 
 
Figure 3.59 shows the immunofluorescence double labelling method for the co-
localization of insulin (green) cells (A) and catalase (red) cells (B) and (C) the merging 
of the two cell types in normal rats in (1) untreated normal rat (2) GLP-1 treated normal 
rat (3) exenatide treated normal rat. This figure shows that catalase is co-localized with 
both insulin and glucagon in pancreatic islets. The islets of untreated normal rats 
contained fewer either insulin-positive cells in (A1) or catalase-positive cells in (B1) 
compared to treated rats. The number of insulin cells increased in normal rats treated 
with either GLP-1 (A2) or exenatide (A3). Similar increase in catalase stained cells was 
detected in normal rats treated with either GLP-1 (B2) or exenatide (B3). 
 
3.6.10 The distribution of insulin with catalase in the pancreatic islet of diabetic rats 
 
Figure 3.60 shows the immunofluorescence double labelling for the co-localization of 
pancreatic insulin (green) cells (A) and catalase (red) cells (B) and (C) the merging of 
the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 treated diabetic 
rat (3) exenatide treated diabetic rat. This figure shows that catalase is randomly co-
localized with both insulin and glucagon in pancreatic islets. The islets of untreated 
diabetic rats contained fewer either insulin-positive cells in (A1) or catalase-positive 
cells in (B1) compared to treated rats. The number of insulin immunoreactive cells 
increased in diabetic rats after treatment with either GLP-1 (A2) or exenatide (A3). 
Similar increase in catalase stained cells was detected in diabetic rats treated with either 
GLP-1 (B2) or exenatide (B3). 
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Figure 3.59: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) catalase cells (red) in the pancreatic 
islet of normal rats while (C) shows the merging of the two cell types. The micrographs 
are typical of similar micrographs taken from 10 different rats in each group. 
Magnification: X 400. Normal rats (N), insulin (INS), catalase (CAT), glucagon like 
peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated normal rat (1), 
GLP-1 treated normal rats (2) and exenatide normal treated rats (3). 
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Figure 3.60: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) catalase cells (red) in the pancreatic 
islet of diabetic rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), insulin (INS), catalase (CAT), glucagon 
like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated diabetic rat 
(1), GLP-1 treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.11 The distribution of insulin with glutathione reductase in the pancreatic islet of 
normal rats 
Figure 3.61 shows the immunofluorescence double labelling images for the co-
localization of  insulin (green) cells (A) and glutathione reductase (red) cells (B) and 
(C) the merging of the two cell types in normal rats in (1) untreated normal rat (2) GLP-
1 treated normal rat (3) exenatide treated normal rat. This figure shows that glutathione 
reductase is co-localized with both insulin and glucagon in pancreatic islets. The islets 
of untreated normal rats contained fewer either insulin-positive cells in (A1) or 
catalase-positive cells in (B1) compared to treated rats. The number of insulin-positive 
cells increased in normal rats treated with either GLP-1 (A2) or exenatide (A3). Similar 
increase in glutathione reductase stained cells was detected in normal rats treated with 
either GLP-1 (B2) or exenatide (B3). 
 
3.6.12 The distribution of insulin with glutathione reductase in the pancreatic islet of 
diabetic rats 
Figure 3.62 shows the immunofluorescence double labelling images for the co-
localization of insulin (green) (A) and glutathione reductase (red) (B) and (C) the 
merging of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 
treated diabetic rat (3) exenatide treated diabetic rat. This figure shows that glutathione 
reductase is randomly co-localized with both insulin and glucagon in pancreatic islets. 
The islets of untreated diabetic rats contained fewer either insulin-positive cells in (A1) 
or catalase-positive cells in (B1) compared to treated rats. The number of insulin 
immunoreactive cells increased in diabetic rats treated with either GLP-1 (A2) or 
exenatide (A3). Similar increase in glutathione reductase stained cells were detected in 
diabetic rats treated with either GLP-1 (B2) or exenatide (B3). 
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Figure 3.61: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) glutathione reductase cells (red) in the 
pancreatic islet of normal rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Normal rats (N), insulin (INS), glutathione reductase 
(GSH), glucagon like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), 
untreated normal rat (1), GLP-1 treated normal rats (2) and exenatide normal treated 
rats (3). 
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Figure 3.62: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) insulin cells (green) and (B) glutathione reductase cells (red) in the 
pancreatic islet of diabetic rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), insulin (INS), glutathione reductase 
(GSH), glucagon like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), 
untreated diabetic rat (1), GLP-1 treated diabetic rats (2) and exenatide diabetic treated 
rats (3). 
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3.6.13 The distribution of glucagon with catalase in the pancreatic islet of normal 
rats 
Figure 3.63 shows the immunofluorescence double labelling for the co-localization of 
glucagon (green) cells (A) and  catalase (red) cells (B) and (C) the merging of the two 
cell types in normal rats in (1) untreated normal rat (2) GLP-1 treated normal rat (3) 
exenatide treated normal rat. This figure shows that catalase is co-localized with both 
insulin and glucagon in pancreatic islet cells. Many cells contain either glucagon (A1) 
or catalase (B1) in normal untreated rats. The number of glucagon cells seemed to 
decrease in normal rats treated with either GLP-1 (A2) or exenatide (A3). An increase 
in catalase stained cells was detected in normal rats treated with either GLP-1 (B2) or 
exenatide (B3). 
 
3.6.14 The distribution of glucagon with catalase in the pancreatic islet of diabetic 
rats 
Figure 3.64 shows the immunofluorescence double labelling images for the co-
localization of glucagon (green) cells (A) or catalase (red) cells (B) and (C) the merging 
of the two cell types in diabetic rats in (1) untreated diabetic rat (2) GLP-1 treated 
diabetic rat (3) exenatide treated diabetic rat. This figure shows that catalase is 
randomly co-localized with insulin and glucagon in the pancreatic islets. Fewer cells 
contain either glucagon (A1) or catalase (B1) in untreated diabetic rats. The number of 
glucagon cells seemed to decrease in diabetic rats treated with either GLP-1 (A2) or 
exenatide (A3). An increase in catalase stained cells was detected in diabetic rats 
treated with either GLP-1 (B2) or exenatide (B3). 
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Figure 3.63: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) catalase cells  in the pancreatic islet 
of normal rats while (C) shows the merging of the two cell types. The micrographs are 
typical of similar micrographs taken from 10 different rats in each group. 
Magnification: X 400. Normal rats (N), glucagon (GLCG), catalase (CAT), glucagon 
like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated normal rat 
(1), GLP-1 treated normal rats (2) and exenatide normal treated rats (3). 
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Figure 3.64: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) catalase cells (red) in the pancreatic 
islet of diabetic rats while (C) shows the merging of the two cell types. The 
micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), glucagon (GLCG), catalase (CAT), 
glucagon like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), untreated 
diabetic rat (1), GLP-1 treated diabetic rats (2) and exenatide diabetic treated rats (3). 
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3.6.15 The distribution of glucagon with glutathione reductase in the pancreatic islet 
of normal rats 
Figure 3.65 shows the immunofluorescence double labelling  images for the co-
localization of glucagon (green) cells (A) and glutathione reductase (red) cells (B) and 
(C) the merging of the two cell types in normal rats in (1) untreated normal rat (2) GLP-
1 treated normal rat (3) exenatide treated normal rat. This figure shows that glutathione 
reductase is co-localized with both insulin and glucagon in pancreatic islets. Some cells 
contain either glucagon (A1) or catalase (B1) in untreated normal rats. The number of 
glucagon-positive cells seemed to decrease in normal rats treated with either GLP-1 
(A2) or exenatide (A3). An increase in glutathione reductase stained cells was detected 
in normal rats treated with either GLP-1 (B2) or exenatide (B3). 
 
3.6.16 The distribution of glucagon with glutathione reductase in the pancreatic islet 
of diabetic rats 
 
Figure 3.66 shows the immunofluorescence double labelling  images for the co-
localization of glucagon (green) cells (A) and glutathione reductase (red) cells (B) and 
(C) the merging of the two cell types in diabetic rats in (1) untreated diabetic rat (2) 
GLP-1 treated diabetic rat (3) exenatide treated diabetic rat. This figure shows that 
glutathione reductase is randomly co-localized with both insulin and glucagon in 
pancreatic islets. Few cells contain either glucagon (A1) or catalase (B1) in untreated 
diabetic rats. The number of glucagon cells seemed to decrease in diabetic rats treated 
with either GLP-1 (A2) or exenatide (A3). However, an increase in glutathione 
reductase stained cells was also detected in diabetic rats treated with either GLP-1 (B2) 
or exenatide (B3). 
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Figure 3.65: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) glutathione reductase cells (red) in 
the pancreatic islet of normal rats while (C) shows the merging of the two cell types. 
The micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Normal rats (N), glucagon (GLCG), glutathione reductase 
(GSH), glucagon like peptide-1 (GLP-1), exenatide (EXN), merged cells (Merg), 
untreated normal rat (1), GLP-1 treated normal rats (2) and exenatide normal treated 
rats (3). 
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Figure 3.66: Micrographs of immunofluorescence double labelling  showing the 
distribution of (A) glucagon cells (green) and (B) glutathione reductase cells (red) in 
the pancreatic islet of diabetic rats while (C) shows the merging of the two cell types. 
The micrographs are typical of similar micrographs taken from 10 different rats in each 
group. Magnification: X 400. Diabetic rats (D), glucagon (GLCG), glutathione 
reductase (GSH), glucagon like peptide-1 (GLP-1), exenatide (EXN), merged cells 
(Merg), untreated diabetic rat (1), GLP-1 treated diabetic rats (2) and exenatide diabetic 
treated rats (3). 
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3.7 Electron microscopic study 
3.7.1 Electron microscopy of islet β-cells of untreated normal and diabetic rats 
Figure 3.67 shows electron micrographs of β-cells in the pancreas of normal (A) and 
diabetic (B) rats. The results reveal that the β-cells are the most numerous cell type in 
the endocrine pancreas. They have secretory granules with a diameter of 400 nm. These 
insulin secretory granules are oval to round in shape with a dense core. The dense core 
of these granules is surrounded by relatively a large halo area. Other cytoplasmic 
organelles including mitochondria, rough and smooth endoplasmic reticulum and Golgi 
apparatus were dispersed between the secretory granules. The ultrastructure of 
pancreatic β-cells in the diabetic pancreas was displayed by loss of nuclear envelope, 
mitochondrial vacuolization, swelling and dilatation of the endoplasmic reticulum. It 
was noticed that the secretory granules were scanty and they seem to be scattered 
between a large numbers of empty vesicles and moreover, they are significantly fewer 
than those found in normal rat pancreas. 
 
3.7.2 Electron microscopy of islet β-cells in normal and diabetic rats treated with   
GLP-1 
Figure 3.68 shows electron micrographs of β-cells in the pancreas of GLP-1 treated 
normal rats (A). These β-cells show many intact and abundant secretory granules. In 
contrast, the β-cells of diabetic rats (B) treated with GLP-1 show few secretory 
granules. From this figure, it can be noted that, treatment of normal and diabetic rats 
with GLP-1 increased the number of insulin secretory granules and GLP-1 was more 
effective in increasing the number of insulin secretory granules in the pancreas of 
normal rats compared to diabetic rats. 
 
3.7.3 Electron microscopy of the islet β-cells of diabetic and normal rats treated with 
exenatide 
Figure 3.69 shows the electron micrographs of β-cells in the pancreas of exenatide 
treated normal rats (A) and (B) exenatide treated diabetic rats. The results show that 
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many intact and abundant secretory granules were found in β-cells of exenatide treated 
normal rats. In contrast, in diabetic rats treated with exenatide, there were fewer 
secretory granules. From this figure, it can be noted that, treatment of normal and 
diabetic rats with exenatide resulted in an increase in the number of insulin secretory 
granules. However, this increase was much more pronounced in the β-cells of exenatide 
treated normal rats compared to islet cells of diabetic rats treated with exenatide.  
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Figure 3.67: Electron micrographs showing (A) β-cell of normal untreated rats with 
intact secretory granules (large arrow) and (B) β-cell of untreated diabetic rat with an 
empty secretory granule (small arrow). The electron micrographs are typical of 10 such 
different experiments taken from 10 different rats in each group. Magnification: X 
14,000. 
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Figure 3.68: Electron micrographs showing (A) β-cell of GLP-1 treated normal rats 
with intact secretory granule (large arrow) and (B) β-cell of GLP-1 treated diabetic rats 
with some secretory granules (small arrow). The electron micrographs are typical of 10 
such different experiments taken from 10 different rats in each group. Magnification: X 
14,000. 
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Figure 3.69: Electron micrographs showing (A) β-cell of exenatide treated normal rats 
with a large number of intact secretory granules after exenatide treatment (large arrows) 
and (B) β-cell of exenatide treated diabetic rats with some secretory granules (small 
arrows) after exenatide treatment. The electron micrographs are typical of 10 such 
different experiments taken from 10 different rats in each group. Magnification: X 
14,000. 
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3.7.4  Immunogold double labelling of insulin and GLP-1 in β-cells of pancreatic 
islets of normal and diabetic rats 
Figure 3.70 shows immunoelectron microscopy of insulin and GLP-1 in pancreatic β-
cells of normal (A) and diabetic (B) rats. The number of insulin secretory granules in 
normal rats was much greater than in diabetic rats. In addition, normal and diabetic rats 
showed insulin secretory granules (20 nm gold particles) with GLP-1 (15 nm gold 
particles). This indicates that insulin and GLP-1are co-localized in pancreatic β-cells. 
 
 
3.7.5 Immunogold double labelling of insulin and exenatide in β-cells of pancreatic 
islets of normal and diabetic rats 
Figure 3.71 shows immunoelectron microscopy of insulin and exenatide in pancreatic 
β-cells of normal (A) and diabetic (B) rats. The number of insulin secretory granules in 
normal rats was much greater than in diabetic rats. Normal and diabetic rats also 
showed insulin secretory granules (20 nm gold particles) with exenatide (15 nm gold 
particles). This indicates that insulin and exenatide are co-localized pancreatic β-cells. 
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Figure 3.70: Electron micrographs showing immunogold labelling of insulin secretory 
granules in β-cells of (A) normal and (B) diabetic rats. Large arrows in (A) and (B) 
show insulin granules (20 nm gold particles) with GLP-1 (15 nm gold particles) small 
arrows. The electron micrographs are typical of 10 such different experiments taken 
from 10 different rats in each group. Magnification: X 27,500. 
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Figure 3.71: Electron micrographs showing immunogold labelling of β-cells in (A) 
normal and (B) diabetic rats. Large arrows in (A) and (B) show insulin granules (20 nm 
gold particles) with exenatide (15 nm gold particles) small arrows. The electron 
micrographs are typical of 10 such different experiments taken from 10 different rats in 
each group. Magnification: X 27,500. 
162 
 
3.7.6 Immunogold double labelling of glucagon and GLP-1 in α-cells of pancreatic 
islets of normal and diabetic rats 
Figure 3.72 shows immunogold double labelling of glucagon and GLP-1 in α-cells of 
normal (A) and diabetic (B) rats. The results show that the number of glucagon 
secretory granules in normal rats was much less than that of diabetic rats. The data also 
show that the pancreatic α-cells of normal and diabetic rats have glucagon secretory 
granules (20 nm gold particles) with GLP-1 (15 nm gold particles). This indicates that 
glucagon and GLP-1 are co-localized in pancreatic α-cell. 
 
 
3.7.7 Immunogold double labelling of glucagon and exenatide in α-cells of 
pancreatic islets of normal and diabetic rats 
Figure 3.73 shows immunogold double labelling of glucagon and exenatide in α-cells 
of pancreatic islets of normal (A) and diabetic (B) rats. The number of glucagon 
secretory granules in normal rats was much less than diabetic rats.  The results also 
reveal that normal and diabetic rats have glucagon secretory granules (20 nm gold 
particles) with exenatide (15 nm gold particles). This indicates that glucagon and 
exenatide are co-localized in pancreatic α-cells. 
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Figure 3.72: Electron micrographs showing immunogold labelling of α-cells of 
pancreatic islets in (A) normal and (B) diabetic rats. Large arrows in (A) and (B) show 
glucagon granules (20 nm gold particles) with GLP-1 (15 nm gold particles) small 
arrows. The electron micrographs are typical of 10 such different experiments taken 
from 10 different rats in each group. Magnification: X 27,500. 
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Figure 3.73: Electron micrographs showing immunogold labelling of α-cells of 
pancreatic islets in (A) normal and (B) diabetic rats. Large arrows in (A) and (B) show 
glucagon granules (20 nm gold particles) with exenatide (15 nm gold particles) small 
arrows. The electron micrographs are typical of 10 such different experiments taken 
from 10 different rats in each group. Magnification: X 27,500. 
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3.8 The effect of treatment with either GLP-1 or exenatide on 
gene expression in normal and diabetic rats. 
 
3.8.1 The effect of treatment with either GLP-1 or exenatide on pancreatic duodenal 
homeobox-1 (PDX-1) gene expression in normal and diabetic rats. 
 
Figure 3.74 shows the pancreatic duodenal homeobox-1 mRNA levels in normal rats 
treated with either GLP-1 (50 nmol/kg body weight) or exenatide (1 μg/kg body 
weight) compared to normal untreated rats, measured by relative real-time PCR and 
normalized to β-actin expression, the reference housekeeping gene. The results show 
that, there was a significant (p < 0.05) increase in the levels of pancreatic duodenal 
homeobox-1 (PDX-1) mRNA in normal rats treated with either GLP-1 or exenatide 
compared to normal untreated rats.  
  
 
Figure 3.75 shows the pancreatic duodenal homeobox-1 mRNA levels in diabetic rats 
treated with either GLP-1 or exenatide compared to untreated diabetic rats, measured 
by relative real-time PCR and normalized to β-actin expression, the reference 
housekeeping gene. The results show that, there was a small but significant (p < 0.05) 
increase in the levels of PDX-1 mRNA in diabetic rats treated with GLP-1 compared to 
diabetic untreated rats. Similarly, there was a marked and highly significant (p < 0.001) 
increase in the levels of PDX-1 mRNA in diabetic rats treated with exenatide compared 
to diabetic untreated rats. 
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Figure 3.74: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on mRNA expression of 
pancreatic duodenal homeobox-1 in treated normal rats compared to normal untreated 
rats. The level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample.  * P < 0.05 for both GLP-1 and 
exenatide treated normal rats compared to normal untreated rats. Note that the 
significant increase in gene expression after either GLP-1 or exenatide treatment. Data 
are mean ± SEM, n = 10 rats for each point. 
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Figure 3.75: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on mRNA expression of 
pancreatic duodenal homeobox-1 in treated diabetic rats compared to untreated diabetic 
rats. Level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample. * P < 0.05 and *** P < 0.001 for both 
GLP-1 and exenatide, respectively, treated diabetic rats compared to untreated diabetic 
rats. Note that exenatide elicited stronger effect compared to GLP-1 action. Data are 
mean ± SEM, n = 10 rats for each point. 
 
3.8.2 The effect of treatment with either GLP-1 or exenatide on heat shock protein-70 
(HSP-70) gene expression in normal and diabetic rats. 
Figure 3.76 shows the heat shock protein-70 mRNA levels in normal rats treated with 
either GLP-1 or exenatide compared to normal untreated rats measured by relative real-
time PCR and normalized to β-actin expression, the reference housekeeping gene. The 
results show that, there was a significant (p < 0.05) increase in the levels of heat shock 
protein-70 mRNA in normal rats treated with either GLP-1 or exenatide compared to 
normal untreated rats.  
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Figure 3.77 shows the levels of heat shock protein-70 mRNA in diabetic rats treated 
with either GLP-1 or exenatide compared to diabetic untreated rats measured by 
relative real-time PCR and normalized to β-actin expression, the reference 
housekeeping gene. The results show that there was a significant (P < 0.05; P < 0.01) 
increase in heat shock protein-70 mRNA levels in diabetic rats treated with either GLP-
1 or exenatide, respectively, compared to untreated diabetic rats. The effect of 
exenatide was much more pronounced compared to that of GLP-1. 
 
 
Figure 3.76: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of heat shock protein-70 in treated normal rats compared to untreated 
normal rats. Level of mRNA expression was measured by relative real-time PCR 
following normalization for β-actin mRNA in each sample.  * P < 0.05 for both GLP-1 
and exenatide, treated normal rats compared to normal, untreated rats. Note that both 
GLP-1 and exenatide can evoke significant increases in HSP-70 gene expression in the 
pancreas of normal treated rats compared to untreated normal rats. Data are mean ± 
SEM, n = 10 rats for each point. 
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Figure 3.77: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of heat shock protein-70 in treated diabetic rats compared to untreated 
diabetic rats. Level of mRNA expression was measured by relative real-time PCR 
following normalization for β-actin mRNA in each sample. * P < 0.05 and ** P < 0.01 
for both GLP-1 and exenatide, respectively, treated diabetic rats compared to untreated 
diabetic rats. Note that exenatide was more effective in enhancing HSP-70 mRNA 
expression compared to GLP-1. Data are mean ± SEM, n = 10 rats for each point. 
 
3.8.3 The effect of treatment with either GLP-1 or exenatide on glutathione 
peroxidase (GPx) gene expression in normal and diabetic rats. 
Figure 3.78 shows the levels of glutathione peroxidase mRNA in normal rats treated 
with either GLP-1 or exenatide compared to untreated normal rats measured by relative 
real-time PCR and normalized to β-actin expression, the reference housekeeping gene. 
The results show that both GLP-1 and exenatide can, respectively, evoke significant (p 
< 0.05; p < 0.01) increases in glutathione peroxidase mRNA expression in the pancreas 
of normal rats compared to untreated normal rats. The effect of GLP-1 was more 
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pronounced compared to exenatide on glutathione peroxidase mRNA expression in 
treated normal rats. 
 
Figure 3.79 shows the levels of glutathione peroxidase mRNA expression in diabetic 
rats treated with either GLP-1 or exenatide compared to untreated diabetic rats 
measured by relative real-time PCR and normalized to β-actin expression, the reference 
housekeeping gene. The results show a significant (p < 0.01) increase in the levels of 
glutathione peroxidase mRNA levels in diabetic rats treated with either GLP-1 or 
exenatide compared to untreated diabetic rats.    
 
 
Figure 3.78: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the levels of mRNA 
expression of glutathione peroxidase in normal treated rats compared to normal 
untreated rats. Level of mRNA expression was measured by relative real-time PCR 
following normalization for β-actin mRNA in each sample.  ** P < 0.01 for GLP-1 and 
* P < 0.05 for exenatide treated normal rats compared to normal untreated rats. Note 
that the increase in gene expression after GLP-1 treatment compared to exenatide. Data 
are mean ± SEM, n = 10 rats for each point. 
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Figure 3.79: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the levels of mRNA 
expression of glutathione peroxidase in treated diabetic rats compared to untreated 
diabetic rats. Level of mRNA expression was measured by relative real-time PCR 
following normalization for β-actin mRNA in each sample. ** P < 0.01 for both GLP-1 
and exenatide, treated diabetic rats compared to untreated diabetic rats. Data are mean ± 
SEM, n = 10 rats for each point. 
 
3.8.4 The effect of treatment with either GLP-1 or exenatide on glucagon gene 
expression in normal and diabetic rats. 
 
Figure 3.80 shows the levels of glucagon mRNA in normal rats treated with either 
GLP-1 or exenatide compared to normal untreated rats measured by relative real-time 
PCR and normalized to β-actin expression, the reference housekeeping gene. The 
results show that there was a significant (p < 0.01; p < 0.001) decrease for GLP-1 
exenatide, respectively, in the levels of glucagon mRNA expression in normal treated 
rats compared to normal untreated rats.  
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Figure 3.81 shows the levels of glucagon mRNA in diabetic rats treated with either 
GLP-1 or exenatide compared to diabetic untreated rats measured by relative real-time 
PCR and normalized to β-actin expression, the reference housekeeping gene. The 
results show that there was a significant (p < 0.001; p < 0.05) decrease for GLP-1 
exenatide, respectively, in the levels of glucagon mRNA in diabetic treated rats 
compared to diabetic untreated rats. However, the reduction in glucagon mRNA levels 
in diabetic rats treated with GLP-1 was more pronounced than exenatide treatment.   
  
 
Figure 3.80: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the levels of mRNA 
expression of glucagon in normal treated rats compared to normal untreated rats. Level 
of mRNA expression was measured by relative real-time PCR following normalization 
for β-actin mRNA in each sample.  ** P < 0.01 for GLP-1 and *** P < 0.001 for 
exenatide treated normal rats compared to normal untreated rats. Data are mean ± SEM, 
n = 10 rats for each point. 
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Figure 3.81: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on the levels of mRNA 
expression of glucagon in treated diabetic rats compared to untreated diabetic rats. 
Level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample. *** P < 0.001 for GLP-1 and * P < 
0.05 for exenatide treated diabetic rats compared to untreated diabetic rats. Note that 
GLP-1 treatment was more effective in inhibiting glucagon mRNA expression 
compared to exenatide. Data are mean ± SEM, n = 10 rats for each point.  
 
3.8.5 The effect of treatment with either GLP-1 or exenatide on insulin receptor (IR) 
gene expression in normal and diabetic rats. 
Figure 3.82 shows the levels of insulin receptor mRNA in normal rats treated with 
either GLP-1 or exenatide compared to normal untreated rats as measured by relative 
real-time PCR and normalized to β-actin expression, the reference housekeeping gene. 
The results show that there were increases in insulin receptor mRNA levels in normal 
rats treated with either GLP-1 or exenatide compared to untreated normal rats. 
However, there was a significant (p < 0.05) increase in insulin receptor mRNA 
expression for exenatide treated rats compared to untreated normal rats. 
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Figure 3.83 shows the levels of insulin receptor mRNA in diabetic rats treated with 
either GLP-1 or exenatide compared to diabetic untreated rats as measured by relative 
real-time PCR and normalized to β-actin expression, the reference housekeeping gene. 
There was a significant (p < 0.01) increase in insulin receptor mRNA levels in diabetic 
rats treated with either GLP-1 or exenatide compared to untreated diabetic rats. Both 
GLP-1 and exenatide seem to exert similar elevation in insulin receptor mRNA 
expression in treated diabetic rats.  
 
 
Figure 3.82: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of insulin receptor in normal treated rats compared to normal untreated rats. 
Level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample.  * P < 0.05 for exenatide treated 
normal rats compared to normal untreated rats. GLP-1 was able to cause a small but not 
significant increase in insulin receptor mRNA. In contrast, exenatide induced 
significant expression of insulin receptor mRNA compared to normal untreated rats. 
Data are mean ± SEM, n = 10 rats for each point. 
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Figure 3.83: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of insulin receptor in treated diabetic rats compared to untreated diabetic 
rats. Level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample. ** P < 0.01 for both GLP-1 and 
exenatide treated diabetic rats compared to untreated diabetic rats. Note that both GLP-
1 and exenatide produced more or less similar effect on insulin receptor mRNA 
expression. Data are mean ± SEM, n = 10 rats for each point. 
 
3.8.6 The effect of treatment with either GLP-1 or exenatide on glucagon like 
peptide-1 receptor (GLP-1R) gene expression in normal and diabetic rats. 
Figure 3.84 shows the levels of GLP-1R mRNA in normal rats treated with either GLP-
1 or exenatide compared to normal untreated rats measured by relative real-time PCR 
and normalized to β-actin expression, the reference housekeeping gene. The results 
show that there was a little but not significant increase in GLP-1R mRNA levels in 
normal rats treated with GLP-1 compared to normal untreated rats. However, in normal 
rats treated with exenatide there was a significant (p < 0.05) increase in GLP-1R 
mRNA expression compared to normal untreated rats.  
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Figure 3.85 shows the levels of GLP-1R mRNA in diabetic rats treated with either 
GLP-1 or exenatide compared to diabetic untreated rats measured by relative real-time 
PCR and normalized to β-actin expression, the reference housekeeping gene. The 
results reveal a significant increase (p < 0.001) in glucagon like peptide-1 receptor 
mRNA levels in GLP-1 and exenatide treated diabetic rats compared to untreated 
diabetic rats. The effect of exenatide treatment was more prominent than that of GLP-1.  
 
 
Figure 3.84: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of GLP-1 receptor in normal treated rats compared to normal untreated rats. 
Level of mRNA expression was measured by relative real-time PCR following 
normalization for β-actin mRNA in each sample. Note that the increase in GLP-1 
receptor mRNA expression after GLP-1 treatment was not significant compared to the 
normal untreated rats. In contrast, exenatide evoked significant (p < 0.05) increase in 
glucagon like peptide-1 receptor mRNA expression compared to normal untreated rats.  
Data are mean ± SEM, n = 10 rats for each point. 
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Figure 3.85: Histograms showing the effect of 10 weeks of treatment with either GLP-1 
(50 nmol/kg body weight) or exenatide (1 μg/kg body weight) on levels of mRNA 
expression of GLP-1 receptors in treated diabetic rats compared to untreated diabetic 
rats. Level of GLP-1 receptor mRNA expression was measured by relative real-time 
PCR following normalization for β-actin mRNA in each sample. *** P < 0.001 for 
GLP-1 and exenatide treated diabetic rats compared to diabetic untreated rats. Note that 
exenatide treatment was more effective than that of GLP-1 in increasing glucagon like 
peptide-1 receptor mRNA expression. Data are mean ± SEM, n = 10 rats for each point. 
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The present in vivo and in vitro studies were designed to investigate the beneficial 
effects of the two incretins, GLP-1 and its agonist, exenatide on the STZ-induced 
diabetic pancreas compared to age-matched controls. In both conditions, two control 
untreated groups of rats (normal and diabetic) did not receive either GLP-1 or 
exenatide.  
DM is a major metabolic disorder currently affecting more that 225 million people 
globally. The disease is highly prevalent globally and in the United Arab Emirates 
(UAE) in particular. A prevalence study on adults in the UAE, in which fasting blood 
glucose levels were above normal, showed that the incidence of DM was higher than 
6% (El Mugamer et al., 1995). A more recent survey suggests a much higher 
prevalence of about 20-40% of the urban adult population in the UAE (Malik et al., 
2005). 
Many T2DM complications are implicated with prolonged elevated blood glucose 
levels, pancreatic β-cell failure and insulin resistance (Bouwens and Rooman, 2005). 
Most of the available anti-diabetic drugs are involved in improvement of glucose 
tolerance, insulin secretion, insulin resistance and reducing diabetic complications. 
Recent hypoglycaemic drugs focus on inducing insulin secretion in a glucose-
dependent way (Farret et al., 2005). 
Presently, there is an increased demand for the development of new and novel 
antidiabetic drugs, which are capable not only in reducing blood glucose level in the 
body but also in inducing insulin secretion from the endocrine pancreas. Moreover, the 
drugs must also improve the β-cell functions, induce its proliferation and suppress its 
apoptosis. The discussion of this study will cover the beneficial effects of either GLP-1 
or exenatide in diabetic conditions compared to control.   
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4.1 Effect of GLP-1 and exenatide treatment on metabolic 
parameters of normal and diabetic rats 
 
In vivo study 
4.1.1 Body weight 
The results of this study have demonstrated that there was no significant body weight 
change in all normal and diabetic rats treated with either GLP-1 or exenatide. However, 
the results showed a small but not significant gain in body weight of normal treated 
rats, which was most likely due to normal body growth and ageing during the 10 weeks 
of the experiment period. All groups of were under the same conditions of open access 
to food without any restrictions and this was a constant factor for all experimental rats. 
Although, GLP-1 and exenatide suppress gastric emptying and appetite, they have the 
ability to induce insulin release and therefore improve the well-being of the animals 
(Meier et al., 2002). The secreted insulin will help in glucose absorption and therefore 
in the weight of the animal (Patel et al., 2006a). However, the effect of ageing on the 
overall weight cannot be excluded. The results of the present study are in agreement 
with previous reports in which a prolonged intracerebroventricular treatment of GLP-1 
leads to body weight gain that may be induced via GLP-1 receptors in the central 
nervous system (CNS) (Goke et al., 1995; Davis et al., 1998).  
On the other hand, the results of the present study showed a non significant body 
weight loss in diabetic rats treated with either GLP-1 or exenatide. This is in agreement 
with other studies that have reported reductions in body weight after treatment of 
diabetic models and patients with either GLP-1 or exenatide (Bergenstal et al., 2010). 
These authors suggested that GLP-1 and exenatide initiate their effects by reducing 
gastric emptying, appetite and enhancing satiety (Bloomgarden, 2004; Kaushal et al., 
2006; Murphy and Bloom, 2006; Mudaliar and Henry, 2010). The difference between 
the observations of the present study and others in the literature may be due to the 
methodology and dosage used. A relatively lower dose of 1 µg/kg/day of exenatide was 
used in the present study while a larger dose of 10 µg/kg/day of exenatide was used in 
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other study (Nachnani et al., 2010). This larger dose is 10-fold higher and may play a 
role in the magnitude of the effects caused by exenatide. In addition, the variations may 
be due to the 10-week period of treatment in the present study compared to other 
investigation with longer treatment time (3 months to 3 years ) (Klonoff et al., 2008). 
Additionally, other previous studies also documented that on the average, the reduction 
in body weight was either moderate or insignificant, while in others it was significant. 
The explanation for these differences may depend on the dose and duration of the 
study. It is suffice to say that significant body weight reduction is associated with 
higher doses and longer period of treatment of incretins (Moretto et al., 2008; Marre et 
al., 2008). 
 
4.1.2 Blood glucose level 
This study revealed no pronounced differences in fasting blood glucose levels between 
the normal rats treated with either GLP-1 or exenatide compared to normal untreated 
rats. On the other hand, the present study detected a significant reduction in fasting 
blood glucose levels in diabetic rats treated with either GLP-1 or exenatide. This 
reduction of fasting blood glucose level was consistent with other reports (Bosi et al., 
2008; Buse et al., 2009). Both GLP-1 and exenatide have insulinotropic actions since 
they can stimulate insulin secretion in glucose-dependent way. Moreover, they can 
exert their beneficial effects by increasing plasma insulin concentrations, leading to a 
reduction and improvement in blood glucose levels (Patel et al., 2006a). Glucose 
homeostasis is under continuous antagonistic actions of both insulin and glucagon. 
GLP-1 reduces glucagon secretion from pancreatic α-cells, probably through inhibitory 
binding effect of GLP-1 to its receptors expressed in pancreatic α-cell (Heller et al., 
1997). Alternatively, GLP-1-induced glucagon inhibition may be an indirect way via 
binding to δ-cell receptor and stimulation of somatostatin release, which suppresses 
glucagon secretion from α-cells in a paracrine mode of action (de Heer et al., 2008). In 
addition, GLP-1 plays a significant role in stimulation of β-cell to secrete insulin that 
also inhibits glucagon release from α-cell (Creutzfeldt et al., 1996). Oral glucose and 
other food components can enhance GLP-1 release from the intestinal mucosal L-cells, 
which directly influence insulin secretion from pancreatic β-cells in a glucose-
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dependent response and inhibit glucagon secretion from α-cells. These actions, besides 
the delay in gastric emptying, feel of stomach fullness and reduction of appetite will 
lead to hypoglycaemic effect following GLP-1 administration (Vilsbøll and Holst, 
2004; Mudaliar and Henry, 2009). The small influence of GLP-1 on glucose 
homeostasis might be minor in normal subjects and this may explain the result of the 
present study that showed no significant changes in blood glucose levels in normal rats 
treated with either GLP-1 or exenatide compared to normal control rats (Nauck et al., 
1997). 
 
4.1.3 Intraperitoneal glucose tolerance test (IGTT) 
This study showed that treatment with either GLP-1 or exenatide improved glucose 
tolerance in both normal and diabetic rats. In all normal and diabetic rats treated with 
either GLP-1 or exenatide there were significant reductions in blood glucose levels at 
different periods of the glucose tolerance test. The improvement in glucose tolerance 
was more prominent in diabetic rats treated with GLP-1. All rats were 10 weeks old at 
the beginning of the experimental period (zero week) and were aged 20 weeks after the 
10-week study period. There was a difference in the fasting blood glucose levels within 
diabetic and normal groups at the beginning of the study at 0 week and at the end of the 
study period after 10 weeks. This difference was probably due to the effect of ageing 
and also to the beneficial effect of 10 week-treatment period with either GLP-1 or 
exenatide (See figures 3.3 and 3.5 for normal rats and figures 3.4 and 3.6 for diabetic 
rats). The beneficial effect of either GLP-1 or exenatide established in the present study 
may be due to the insulinotrobic effect of these incretins. This result is consistent with 
those detected in other studies, which reported the effectiveness of GLP-1 and 
exenatide in improving blood glucose levels in treated rats. GLP-1 maintains glucose 
homeostasis via enhancement of insulin release and suppression of glucagon secretion 
in response to blood glucose levels without inducing hypoglycaemia (Schwartz et al., 
2008; Verspohl, 2009). The inhibition of glucagon secretion is under the GLP-1 effect 
via stimulation of both insulin secretion from β-cells and somatostatin from δ-cells of 
the pancreas. Both are involved in suppressing glucagon release from α-cells. In 
addition, the stimulatory effect of GLP-1 on insulin secretion also lowers blood glucose 
183 
 
levels after glucose load in glucose tolerance test. At the same time, GLP-1 stimulates 
insulin biosynthesis in glucose-dependent way. Therefore, GLP-1 seems to stimulate 
insulin secretion at both early and late phases following its treatment (Doyle and Egan, 
2007). 
 
4.2 Effect of GLP-1 and exenatide treatment on biochemical 
parameters of normal and diabetic rats 
4.2.1 Liver function tests 
In the present study, the plasma levels of AST increased markedly after the onset of 
diabetes. In addition, in both groups of normal and diabetic rats treated with either 
GLP-1 or exenatide, the levels of AST were reduced significantly. On the other hand, in 
this study, the AL 
T levels were reduced in normal and diabetic rats after treatment with either GLP-1 or 
exenatide. The reduction was significant in all groups except in normal rats treated with 
GLP-1. However, the effect of GLP-1 in lowering the ALT levels was much more 
pronounced in diabetic-treated rats than in exenatide-treated diabetic rats. These 
reductions of both AST and ALT indicate the protective action of either GLP-1 or 
exenatide in improving liver functions especially in diabetic rats and these results are in 
agreement with a previous study (Vaghasiya et al., 2010).  
Liver enzymes, including AST and ALT, are consider as markers that reflect liver 
functions including hepatocellular integration and protein synthesis in the liver. 
Elevation in the levels of these two enzymes is an important indicator of hepatocellular 
damage since they play vital roles in gluconeogenesis. AST is found in several body 
organs such as the liver, brain, kidney, lung and pancreas and it is present in both the 
cell cytoplasm and mitochondria. However, ALT is mainly a cytosolic enzyme which is 
found in large quantities in hepatocytes (Opara, 2002).  
In a previous report and in agreement with the present study, the plasma level of ALT 
was increased after the onset of diabetes (Aragon and Younossi, 2010). This indicates 
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that diabetes mellitus can cause liver damage if not treated. Hepatocellular damage 
leads to a release of these two liver enzymes into blood circulation. STZ-induced 
diabetic rats are mainly characterized by elevation in the plasma AST and ALT due to 
the toxic effect of STZ on hepatocytes. As indicated in the STZ-induced diabetic rats in 
the present study, treatment with either GLP-1 or exenatide can lead to significant 
reductions in the levels of these two enzymes. These protective effects are consistent 
with the results of a previous study in which T2DM patients with impaired elevated 
liver enzymes were treated with exenatide for 3 years showing improvement in the 
ALT levels (Klonoff et al., 2008). In addition, elevation in the liver enzymes, ALT and 
AST were mainly associated with excessive lipid peroxidation and oxidative stress in 
diabetic rats. These toxic markers were principally due to excessive production of 
reactive oxygen species. Treatment with either GLP-1 or exenatide improves liver 
functions (Bulchandani et al., 2009), probably due to an increase in the liver uptake of 
glucose which reduces the glucotoxic effect of prolonged hyperglycaemia in diabetic 
rats (Arnés et al., 2009).  
Furthermore, increased serum ALT and AST levels in obese mice confirm the strong 
relationship between obesity and liver steatosis. Reduction of liver fat content and liver 
cells injury were detected after exenatide treatment of either ob/ob obese mice or 
T2DM patients (Ding et al., 2006; Klonoff et al., 2008; He et al., 2010).  
Exenatide-treated rats have revealed an improvement of liver functions via elevation in 
the activities of antioxidant enzymes, superoxide dismutase and catalase with reduction 
in nuclear oxidative stress (Bose et al., 2005; Bose et al., 2007). In agreement with 
these previous studies, the results of the present study have shown similar significant 
increases in both catalase and glutathione reductase-positive cells in pancreatic islets of 
either normal and diabetic rats treated with either GLP-1 or exenatide. This observation 
suggests that either GLP-1 or exenatide-treated rats have increased levels of these 
protective antioxidant enzymes, which explains the lowering effect on AST and ALT. 
Suppression of oxidative stress by exenatide treatment may lead to a protective effect 
on the liver. The protective effect of exenatide in the reduction biomarkers of hepatic 
injury, AST and ALT may be due to the elevation of antioxidant enzyme activities 
(Vaghasiya et al., 2010; Mudaliar and Henry, 2010; Sathyanarayana et al., 2011). 
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4.2.2 Kidney functions tests 
Levels of blood urea nitrogen, serum creatinine and uric acid contents are 
pathophysiological markers used in the evaluation of kidney function (Zhu et al., 2005). 
The results of the present study have shown that STZ-induced diabetes could elevate 
the levels of blood urea nitrogen, serum uric acid and to slight degree, serum creatinine 
levels compared to normal, untreated control rats. The present study also shows that 
treatment of diabetic and normal rats with either GLP-1 or exenatide can lead to a 
general reduction in the levels of blood urea nitrogen, serum creatinine and serum uric 
acid. The reduction of blood urea nitrogen levels was significant in diabetic rats treated 
with GLP-1. In addition, the reduction of serum creatinine was also significant in 
normal and diabetic rats treated with exenatide and non-significant in GLP-1 treated 
normal and diabetic rats. These differences may be due to the fact that GLP-1 has a 
very short half-life of about 2 minutes because of fast degradation by DPP-IV enzyme. 
In contrast, exenatide is a long-acting agonist and DPP-IV resistant drug (Perry and 
Greig, 2003). This may make exenatide more effective in reducing serum creatinine 
levels. In addition, the reduction of serum uric acid was significant in normal and 
diabetic rats treated with exenatide and diabetic rats treated with GLP-1. 
These reductions in three kidney function markers including blood urea nitrogen, serum 
creatinine and uric acids indicate the beneficial effects of either GLP-1 or exenatide on 
the kidney functions in normal and diabetic rats. The results of the present study have 
shown a better improvement in kidney functions compared to a previous study, which 
demonstrated no significant difference in kidney markers between db/db mice treated 
with exenatide and control group (Park et al., 2007). In another study, the exenatide 
agonist, AC3174 and GLP-1 treatment in Dahl salt-sensitive rats revealed reduction of 
renal injury and improvement in renal function (Liu et al., 2010a). The beneficial effect 
of GLP-1 and exenatide on renal functions may be due to a reduction in blood 
hypertension, which is normally associated with diabetes via elevation of circulating 
angiotensin, enhancement of sodium and water excretion in urine or through the 
reduction of corticosterone-induced hypertension (Kohara et al., 1993; Hirata et al., 
2009; Timmers et al., 2009). In addition, GLP-1 and exenatide may prevent the 
formation of renal glomerulosclerosis, tubular necrosis, interstitial fibrosis, leading to 
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improved renal morphology (Yu et al., 2003). All of these effects of GLP-1 and 
exenatide may lead to enhancement of the overall kidney function markers, including 
blood urea nitrogen, serum creatinine and serum uric acid, as confirmed in the present 
study.   
In contrary to the beneficial results on renal function in the present study, a previous 
study done on four diabetic patients (age 52-73 years) treated with exenatide and 
diuretic drugs has shown a deterioration of renal function due to renal failure. As such, 
exenatide treatment was curtailed. This adverse effect of exenatide was observed in 
those patients taking both diuretic drugs beside the exenatide. In turn, this case was 
associated with a synergistic action of both drugs and a severe reduction of body fluids 
that cause renal failure (Weise et al., 2009). However, the study of Weise and co-
workers had a limited number of patients, four, and they were mainly over age. As 
such, this referred study could not be considered as a reliable study. 
 
4.2.3 Lipid profile 
The present study has shown that GLP-1 and exenatide can evoke marked reductions in 
serum cholesterol and triglyceride levels in both normal and diabetic rats. The reduction 
of serum cholesterol and triglyceride was significant in normal rats treated with 
exenatide and in diabetic rats treated with GLP-1. In addition, the reduction was also 
significant in serum cholesterol and triglyceride in diabetic rats treated with either 
GLP-1 or exenatide except in diabetic rats treated with exenatide where the reduction in 
serum cholesterol was not significant. The reduction in serum cholesterol and 
triglyceride under the influence of either GLP-1 or exenatide in both normal control and 
diabetic rats was consistent with previous studies (Blonde et al., 2006; Klonoff et al., 
2008; Mudaliar and Henry, 2010). All normal and diabetic groups in the present study 
have free access to food and water. This means that the food ingestion was considered 
as a constant factor for all rats and had no specific influence on serum triglyceride on 
certain group of rats. The reduction in serum triglyceride levels in rats treated with 
either GLP-1 or exenatide may be due to an increase in the consumption of triglyceride 
in body cells rather than their storage. A recent study has reported that GLP-1 and 
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exenatide treatment can inhibit lipolysis and decrease the release of triglyceride in 
plasma resulting in reduced levels of serum triglyceride and total cholesterol. The 
mechanism of this suppression may be due to the delay in gastric emptying that causes 
a slowing in food reaching the intestine from the stomach (Nuche-Berenguer, et al., 
2011). This observation is in agreement with the reduction of serum cholesterol and 
triglyceride discerned in the present study. In another previous study, GLP-1 and 
exenatide treatments lead to a suppression of postprandial increase in plasma 
triglyceride and non-esterified fatty acid in normal and T2DM subjects (Cervera et al., 
2008). This reduction of triglyceride after a meal may be due to the suppression of the 
action of lipase, inhibition of intestinal apolipoproteins synthesis, reduction of lymph 
flow in intestinal cells and an inhibition of lipid absorption (Qin et al., 2005; Hsieh et 
al., 2009). 
T2DM revealed an elevation in hepatic fat levels, decreased plasma adiponectin, and 
hepatic insulin resistance (Bajaj et al., 2004). Reduced plasma adiponectin 
concentrations may be related to peripheral insulin resistance, elevated fasting plasma 
triglyceride and diminished plasma high-density lipoprotein (HDL) cholesterol level 
(Yu et al., 2002). In a previous study, exenatide treatment elevates plasma adiponectin 
concentrations and suppresses the fat content in rodent liver (Li et al., 2008). The action 
of exenatide in reducing the food intake may play an essential role in decreasing the fat 
content in rodent liver. Exenatide enhancement of adiponectin can lead to stimulation 
of cAMP-activated protein kinase, improvement of mitochondrial fat oxidation and 
reduction of lipogenesis in the liver (Ding et al., 2006).  Moreover, GLP-1 treatment 
can also cause marked suppression in liver lipogensis and enhancement of fatty acid 
oxidation (Yamauchi et al., 2002). The results of these previous studies confirm the 
lowering action of either GLP-1 or exenatide treatments on the serum cholesterol and 
triglyceride levels confirmed the data obtained in the present study. 
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4.3 Effect of GLP-1 and exenatide treatment on serum insulin 
in normal and diabetic rats 
The present study has shown a pronounced reduction in levels of serum insulin in 
untreated diabetic rats compared to normal rats. Treatment of both normal and diabetic 
rats with either GLP-1 or exenatide showed a significant elevation in serum insulin 
levels. These results suggest that both GLP-1 and exenatide may improve glucose 
tolerance via enhancement of insulin secretion in glucose-dependent manner only when 
the blood glucose level was above the normal range. This finding is consistent with 
previous studies, which showed an elevation of serum insulin in healthy cats treated 
with exenatide (Gilora et al., 2011). An increase in serum insulin was also detected 
after GLP-1 treatment either in healthy humans or in diabetic animal models (Edwards 
et al., 1998; Henquin, 2000).  
The insulinotropic action of GLP-1 is maintained via potentiation of β-cell function and 
an increase of β-cell mass by enhancement of β-cell neogenesis and proliferation. In 
addition, GLP-1 is associated with the activation of insulin gene expression and it also 
stimulates many steps during insulin production and release from β-cells (Holz and 
Chepurny, 2003; Dungan and Buse, 2005). In addition, one of the indirect actions of 
GLP-1 in stimulating insulin secretion may be through inhibition of glucagon release as 
the main insulin antagonistic hormone. Moreover, GLP-1 may also suppress β-cell 
apoptosis, especially in diabetic rats as demonstrated in previous studies (Arulmozhi 
and Portha, 2006; Nayak et al., 2010). GLP-1 prevents the apoptosis of pancreatic β-
cell by inhibiting caspase-3 enzyme activities, an enzyme involved mainly in the last 
steps of β-cell death. In addition, GLP-1-treated islets revealed an elevation in the 
concentrations of antiapoptotic survival protein (Bcl-2). At the same time, GLP-1 
treatment can also improve the number of insulin-immunopositive cells with elevation 
of insulin content and enhancement of insulin release in response to glucose level. The 
decrease in β-cells apoptosis in GLP-1-treated diabetic rats may be due to the ability of 
GLP-1 to preserve normal morphology of islet cells (Farilla et al., 2003). 
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In vitro studies 
4.4 The physiological roles of GLP-1 and exenatide on insulin 
secretion (release) from the pancreatic tissue fragments 
of normal and diabetic rats 
The results in the present study have shown that diabetic pancreatic fragments produce 
about 50% less insulin compared to the normal healthy pancreas. Similar results have 
also been reported in several previous studies, which employed STZ-induced diabetic 
rats (Noguchi, 2007; Spellman, 2007). Moreover, the present study has also 
demonstrated that either GLP-1 or exenatide can evoke dose-dependent increases in 
insulin secretion from both normal and diabetic pancreatic fragments compared to basal 
secretion. The maximum effect was obtained with 10
-6 
M concentration of either GLP-1 
or exenatide. Together, these results clearly confirm the beneficial use of either GLP-1 
or exenatide in inducing insulin secretion from pancreatic fragments confirming their 
secretagogue effect. These results are in agreement with previous studies (Irwina et al., 
2010). The possible explanation of either GLP-1 or exenatide in inducing a lower level 
of insulin secretion from pancreatic fragments of diabetic rats compared to normal rats 
is probably due to the destruction of transduction signals associated with calcium 
release in diabetic pancreatic rats (Adeghate and Ponery, 2002). The results of the 
present study confirm those of a previous study, in which, exenatide treatment 
potentiates the normalization of insulin release under glucose stimulation in T2DM 
patients (Quddusi et al., 2003). Exenatide is believed to exert its effect by binding to its 
GLP-1 receptors that induce proinsulin production and substituting the released insulin 
secretory granules with stimulation of new insulin granules synthesis. The stimulation 
of insulin release via exenatide in T2DM patients was about 50% of that estimated in 
normal volunteers as reported in a previous study (Fehse et al., 2005). This could be 
related to the reduced number of β-cells in diabetic rats as confirmed in the present 
study. It is well known that GLP-1 stimulates insulin release from β-cell via its binding 
to GLP-1 receptor generating such second messenger as cAMP that provokes protein 
kinase A and guanine nucleotide exchange factor cascades. In turn, these induce the 
secretion of insulin from its granules in β-cell into the blood (Song et al., 2011). 
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The results of the present study have shown that there was a marked reduction in the β-
cell number in diabetic pancreatic fragments. Surprisingly, the β-cells were still able to 
secrete insulin in a concentration-dependent manner to either GLP-1 or exenatide 
stimulation. One possible explanation for the effect of either GLP-1 or exenatide to 
induce the secretion of insulin from pancreatic fragments, although there was a 
reduction in β-cells number, is probably due to their ability to enhance β-cell functions. 
The insulinotropic action of GLP-1 and exenatide seen in the present study is consistent 
with a previous study employing aged rats. In this study, the aged rats have age-
dependent reduction in β-cells number, reduced function and moreover diminished 
glucose homeostasis. These aged rats restored the normoglycaemia after GLP-1 
treatment in accordance with the results in the present study (Farilla et al., 2003).  
The in vitro study on β-cells revealed that GLP-1 treatment can lead to an elevation in 
insulin release with improvement in glucose tolerance (Hui et al., 2003). In T2DM 
patients with reduced β-cells mass, GLP-1 treatment can restore normal fasting blood 
glucose levels with enhancement of insulin release (Kim and Egan, 2008). Exenatide 
treatment of isolated pancreatic rat islets showed an activation of the glucose-induced 
insulin release (Doggrell, 2007). In db/db diabetic mice treated with exenatide, 
pancreatic insulin level was 38% more than that in untreated diabetic db/db (Wang and 
Brubaker, 2002). This action of GLP-1 in improving insulin sensitivity and stimulation 
of insulin release may be via the activation of the expression of insulin gene (Sinclair 
and Drucker, 2005). In another previous study, it was shown that a culture of human 
islet β-cell line treated with GLP-1 has revealed a conservation of the normal islet cell 
structure, incensement of cell survival, enhancement of the glucose-stimulated insulin 
release and elevation in insulin cytosolic granules. Therefore, GLP-1 seems to maintain 
β-cells structure, function and decreases in β-cells death (Farilla et al., 2003).           
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4.5 Effect of GLP-1 and exenatide treatment on the 
distribution pattern of pancreatic islet cells in normal 
and diabetic rats 
4.5.1 Distribution of insulin immunoreactive cells in normal and 
diabetic rats 
The results presented in this study have demonstrated significant changes in the pattern 
of distribution of insulin-positive cells in the pancreas of diabetic rats when compared 
to normal control. Insulin-positive cells were located mainly in the central area of the 
pancreatic islet and to a certain extent in the peripheral parts of the islets in normal 
pancreas. In contrast, the diabetic pancreas had less insulin-positive cells in both the 
central and peripheral parts. This observation on the pattern of distribution of insulin 
producing β-cells is similar to other previous report (Ahmed et al., 1998). The number 
of insulin-positive cells was higher in normal pancreas compared to STZ-induced 
diabetic rats and this decrease was due to the destruction of pancreatic beta cells. From 
the present study, it was obvious that STZ does not destroy all the β-cells in the islets of 
diabetic rat pancreas. It is possible that some cells were partially destroyed and with 
time, they survived and subsequently recover. A previous study has also reported that 
STZ does not completely destroy all the pancreatic beta cells after STZ treatment 
(Adeghate and Parvez, 2000). The present study has also shown that treatment of rats 
with either GLP-1 or exenatide can lead to a significant increase in insulin 
immunoreactive β-cells in both diabetic and normal healthy rats. GLP-1 had been 
previously shown to exert beneficial effects on β-cell mass and function (Buteau et al., 
2004). GLP-1 exerts its action by the enhancement of glucose-induced insulin release, 
improvement of β-cell quantity, insulin gene expression and suppression of β-cell 
death. These actions lead to the control of insulin release via preserving normal action 
and β-cell mass. The action of exenatide as GLP-1 agonist on pancreatic cells is mainly 
similar to GLP-1 due to the fact that exenatide can exert its action via binding to GLP-1 
receptor (Drucker, 2006). 
A previous study, using a pancreatic necropsy for T2DM patients, has demonstrated a 
decrease in the number and action of β-cells. The decline of β-cells number is related to 
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elevated β-cell death in diabetes. The causes of increased rate of either β-cells death or 
dysfunction were related to increased toxic elements including chronic hyperglycaemia, 
elevated lipids concentration, induced cell inflammation and increased level of amyloid 
secretion from pancreatic islet cells (Muoio and Newgard, 2008). In another study, 
elevation in β-cell death and reduction in β-cell growth can lead to a decrease in β-cell 
number in T2DM. This may be due to destructive glucolipotoxic effect on β-cell 
functions as this was associated with reduced insulin release, inhibition of insulin gene 
expression and increase in β-cell apoptosis (Poitout and Robertson, 2008).  
In diabetes mellitus, β-cells are under persistent oxidative stress because of elevated 
concentrations of reactive oxygen species due to prolonged hyperglycaemia, leading to 
impaired β-cell function (Robertson, 2004). At the same time, the levels of harmful 
lipid derived products increase and thus, disrupting β-cells function (Poitout and 
Robertson, 2002). All of these β-cell toxins propagate an endoplasmic reticulum stress 
and eventually failure, all of which are hallmarks of T2DM. In turn, these are 
associated with insulin resistance and hyperinsulinaemia. The condition of endoplasmic 
reticulum failure is due to the fact that it loses its normal function of protein folding 
that cause β-cell death at the end (Fonseca et al., 2007). 
In the beginning of T2DM before the progressive deterioration of the disease, the 
normal action and number of β-cells may be restored by incretin treatment because 
GLP-1 and exenatide enhance β-cells proliferation, neogenesis and decrease β-cells 
apoptosis. These effects lead to an increase in the number of β-cells, a vital action of 
incretins (Wajchenberg, 2007). GLP-1 and exenatide are also able to enhance insulin 
release and elevate both β-cells mass and proliferation (Buteau et al., 2004).  
Pancreatic β-cell number is controlled by a preservation of the equilibrium between β-
cell differentiation and apoptosis. In addition, β-cell size variation is also associated 
with controlling the β-cell number (Bonner-Weir, 2001). In rodents, β-cells mass 
propagated under GLP-1 treatment through increasing β-cells neogenesis, proliferation 
and reduction of apoptosis (Hanley et al. 2008). 
Previous in vitro studies have shown that exenatide treatment enhances the proliferation 
of pancreatic islet tumour cells and progenitor cells toward insulin-secreting β-cells 
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(Abraham et al., 2002). In addition, the proliferative effect of exenatide treatment on β-
cells may, indirectly, via reduction of the elevated blood glucose levels in diabetes 
leading to increased β-cells mass (Dungan and Buse, 2005). 
The actions of GLP-1 on β-cells may lead to prolongation of its life span with 
enhancing increase in β-cells and finally, insulin release. These beneficial effects of 
GLP-1 may therefore be due to its effect on improving β-cells mass. The authors have 
shown that GLP-1-receptor double knockout mice have a reduced β-cells mass 
(Hansotia and Drucker, 2005). Additionally, in another study, GLP-1 G-protein (αs) 
subunit receptor deletion in β-cell of mice causes prominent reduction in β-cell volume, 
number and growth with elevation of β-cell death rate (Xie et al., 2007). 
The results of previous studies have clearly shown a beneficial effect of either GLP-1 
or its agonist exenatide in increasing β-cells mass and reducing their apoptosis leading 
to a significant increase in the number of insulin immunoreactive cells observed in the 
present study.  
A different in vitro study employing human pancreatic islet, GLP-1 treatment was 
shown to abolish gluco-lipotoxicity. This beneficial effect of GLP-1 may be due to 
enhancement of antiapoptotic proteins (Bcl-2, IAP-2) gene expression (Buteau et al., 
2004). Furthermore, the mechanism of action of GLP-1 may be related to the 
stimulation of the transcription factor (NF-B) and protein kinase B. The action of GLP-
1 on β-cells mass may also be through cAMP and protein kinase A-dependent pathways 
(Karaca et al., 2009). This mode of action protects the β-cells through inhibiting 
mitochondrial dysfunction, increasing the expression of β-cell protective genes and 
suppression of β-cell apoptosis (Hausenloy and Yellon, 2011).  
  
4.5.2 Distribution of glucagon immunoreactive cells in normal and 
diabetic rats  
The results of the present study have also shown a pronounced disturbance in the 
number and arrangement of glucagon-positive, α-cells in the pancreas of diabetic rats in 
comparison with normal control rats. In the normal pancreas, glucagon-positive α-cells 
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were located mainly on the peripheral areas of the islets and this is similar to previous 
report (Ahmed, 2002). In STZ-induced diabetic pancreas, the number and the way of 
organization of glucagon-positive α-cells altered prominently when compared to 
normal controls. Glucagon-positive α-cells were found both in the peripheral and 
central regions of the islets of diabetic rats (Ahmed et al., 1998). This may be due to the 
fact that the number of glucagon-positive α-cells increased greatly in such a way that 
makes the peripheral region of pancreatic islets too small for them to occupy or some 
glucagon-positive cells may migrate into the central area of the islet to replace the 
diminishing β-cells. Aberrations in the quantity and action of the β- and α-cells can lead 
to a reduction in insulin secretion and increased glucagon release that are an added 
value for worsening the complications of DM (Irwin et al., 2009). However, treatment 
of normal and diabetic rats with either GLP-1 or exenatide as demonstrated in the 
present study has resulted in a significant reduction in the number of immunoreactive 
glucagon α-cells in pancreatic islets. This beneficial effect of GLP-1 and exenatide may 
be due to their essential action in lowering the harmful effect of prolonged elevated 
blood glucose levels via inhibiting the glucagon release in a glucose-dependent way 
from pancreatic α-cell (Schirra et al., 2006).  
A previous investigation had reported that GLP-1 and exenatide can suppress the 
release of glucagon and enhance α-cell glucose sensing in T2DM patients (Dunning et 
al., 2005). Another previous study had also reported the ability of GLP-1 in the 
suppression of α-cells (Hare, 2010). In another study, it was shown that treatment of 
STZ-induced diabetic rats with chlorella, an antioxidant agent, can result in a 
significant reduction of α-cells number with increase in β-cells count (Amin et al., 
2011). These results are consistent with the suppression of α-cells and elevation β-cells 
in the current study. According to these results, it is tempting to suggest that GLP-1 not 
only decreased the mass of α-cells, but also improves the function of the existing β-
cells thereby improving glucose tolerance.  
The mechanism of action of GLP-1 and exenatide treatments in readjusting the 
disturbed numbers of both β- and α-cells in STZ-induced diabetic rats may be explained 
via the enhancement of the antioxidant effects of the both GLP-1 and exenatide. It was 
demonstrated in this study that both GLP-1 and exenatide can increase the number of 
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both catalase and glutathione reductase-positive cells in pancreatic islets of diabetic 
rats. This observation is consistent with the finding of a previous study in which STZ-
induced diabetic rats were treated with the antioxidant product such as chlorella leading 
to an elevation of β-cells and reduction in α-cells mass. These effects were associated 
with increase in the levels of the antioxidant enzymes catalase and glutathione 
reductase (Amin et al., 2011). Therefore, enhancing the antioxidant protective system 
may cause a reduction of the oxidative stress and gluco-lipotoxicity, resulting in less 
destruction of pancreatic islet cells in DM (Robertson, 2004). Through this beneficial 
antioxidant effect of GLP-1 and exenatide treatments, the increase in the number of β-
cells and reduction in α-cells number may be explained in the present study. The results 
of the present study are supported by those of a previous study in which genetically 
engineered mice with a reduced β-cell were treated with insulin. The mice showed 
regeneration of β-cells, which developed from α-cells precursors (Thorel et al., 2010). 
This result confirms the data of the present study, which shows a reduction in α-cells 
coupled with an increase in β-cells under the insulinotropic action of GLP-1. Therefore, 
α-cells may act as a potential source for β-cells following GLP-1 treatment. In turn, this 
will lead to elevation in insulin secretion.   
  
4.5.3 Distribution of GLP-1 and exenatide immunoreactive cells in 
normal and diabetic rats 
The immunohistological figures of the present study have shown that the percentage of 
either GLP-1- or exenatide-positive cells were increased in pancreatic islets in normal 
and diabetic rats treated with either GLP-1 or exenatide. This elevation was significant 
in all the groups of rats except for exenatide-positive cells in normal rats treated with 
either GLP-1 or exenatide. In addition, the distribution of the immunoreactive GLP-1- 
and exenatide-positive cells were seen at the periphery of pancreatic islets of normal 
rats while their location were randomly distributed in diabetic rats. They were 
associated with both β- and α-cells, probably, due to the distortion of islet cells 
organization pattern in diabetic rats (Adeghate and Parvez, 2000). These results are 
mainly related to the beneficial effects of GLP-1 and exenatide in increasing the 
numbers of GLP-1- and exenatide-positive cells with relative increases in β-cells as 
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detected in the present study. The results of the present study have also shown that the 
GLP-1- and exenatide-positive cells in pancreatic islets of diabetic rats treated with 
either GLP-1 or exenatide were distributed randomly in the islets due to the disruption 
of the organization of all cells in the diabetic islets (Ahmed, 2002).  
In the present study, the higher number of GLP-1-positive cells observed in diabetic 
rats compared to control can be explained as follows, (1): GLP-1 and glucagon are 
derived from the same proglucagon gene. It has been shown that proglucagon gene is 
processed differently according to tissue specificity. The processing action is activated 
via prohormone convertase (PC) enzymes, which post-translates the proglucagon to 
glucagon by PC2 in pancreatic α-cells or to GLP-1 by PC1/3 in intestinal L-cells 
(Sinclair and Drucker, 2005). In addition, glucagon-positive cells are higher in diabetic 
rats compared to control. Since GLP-1 and glucagon are derived from the same gene, it 
is imperative that the levels of the two peptides will be high (Ahmed et al., 1998; 
Adeghate and Ponery 2003), (2): High glucose concentrations induce PC1 expression, 
which processes proglucagon to produce GLP-1 from α-cells of islets. The mechanism 
of α-cells induced production of GLP-1 is related mainly to TGR5 receptor stimulation 
pathway (Whalley et al., 2011). Similar findings were also detected in the α-cell line 
(αTC1-6). Incubation of these cells in high glucose concentration resulted in GLP-1 
formation and reduced glucagon release from α-TC1-6 cells (Whalley et al., 2011). In 
another study, transplanting encapsulated α-PC1/3-expressing cells in mice showed 
induction of GLP-1 formation, which in turn improves glucose homeostasis and initiate 
β-cell propagation (Wideman et al., 2007). A similar result was detected in db/db 
diabetic mice of α-PC1/3-expressing cells that revealed enhanced glucose reduction via 
increased proglucagon processing to GLP-1 (Wideman et al., 2009). Furthermore, 
induction of isolated α-cell of mouse islets by adenovirus-mediated PC1/3 expression 
causes elevation of GLP-1 secretion. In turn, GLP-1 enhances glucose tolerance and 
activates β-cells function within the islets (Wideman et al., 2006). The conversion of 
adult pancreatic α-cells to β-cells was also confirmed in another study, which showed 
that β-cell restoration after insulin treatment in diphtheria-toxin-induced β-cell 
destruction (Thorel et al., 2010), (3): GLP-1- or exenatide-positive cells can be 
expressed in both β- and α-cells of the diabetic islets under specific circumstances 
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mentioned in the previous studies. In turn, this condition induces both β- and α-cells to 
increase GLP-1 production, which is significantly more in diabetic pancreatic islet cells 
compared to normal rats (Wideman et al., 2006).  
 
4.5.4 Distribution of catalase and glutathione reductase 
immunoreactive cells in normal and diabetic rats treated with 
either GLP-1 or exenatide 
In the present study, the treatment of normal and diabetic rats with either GLP-1 or 
exenatide leads to an increase in catalase and glutathione reductase immunoreactive 
cells. This increase in both catalase and glutathione reductase-positive cells was not 
significant in pancreatic islets of normal treated rats. However, there was a significant 
and marked increase in both catalase and glutathione reductase-positive cells in 
pancreatic islets of diabetic treated rats. 
STZ is a powerful reactive oxygen species (ROS) producer that causes the formation of 
nitric oxide (NO). It has been reported that β-cell dysfunction with impaired insulin 
synthesis and release are caused by ROS produced after STZ uptake by β-cells through 
GLUT-2 (Thulesen et al., 1997). STZ-induced diabetes in rats caused an elevation of 
blood glucose levels that worsen during the oxidative stress, leading to major chronic 
complications of DM (Vincent et al., 2005). The ROS are considered as metabolic 
products of exaggerated blood glucose oxidation and glycation, which disturb the β-
cells antioxidant defence mechanisms (Bonnefont-Rousselot et al., 2004: D‟Souza et al, 
2009).  
Consistent with the results in this study, a previous study on untreated diabetic rats has 
shown a significant concentration of oxidative stress (Vaghasiya et al., 2010a). 
Untreated diabetes causes depletion of glutathione, superoxide dismutase, catalase and 
glutathione peroxidase. Exenatide ameliorates the effect of oxidative stress by 
increasing the levels of antioxidant enzymes (Vaghasiya et al., 2010a).  
Similar results were achieved in another previous study in which STZ-induced diabetic 
mice were treated with exenatide. The results showed a reduction of blood glucose 
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levels, enhancement of insulin secretion, suppression of β-cells death and marked 
elevation in pancreatic antioxidant enzymes, catalase, glutathione peroxidase, and 
superoxide dismutase. GLP-1 and its agonist, exenatide treatment may exert their 
antioxidant protective effects through the nerve growth factor/p75 neurotrophin 
receptor (NGF/p75NTR) system which evokes PKA and nuclear factor kappa-B (NF-
kB) that induce the expression of antioxidant enzymes and sustain β-cells survival 
(Gezginci-Oktayoglu and Bolkent, 2009). 
In agreement with these studies, the increases in catalase and glutathione reductase-
positive cells observed in the present study can be explained by the ability of either 
GLP-1 or exenatide to increase the expressions of catalase and glutathione reductase in 
pancreatic islet cells of diabetic rats. 
  
4.6 Immunofluorescent double labelling study in pancreatic 
islet cells of normal and diabetic rats treated with either 
GLP-1 or exenatide  
In the present study, the immunofluorescent double labelling examination has shown an 
increase in the number and distribution of insulin secreting β-cells and reduction in 
glucagon secreting α-cells in normal and diabetic rats treated with either GLP-1 or 
exenatide. In addition, the immunofluorescent double labelling in the present study has 
shown that the intra-islet random co-localization of either GLP-1 or exenatide with both 
insulin and glucagon in β-cells and α-cells, respectively. There was not much overlap 
between insulin and GLP-1 in diabetic rats treated with either GLP-1 or exenatide 
because GLP-1 is more related to glucagon rather than insulin. The increase in the 
number (staining) of insulin is due to treatment with either GLP-1 or exenatide. It has 
been shown that either GLP-1 or exenatide can induce neogenesis and proliferation of 
pancreatic β-cell (Tornehave et al., 2008; Dungan and Buse, 2005). In normal and 
diabetic rats treated with either GLP-1 or exenatide there was an increased co-
localization GLP-1 and exenatide with insulin in pancreatic β-cells. These findings of 
co-localization of either GLP-1 or exenatide with insulin in β-cells may indicate the 
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beneficial interaction of either GLP-1 or exenatide in insulin production and secretion 
as indicated in a previous study (Tornehave et al., 2008). In addition, association of 
either GLP-1 or exenatide with insulin in β-cells can lead to enhanced action of β-cell 
function, stimulated insulin secretion, improved glucose tolerance, initiated β-cell 
differentiation and reduced β-cell death (Garber, 2011).  
However, in the present study, the number of glucagon-positive cells increases 
significantly after the onset of diabetes (Ahmed et al., 1998; Adeghate and Ponery, 
2003). Since GLP-1 is closely related to glucagon, it is imperative that the number of 
either GLP-1 or exenatide stained cells will increase during the onset of diabetes. The 
co-localization of either GLP-1 or exenatide with glucagon in α-cells may indicate that 
pancreatic α-cells may be stimulated by GLP-1 via binding of GLP-1 to its receptors on 
α-cells. This in turn leads to suppression of glucagon secretion thereby playing an 
important role in reduction of postprandial glucose excursions as reported in a previous 
study (Holst, 2007). In addition, the co-localization of GLP-1 and exenatide with 
glucagon in α-cells may enhance α-cell glucose sensing in patients with T2DM who 
improve their blood glucose homeostasis (Dunning et al., 2005). At the same time, 
GLP-1 may lead to α-cells re-programming to insulin producing β-cell (Thorel et al., 
2011). A recent investigation showed that mature α-cells produce small quantity of 
GLP-1. In addition, results from diabetic rodents have demonstrated an elevated level 
of GLP-1 secretion from α-cells with increased proglucagon and prohormone 
convertase 1/3 expression via elevated plasma levels of interleukin-6. This in turn, 
promotes GLP-1 release from pancreatic α-cells and GLP-1 enhances insulin release 
from β-cells and improves the overall glucose homeostasis. Therefore, interleukin-6 
may be considered as a link among insulin-sensitive tissues and pancreatic islet cell via 
GLP-1 (Ellingsgaard et al., 2011). As revealed from these data and confirmed in the 
present study, the co-localization of either GLP-1 or exenatide within α-cells may play 
a beneficial effects of GLP-1 on both β- and α-cells in decreasing diabetic 
complications (Ellingsgaard et al., 2011). Additionally, the findings of the present study 
are in agreement with a previous related study in which the expression of the GLP-1 
receptor mRNA and its protein in α-cells was reported in both rat islets α-cells and in α-
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cell lines (Heller et al., 1997). Therefore, GLP-1 may have pronounced actions on 
isolated α-cells (Gromada et al., 1998).  
In addition, the present immunofluorescent double labelling study has shown the co-
localization of either catalase or GSH with both insulin and glucagon in β- and α-cells, 
respectively in normal and diabetic rats treated with either GLP-1 or exenatide. This co-
localization may explain the pronounced protective antioxidant action of catalase and 
GSH on increasing insulin secretion and decreasing glucagon secretion. This beneficial 
action of catalase and GSH may act through reduction of the harmful effects of reactive 
oxygen species and chronic gluco-lipotoxicity conditions, which are associated mainly 
with diabetes (Figueroa-Quevedo and Agil, 2011). GLP-1 and exenatide treatment 
increases antioxidant enzymes, which in turn protect against β-cell injury in diabetes 
leading to a reduction in toxic lipid peroxidation and reactive oxygen species. The co-
localization of catalase or GSH antioxidant enzymes with insulin in diabetic β-cell 
under the GLP-1 and exenatide treatment can lead to improvement in β-cell functions 
by suppressing β-cell apoptosis via activation of PKA and PI-3K/PKB pathways and 
reduction of caspase-3 apoptotic action (Vaghasiya et al., 2009). The results of these 
previous studies explain the beneficial action of the co-localization of either catalase or 
GSH within β-cells, which was detected in the present study.  
Like the β-cells, the immunofluorescent double labelling figures of the present study 
have also demonstrated the co-localization of either catalase or GSH glucagon in α-
cells of normal and diabetic rats treated with either GLP-1 or exenatide. GLP-1 induces 
its effect in a glucose-dependent way via both insulin release and glucagon inhibition 
by activating GLP-1 receptors in either β- or α-cells or both (D‟Alessio and Vahl, 
2004). The blood glucose level is normally under continuous control of both insulin and 
glucagon. In T2DM, the normal action of glucose response in both β- and α-cells is 
abolished. This is mainly associated with reduction of insulin secretion and elevated 
glucagon release that lead to a condition of chronic hyperglycaemia. The loss of 
glucose sensitivity on both β- and α-cells not only leads to cell function failure but also 
lead to a structural abnormalities of both cells. The beneficial effect of GLP-1 in 
restoring the normal sensitivity of β- and α-cells to glucose stimulation in turn may lead 
to improved glucose tolerance (Göke, 2008, Vaghasiya et al., 2010).  
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4.7 Electron microscopic study of pancreatic islet cells of 
normal and diabetic rats treated with either GLP-1 or 
exenatide  
In the present study, the ultrastructural findings markedly support the 
immunohistochemical and immunofluorescent data. The β- and α-cells of diabetic 
pancreas differ from that of the normal pancreas in the quantity of secretory granules, 
which are markedly less in diabetic pancreas compared to normal pancreas. The 
electron microscopy used in this study has shown also that treatment of normal and 
diabetic rats with either GLP-1 or exenatide can increase the number of insulin 
secretory granules in treated rats (Persaud and Jones, 2008).  
These findings are in agreement with a previous study in which transplanted pancreatic 
β-cells were treated with exenatide in mice (Toyoda et al., 2008). These authors showed 
that the number of insulin secretory granules was markedly elevated in transplanted 
exenatide treated β-cells. The study also demonstrated an improvement in the action of 
GLP-1R signalling in restoring normal blood glucose levels in diabetic mice. The 
quantity and mass area of the pancreatic islet grafts were pronouncedly increased after 
exenatide treatment with reduction of islet cell death due to enhancement of GLP-1R 
signalling (Toyoda et al., 2008).  
The results of other studies also showed that GLP-1 can activate glucose-stimulated 
insulin release (Lupia and Prato 2008). In another study, the effects of GLP-1 and GLP-
1R agonists were shown to promote insulin gene expression, insulin synthesis, β-cell 
differentiation, islet cells proliferation, suppression of islet cell death and also growth 
of β-cell mass (Wajchenberg, 2007). Murine model of diabetes is associated with the 
development of endoplasmic reticulum (ER) stress in β-cells and treatment with 
exenatide significantly reduced the biochemical markers of islet ER stress thereby 
improving cell organelles structure and survival in a PKA-dependent way (Yusta et al., 
2006).  
In the present study, electron microscopic examination of β-cells in diabetic islet 
showed a pronounced cellular organelle deformation, decreased secretory granules, 
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shrinking of the nucleus, destruction of nuclear envelope, hypertrophied Golgi 
apparatus and swelling of both mitochondrial and rough endoplasmic reticulum. These 
β-cell structural abnormalities can lead to suppression of its functions, practically, 
insulin expression and release. The findings of the present study are in agreement with 
a previous study (Bolkent et al., 2000). 
GLP-1 and exenatide treated diabetic rats showed that β-cells ultrastructure was slightly 
near to normal. In addition, the treated-diabetic rat β-cells showed conservation of cells 
number and mass with an increase in insulin secretory granules, which verified a 
reduction of blood glucose concentrations detected in the present study. The normal 
architecture of β-cells was due to the beneficial effect of either GLP-1 or exenatide on 
insulin secretion and improvement of diabetic cellular abnormalities like degranulated 
secretory vesicles, swollen mitochondria and endoplasmic reticulum stress. These 
results are consistent with those obtained from a previous study (Zhou et al., 2009).  
The deficient antioxidant protective system in diabetic rats may lead to destructive 
effects on β-cells at the level of cellular structure (Degirmenci et al., 2005). The 
inhibition of antioxidant enzymes activity in diabetic rats may be due to excessive 
production of harmful free oxygen species and glucotoxicity of chronic hyperglycaemia 
(Teixeira-Lemos et al., 2011). The levels of both catalase and GSH have shown a 
marked reduction in these protective antioxidant enzymes in pancreatic islet cells of 
STZ-induced diabetic rats (Sathishsekar and Subramanian, 2005; Mahmood et al., 
2003). In the present study, treatment of diabetic rats with either GLP-1 or exenatide 
leads to elevation of catalase and GSH levels in diabetic rat islets. This beneficial effect 
of catalase and GSH on pancreatic isles may help in reducing the production of toxic 
oxygen radicals, lipotoxic products and other xenobiotic elements, which can lead to a 
destruction of β-cells structure (Ilhan et al., 2001; Arulselvan and Subramanian, 2007). 
In addition, catalase and GSH stimulate β-cells regeneration and proliferation via 
cAMP-activated protein kinase that induces insulin production and release in β-cells 
(Richards et al., 2005), that may lead to returning the architecture of the β-cells near 
normal as proved via electron-microscopy figures in the present study under the effect 
of either GLP-1 and exenatide treatment.  
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On the other hand, the electron microscopy figures in the present study have also shown 
a co-localization of insulin with either GLP-1 or exenatide within β-cells in 
immunogold double labelling study. Insulin and GLP-1 co-localize in pancreatic β-
cells. This is more conspicuous in normal rat pancreas. Similarly, the electron 
microscopy figures have also shown co-localization of glucagon with either GLP-1 or 
exenatide within pancreatic α-cells in immunogold double labelling in the present 
study. The absence of staining on some granules may be due to several reasons, 
namely, (1): The concentration of the antibody and incubation time may not be 
sufficient, (2): The unstained granules may be different, because it has been that 
pancreatic endocrine cells contain heterogeneous granules as some cells will contain 
more C-peptide, the precursor of insulin, (3): The plane of section may be outside of the 
antigen-antibody complex. 
The co-localization of insulin with either GLP-1 or exenatide in the pancreatic β-cells 
may be due to the fact that GLP-1 is also co-synthesized in β-cells in a way similar to 
many other peptides including γ-aminobutyric acid (GABA) and galanin, which are 
produced regularly in β-cells (Adeghate and Ponery, 2003). This observation may 
indicate an autocrine action of GLP-1 and exenatide on insulin secretion (Wang et al., 
2002). Suppression of the PDX-1 gene of mice β-cells showed a reduction in normal 
insulin expression and an elevation in glucagon expression (Wang et al., 2002). Similar 
results were detected in PDX-1 gene knockout and in the expression of brain-4 gene in 
INSr-β-cell line leading to inhibition of insulin expression and stimulation of glucagon 
expression (Wang et al., 2004). The possibility of this INSr-β-cell line to secrete insulin 
or glucagon under the effect of stimulation or inhibition of PDX-1 may explain the co-
localization of insulin granules with either GLP-1 or exenatide in β-cells in 
immunogold double labelling in β-cell electron microscopic figures shown in the 
present study. The processing of proglucagon to glucagon and further processing to 
GLP-1 occur in α-TC1-6-cell line. Incubation of α-TC1-6-cell line in high glucose 
concentration resulted in GLP-1 formation and reduced glucagon release (Whalley et 
al., 2011). This may induce a similar mechanism of GLP-1 production in β-cells under 
specific condition such as brain-4 gene stimulation. In addition, the co-localization of 
glucagon with either GLP-1 or exenatide in α-cell as shown by double labelling 
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immunogold electron microscopic figures in this study, clearly support 
immunohistochemical and immunofluorescent results.  
The co-localizations of either insulin or glucagon with either GLP-1 or exenatide may 
also explain the critical role of GLP-1 and exenatide in enhancing insulin secretion 
from β-cells (Kim and Egan, 2008) and the inhibition of glucagon release from α-cells 
(Quesada et al., 2008), as confirmed by electron microscopy in the present study. 
 
4.8 Gene expression in the pancreas of normal and diabetic 
rats treated with GLP-1 and exenatide  
Relative real-time PCR is one of several modern molecular biology techniques, which 
can help in exploring advanced physiological actions in depth at the gene expression 
levels. Estimating the levels of gene transcription factors was done in the present study 
using relative quantification assay by real-time PCR technique. In this study, relative 
quantification was used to compare the levels of gene expression of treated rats relative 
to untreated rats after their normalization by the housekeeping β-actin gene expression 
using relative real-time PCR. Relative quantification provided accurate comparison 
between the gene expression in each group in a direct way and without the use of 
standard curves (Dall‟Oglio et al., 2010). The cause of diabetes mellitus is 
multifactorial and includes factors such as environmental, physical body activities and 
gene-related heredity. For the genetic cause of diabetes, it was decided to investigate 
the changes in the gene expression for a number of transcription factors (mRNA) that 
are associated with insulin gene expression and insulin secretion. These genes include 
pancreatic duodenal homeobox-1, heat shock protein-70, glutathione peroxidase, 
glucagon, insulin receptor and glucagon like peptide-1 receptor in the pancreatic tissues 
of both normal and diabetic rats following treatment with either GLP-1 or exenatide. 
These genes are very important for the control of glucose homeostasis, β-cell functions 
and related to the development of diabetes (Barry et al., 2002). 
The results presented in this study have shown that both GLP-1 and exenatide can 
increase all of the above mRNAs, except for glucagon mRNA expression, which was 
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reduced in both normal and diabetic rats. In the majority of cases, there were significant 
increases in most of the treated rats.  
 
 4.8.1 Pancreatic duodenal homeobox-1 (PDX-1) gene expression in 
normal and diabetic rats treated with either GLP-1 or exenatide  
The results shown in the present study have indicated that either GLP-1 or exenatide 
treatment can lead to significant elevation in the gene expression of pancreatic 
duodenal homeobox-1 (PDX-1) in the pancreas of both normal and diabetic rats. These 
enhancements in the gene expression of PDX-1 correlated well with the increased 
levels of insulin secretion obtained in the in vivo and in vitro studies in the present 
project in agreement with previous study (Shu et al., 2011). 
In addition, the increase in the gene expression for PDX-1 obtained in diabetic rats 
treated with exenatide was much more pronounced compared to diabetic rats, which 
were treated with GLP-1, and also normal rats treated with either GLP-1 or exenatide. 
This observation is in agreement with previous studies, which have shown that rats 
treated with exenatide showed stronger and more extended enhancing effect on insulin 
secretion compared to GLP-1 treatment through the activation of PDX-1 expression 
(Brissova et al., 2002; Doggrell, 2007). Furthermore, the result of PDX-1 gene 
expression in the present study was much higher in diabetic rats than in normal rats. 
This may be due to the fact that diabetic rats exhibited marked reduction in β-cells 
number and function compared to normal rats. This difference revealed an exaggerated 
demand in diabetic rats for more functional β-cells than in normal rats. In addition, 
PDX-1 gene is one of the essential genes that can stimulate the development of the 
pancreas as a whole and also it enhances insulin gene expression, increases β cells 
proliferation, neogenesis and also it inhibits β cell apoptosis. This explanation was in 
agreement with those of Perfeitti et al., (2000), in which PDX-1 protein concentrations 
was reported to be elevated 4-fold in pancreatic tissues of normal rats treated with 
GLP-1 compared to untreated normal control rats. While in another related study on 
C57B16 genetically engineered diabetic rats treated with GLP-1, an increase of about 
5-fold of PDX-1 protein was reported in pancreatic tissues in GLP-1 treated diabetic 
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rats compared to untreated diabetic control (Stoffers et al., 2000). According to the two 
previous studies, the elevation of PDX-1 expression in GLP-1 treated diabetic rats was 
obviously more than in GLP-1 treated normal rats and these results were consistent 
with the results in the present study. 
Several pancreatic transcription factors are associated with the development of the 
pancreas and β-cell differentiation (Cerf, 2006). PDX-1 is considered as one of the 
homeodomain (HD)-containing protein gene family that are essentially involved in the 
development of the pancreas and the preservation of the normal action of β-cell (Kaneto 
et al., 2007). In a previous study, a critical role of the PDX-1 transcription factor on the 
action of GLP-1 receptor in mice β-cells was reported. This study showed that 
exenatide can markedly improve the growth, insulin mRNA expression and insulin 
secretion of pancreatic β-cell in addition to inhibiting cell death. However, exenatide 
could not enhance insulin release in β-cell PDX-1 knockout mice (Li et al., 2005). In a 
similar study, increasing GLP-1 receptor signalling might enhance insulin gene 
expression (Fontes et al., 2010). Exenatide may also improve diabetic β-cell 
transcription factor PDX-1 via reduction of the glucolipotoxicity down regulatory 
adverse effects (McCarty, 2007).  
Many other studies have shown that GLP-1 may enhance the expression of insulin 
gene, insulin secretion and several other involved genes with insulin action including 
glucokinase and GLUT-2 in a glucose-dependent manner. These effects of GLP-1 are 
mediated mainly by enhancing the PDX-1 transcription (Wang et al., 2001; Kemp and 
Habener, 2001; Movassat et al., 2002; Alarcon et al., 2006; Lamont and Drucker, 
2008). A β-cell line cultured in elevated glucose concentration revealed a decrease in 
the expression of PDX-1. In addition, a suppression of GLUT-2 gene transcription was 
also detected in diabetic animal. Therefore, these results postulate that the GLUT-2 
expression could be PDX-1-dependent (Hart et al., 2000). 
A previous study has earlier shown that the expression of murine GLUT-2 cell line was 
activated via binding of PDX-1 to GLUT-2 receptor (Waeber et. al., 1996). Another 
study has revealed that GLP-1 can elevate the expression of PDX-1, GLUT-2, 
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glucokinase and insulin mRNAs through the PDX-1-dependent and PI-3K activation 
cascades (Buteau et al., 1999). 
Another earlier study has demonstrated a reduction in the transcription of β-cells insulin 
related genes and GLUT-2 in rats after 4 weeks of about 90% pancreatectomy (Laybutt 
et al., 2002). The results of this mentioned study have shown a diminished glucose-
stimulated insulin release and reduced ATP production with impaired carbohydrate and 
lipid metabolism (Laybutt et al., 2002). A similar in vitro study has shown that 
prolonged increased concentrations of fatty acids, hyperglycaemia and reduction in 
both insulin secretion and insulin gene transcription could lead to β-cell apoptosis 
(Poitout and Robertson, 2008). All of these adverse effects of chronic gluco-lipotoxic 
action may be attributed to the suppression of the PDX-1 transcription factor (Hagman 
et al., 2005). 
In another previous study, increased neogenesis of pancreatic β-cells under GLP-1 
treatment via enhancement of PDX-1 and insulin genes transcription was shown to 
increase β-cells mass and it also stimulated both insulin synthesis and secretion. The 
action of GLP-1 on PDX-1 expression was mainly specific for β-cell insulin gene 
translation. The GLP-1 exerts its action through binding to its receptor and promotes 
GLP-1R expression cascade (Yue et al., 2006). The action of GLP-1 and exenatide on 
β-cell differentiation in response to PDX-1 activation may be through stimulation of 
protein kinase B and a cAMP-dependent mechanism (Drucker, 2003a; Holz, 2004). 
 
4.8.2 Effect of GLP-1 and exenatide treatment on heat shock protein 
70 (HSP-70) gene expression in normal and diabetic rats 
The results of the present study have shown a significant increase in the expression of 
the anti-apoptotic gene, heat shock protein 70 (HSP-70) in normal and diabetic rats 
treated with either GLP-1 or exenatide.  
HSP-70 is one of cell stress-induced proteins via molecular chaperone control of 
protein synthesis, formation of protein polypeptides, folding, removal of misfolded 
proteins, and reposition of recently produced proteins (Kim et al., 2007a). In addition, 
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HSP-70 extends cell life span and suppresses cell death (Mokhtari et al., 2009). The 
main function of HSP-70 under cell stress is to minimize cell apoptosis via maintenance 
of normal cell protein structure and elimination of injured proteins for demolition 
(Muranyi et al., 2005). Consistent with the result of the present study, elevated blood 
glucose levels in diabetic rats seem to reduce the HSP-70 expression due to decreased 
insulin secretion, which has been shown to stimulate HSP-70 expression (Chen et al., 
2006).  
The concentrations of antioxidant protective enzyme mRNA are mainly related to their 
functions (Tiedge et al., 1997). The β-cell antioxidant is a fragile protective system, 
which can be easily disturbed by excessive formation of either reactive oxygen or 
nitrogen species (Hong et al., 2004). This in turn can cause impaired effects including 
marked production of oxidative stress elements such as lipid peroxidation, proteins 
oxidation, disruption of transduction signal cascades and DNA injures. All of these 
destructive effects add markedly on the disturbance of β-cell function leading to β-cell 
apoptosis in both T1DM and T2DM (Hayden and Tyagi, 2002). Dysfunction and death 
of β-cells can cause overproduction of inflammatory elements in T1DM and excessive 
formation of toxic chromic hyperglycaemia and hyperlipidaemia in T2DM. These are 
probably due to increased toxic oxygen species of superoxide radicals, hydrogen 
peroxide, hydroxyl radicals and peroxynitrite (Vincent et al., 2004; Li et al., 2008). In 
addition, elevation of the level of reactive oxygen species in the mitochondria of 
pancreatic β-cell can lead to impairment of the nutrient-induced insulin release 
(Lenzen, 2008).  
All of these previous studies clearly documented that the destructive effects of elevated 
oxidative stress can be reduced by enhancement of the antioxidant protective system. 
Moreover, the results of the present study have shown an elevation of the antioxidant 
enzymes in pancreatic islet cells of diabetic rats treated with either GLP-1 or exenatide. 
The elevation of the antioxidant protective enzymes can reduce the adverse 
complications in diabetic rats in agreement with previous study (Vaghasiya et al., 
2010a). GLP-1 and its agonist, exenatide can exert their protective effects via 
enhancement of HSP-70 action as confirmed in a previous related study (Kanitkara and 
Bhonde, 2008). In this related study, the pretreatment of pancreatic islets graft with 
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antioxidant agent such as curcumin for transplantation can preserve the grafted β-cells 
from damage. This antioxidant pretreatment increases cell recovery after the 
transplantation. Curcumin seemed to exert its protective effect mainly through the 
elevation of HSP-70 leading to reduction of the harmful action of the oxidative stress 
and enhancement of glucose-induced insulin secretion (Kanitkara and Bhonde, 2008).  
In DM, elevated HSP-70 levels can lead to improvement of glucose tolerance and 
insulin resistance (Kavanagh et al., 2011). GLP-1 and exenatide treatment can also 
increase HSP-70 levels as detected in the present study.  HSP-70 may exert its action 
via normalizing protein homeostasis in β-cell by inhibiting misfolding protein 
signalling pathways. This HSP-70 mode of action may promote insulin production, 
inhibit β-cells apoptosis and enhance β-cell propagation (Hutt et al., 2009). 
 
4.8.3 Effect of GLP-1 and exenatide treatment on glutathione 
peroxidase (GPx) gene expression in normal and diabetic rats 
The results of the present study have shown a significant increase in the expression of 
antioxidant gene, glutathione peroxidase (GPx), in normal and diabetic rats treated with 
either GLP-1 or exenatide.  
The results obtained in the present study in the diabetic rats are consistent with previous 
studies, which demonstrated a marked reduction in gene expression of GPx when 
compared to healthy normal control rats (Otsuka et al., 2002; Wentzel et al., 2008). In 
another previous study, the level of either gene expression of antioxidant enzymes or 
oxidative stress was estimated in diabetic STZ-induced diabetic mice. The expression 
of GPx and superoxide dismutase were diminished due to disturbance of the antioxidant 
enzyme protective system under the effect of reduced insulin secretion and increased 
blood glucose levels in diabetic mice (Fujita et al., 2005). 
Another study has shown that GPx antioxidant enzyme level was elevated in diabetic 
rats treated with such antioxidants agents as vitamin E and C, or in combination with 
insulin. This treatment improved the function and the protein synthesis of GPx leading 
to recovery from diabetic complications (Sindhu et al., 2004). The elevation of GPx 
210 
 
levels in this study after treatment with insulin and antioxidant agents may explain the 
elevation of GPx gene expression level in the present study after either GLP-1 or 
exenatide treatment. This shows that these incretins have insulintropic and antioxidant 
effects (Timmers et al., 2009).   
Several clinical studies have shown a prolonged increase in oxidative stress in T2DM 
patients. The increased production of GPx protects pancreatic β-cells against the 
destructive effects of oxidative stress (Monnier et al., 2006; Robertson, 2010). Other 
studies have also shown that induction of GPx carried on adenovirus into a defective 
human pancreatic β-cell line can lead to enhancement of the GPx expression against the 
harmful action of oxidative stress. The beneficial effect of GPx does not only target 
oxidative stress, but it also causes a reduction in glucose toxicity by improving glucose 
tolerance. In this context, it is able to preserve β-cell morphology and its functions 
(Robertson and Harmon, 2007). 
GLP-1 and exenatide treatment can lead to a reduction in the level of the oxidative 
stress by reducing lipid peroxidation and myeloperoxidase, agents that can induce 
cellular injuries in diabetic rats (Altunoluk et al., 2006). In addition, GLP-1 and 
exenatide may exert their effects on β-cells through the activation of PI-3K/PKB (a 
protective cellular pathway) and suppression of caspase-3 apoptotic activity (Vaghasiya 
et al., 2010). 
 
4.8.4 Effect of GLP-1 and exenatide treatment on glucagon gene 
expression in normal and diabetic rats 
The results of the present study have shown a significant reduction in the expression of 
glucagon gene in both normal and diabetic rats treated with either GLP-1 or exenatide.  
The release of glucagon from pancreatic α-cells is stimulated via several hormones and 
neurotransmitters. However, GLP-1 inhibits glucagon release
 
(Ahren, 2009). In T2DM, 
chronic elevated blood glucose levels can lead to increased glucagon concentrations 
and enlarged α-cell mass relative to β-cell mass with direct elevation of serum 
glucagon/insulin ratio. This condition is reversed with GLP-1 treatment (Ahren, 2009). 
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In diabetic patients, the marked increase in glucagon release is mainly associated with 
lack of insulin inhibition. However, in healthy individuals food intake induces insulin 
secretion, which in turn inhibits glucagon release from α-cell of the pancreas (Strowski 
et al., 2006).  
Another previous study also showed that insulin could decrease glucagon mRNA level 
via suppression of glucagon gene transcription and reduction of glucagon release 
(Kaneko et al., 1999). GLP-1 enhances the release of either insulin or somatostatin and 
reduces glucagon release. GLP-1 inhibits glucagon release in either healthy or diabetic 
individuals through the paracrine action of elevated intra-islet secretion of both insulin 
and somatostatin (Fehmann et al., 1995). GLP-1 also exerts its direct inhibitory action 
on glucagon secretion from pancreatic α-cells through GLP-1 receptors found on α-
cells (Heller et al., 1997). In T2DM, fasting hyperglucagonaemia is present and 
elevated glucagon response to food ingestion can lead to additional increase in blood 
glucose level (Toft-Nielsen et al., 2001). Although the β-cell mass in markedly reduced 
in T1DM, GLP-1 is still capable of reducing the levels of fasting blood glucose, 
probably via the suppression of glucagon secretion (Creutzfeldt et al., 1996). Insulin is 
an inhibitor of glucagon secretion, but the pronounced inhibitory effect of GLP-1 in 
T1DM is without the involvement of β-cells, suggesting that it may be inhibiting 
glucagon secretion from α-cells (Creutzfeldt et al., 1996). The inhibitory effect of GLP-
1 on glucagon secretion is seen only at glucose levels either at or above fasting levels. 
This is important because it implies that treatment with GLP-1 does not lead to 
hypoglycaemia (Holst, 2007), as it tends to correct only abnormal rise in blood glucose 
level. A previous study on mice with a glucagon receptor double knockout was shown 
to be associated with suppression of prohormone convertase-2, which is essential for 
the transformation of proglucagon to active glucagon. This condition can lead to an 
increase in GLP-1 production from mice pancreatic α-cells (Kedees et al., 2009). 
Other studies have also shown that STZ-treatment in rats can result in enhancement of 
prohormone converting enzymes, PC1 and PC2 in pancreatic α-cells with increased 
levels of glucagon. In addition, these results also showed an increase in GLP-1 
production from these α-cells. This increased production of GLP-1 stimulates insulin 
secretion from β-cells in pancreatic islets (Nie et al., 2000). Therefore, activation of 
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PC1 and PC2 enzymes may initiate the processing of glucagon gene to GLP-1 
production in STZ-induced rats. This in turn may explain the reduction of glucagon 
gene expression, and elevation of the number of GLP-1-positive cells, increased insulin 
levels and better glucose homeostasis as observed in the present study.        
 
4.8.5 Effect of GLP-1 and exenatide treatment on insulin receptor (IR) 
gene expression in normal and diabetic rats 
The results of the present study have shown a significant increase in the expression of 
insulin receptor gene (IR) in normal and diabetic rats treated with exenatide. However, 
the increase in the expression of IR gene was not significant in normal rats treated with 
GLP-1. IR is a type of tyrosine kinase receptor and it is a vital element for pancreatic β-
cell growth, normal β-cell action and extended β-cell life. Signalling via IR in the β-cell 
regulates insulin production and secretion (Kitamura et al., 2003). IR signalling also has 
an important role in conserving the β-cell responsiveness for ingested food (Fisher and 
White, 2004; Shamji et al., 2003). Reduction of two receptors, IR and insulin-like 
growth factor-I receptor (IGF-IR) in addition to their associated substrates, can disturb 
the normal action of β-cell. These findings demonstrate the importance of insulin 
signalling in insulin release and the increase in β-cell mass-induced by insulin 
resistance. In consequence, enhancement of IR expression in β-cells could be 
considered as a valuable treatment for diabetes in general and restoring β-cells 
functions (Kitamura et al., 2003; Nandi et al., 2004; Rhodes and White, 2002). The 
results of the present study are in agreement with studies that showed that the 
expression of IR was markedly induced in β-cells after exenatide treatment (Park et al., 
2006). Nutrition and exercise have also been reported to induce
 
IR expression (Belfiore 
et al., 2009).  
The failure of insulin signalling, referred to as insulin resistance, is one of the major 
causes of T2DM. Double deletion of IR in β-cells of animal models can lead to a 
reduction in insulin production in response to β-cell glucose-stimulus (Srinivasan and 
Ramarao, 2007). Moreover, a deficient IR can markedly reduce the influx of glucose 
into β-cells (Escribano et al., 2009). 
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A genetically engineered diabetic mice with IR deletion in pancreatic β-cells, showed a 
reduction in insulin release with elevated blood glucose levels after food consumption 
and this is probably due to failure of β-cell for glucose sensing (Kulkarni et al. 1999). 
In addition, these mice revealed markedly decreased expression levels of both GLUT-2 
and glucokinase. Thus, suppression in glucose uptake by β-cell may be associated with 
a reduction in GLUT-2 level (Otani, et. al., 2004).  
Insulin resistance influences the structure and the normal action of β-cells. Insulin 
releases via β-cells after glucose stimulation influences insulin gene expression in an 
autocrine way (Leibiger et al., 2001). Disturbance of IR gene in mice can cause 
ketoacidosis. In addition, IR expression was reduced in islets isolated from humans 
with T2DM (Gunton et al., 2005). A decrease in IR expression in β-cells can cause 
glucose intolerance, which is accompanied by a decrease in islet volume (Kulkarni et 
al., 1999). Small reduction in IR expression in human islets completely suppressed 
glucose-stimulated insulin gene expression, suggesting that insulin regulates its own 
gene expression in human β-cells. Defects in this regulation may explain the 
association between metabolism dysfunction and T2DM (Muller et al., 2006).  
A previous study has demonstrated that there are two IRs isoforms IR-A and IR-B. 
Both of them seem to initiate dissimilar downstream mechanisms in pancreatic β-cells. 
IR-A activates insulin gene expression while IR-B stimulates glucokinase via various 
types of phosphatidylinositol-3 kinase (PI-3K) (Leibiger et al. 2001). 
 
4.8.6 Effect of GLP-1 and exenatide treatment on GLP-1 receptor 
(GLP-1R) gene expression in normal and diabetic rats 
The results of the present study have shown an increase in the expression level of GLP-
1 receptor gene (GLP-1R) which was significant in normal and diabetic rats treated 
with either GLP-1 or exenatide except in normal rats treated with GLP-1. 
GLP-1R is expressed on the plasma membrane of β- and α-cells in the pancreas and 
many other body tissues including gastrointestinal tract, heart, lung, kidney, peripheral 
(vagus) and central nervous systems (Salehi et al., 2008). GLP-1 can cross the blood 
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brain barrier by simple diffusion and thus contributes to the regulation of the activities 
of the satiety and appetite centres in the brain (Kastin, et. al., 2002). Exenatide 
stimulates GLP-1R in a similar way to the native GLP-1 and it is considered as a GLP-
1R agonist (Drucker, 2003a). GLP-1R mRNA was detected in the β-cells of pancreatic 
tissues of mice and rats (Tornehave et al., 2008). 
Binding of GLP-1 to its GLP-1R on β-cell initiates a signal transduction cascade 
leading to improved β-cell function including elevation of insulin gene expression, 
release of insulin, propagation of many other regulatory genes which are involved in 
the proteins synthesis, increases of β-cell differentiation and reduction of the rate of β-
cell death (Holst and Deacon, 2006; Druker, 2005). It was shown in a previous study 
that treatment of pigs with exenatide inhibits cardiac cell apoptosis via reduction of 
caspase-3 expression (Timmers et al., 2009).  
Many other studies have shown a similar beneficial effect of GLP-1 and exenatide 
treatment in the improvement of the expression of GLP-1R (Scrocchi et al., 1996; 
Dungan and Buse, 2005). In an in vitro study, GLP-1R was shown to enhance 
signalling in pancreatic islets grafted into STZ-induced diabetic mice after treatment 
with exenatide. This in turn could lead to enhancement of the antioxidant protective 
system, normalization of both the blood glucose concentrations and the structure of 
grafted cells (Toyoda et al., 2008). Furthermore, GLP-1R knockout mice showed an 
elevated fasting blood glucose level, which are associated with glucose intolerance and 
decreased insulin release (Preitner et al., 2004; Dungan and Buse, 2005).  
Islets of GLP-1R−/− mice is associated with a significant reduction in islet size 
(Burcelin et al., 2001). This is confirmed by the fact that GLP-1R knockout mice 
showed a reduction in pancreatic islet cells number and size with aberrations of cells 
arrangement (Ling et al., 2001). Earlier studies have shown that exenatide treatment 
causes an increase in β-cell mass and moreover, it can also enhance its action via 
initiation of islet cell differentiation and suppression of cell death. Ablation of GLP-1R, 
results in the reduction of the compensatory growth observed after partial 
pancreatectomy (De Leon et al., 2003). Increase in GLP-1R expression can lead to 
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improvement of β-cell sensitivity to blood glucose levels (Montrose-Rafizadeh et al., 
1997).  
GLP-1R signalling plays a crucial role in controlling β-cell differentiation and 
extending β-cell life span. The exenatide probably acts via GLP-1R as confirmed in 
GLP-1R−/− mice treated with exenatide (Deleon et al., 2003). No islet cell proliferation 
was observed after exenatide treatment. 
Moreover, treatment with either GLP-1 (Bulotta et al., 2002), or exenatide (Stoffers et 
al., 2000), of pancreatic ductal cells can lead to cell differentiation into β-cells 
compared to GLP-1R−/− mice, where this effect is abolished. As documented from 
these studies, GLP-1R is expressed on pancreatic ductal cells and thus could be 
involved in the differentiation of new β-cells. GLP-1 and exenatide may thus be 
exerting their beneficial effects by increasing the expression GLP-1R, as confirmed in 
the present study.          
Exenatide binds to the human pancreatic GLP-1R and initiates glucoregulatory effects 
(Parkes et al., 2001) and induces insulin secretion only under elevated blood glucose 
levels. This stimulating effect of exenatide on insulin gene expression and transcription 
is responsible for a continuous and a prolonged supply of insulin. After the glucose 
level has returned to normal level, the GLP-1 no longer binds to GLP-1R, thus 
preventing further insulin release and thus avoiding unwanted hypoglycaemia (Knop et 
al., 2009). This mechanism of GLP-1 action gives GLP-1 treatment a unique effect over 
the other traditional insulin secretagogue drugs. 
GLP-1 treatment has been shown to increase β-cells regeneration in STZ-model of 
diabetes. In addition, suppression of GLP-1R can prevent β-cells regeneration (Thyssen 
et al., 2006). In addition, in human pancreatic progenitor cells, GLP-1 binds to its 
receptor and propagates cell signalling that initiates cell proliferation (Suen et al., 
2008). The cascade of the GLP-1 receptor signalling is regulated via cAMP and PI-3K 
dependent pathways leading to enhancement of β-cells proliferation (Yew et al., 2005; 
Salehi et al., 2008).  
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4.9 Mode of action(s) of GLP-1 and its agonist exenatide  
The schematic model in figure 4.1 summarizes the main signalling cascades of action 
of either GLP-1 or its receptor agonist, exenatide, after binding to GLP-1R on 
pancreatic β-cell. GLP-1 binds to a specific receptor, GLP-1R, a seven-transmembrane 
domain, G-protein-coupled receptor on pancreatic beta cell (Girard, 2008). This binding 
process initiates the Gαs-receptor subunit of GLP-1R leading to acute insulin release. It 
also induces chronic expression of insulin gene and many other related genes involved 
with insulin gene expression, augment pancreatic cell proliferation and inhibits cell beta 
cell apoptosis (Liu and Habener, 2008). These cascades are regulated in a glucose-
dependent manner and they are only called into play when the blood glucose level is 
increased. At high, abnormal glucose levels, GLP-1 binds to GLP-1R and in turn 
stimulates the expression of GLUT-2 transporter and glucokinase that ultimately 
increase β-cell uptake of glucose via GLUT-2 receptor (Kim and Egan, 2008a). 
Increased cytosolic glucose concentration leads to stimulation of glucokinase, a β-cell 
glucose sensor, leading to enhancement of glycolysis and increased production of 
pyruvate, resulting in the production of more ATPs via the Kreb‟s cycle (Levine and 
Puzio-Kuter, 2010). Increased ATP/ADP ratio causes the closure of KATP channels, 
propagation of action potential, depolarization of the plasmalemma, leading to opening 
of the L-type voltage-dependant Ca
2+
 (VDC) channels that increases the Ca
2+
 influx 
into the cytoplasm. Elevated cytosolic Ca
2+
 binds to insulin-containing secretory 
granules that initiate aggregation, fusion, exocytosis and finally insulin secretion (Holst, 
2007). At the same time, increased ATP level activates the Gαs-receptor subunit of the 
GLP-1R to stimulate adenylate cyclase (AC) that mediate the conversion of ATP to 
cyclic AMP (cAMP). In turn, cAMP activates protein kinase A (PKA) (Wang et al., 
2001a) and exchange protein (Holz, 2006). Simultaneously, after ATP generation, both 
PKA and phosphatidylinositol-3 kinase (PI-3K) take part in the closure and activation 
of KATP channel depolarization and delay the K
+
 voltage channel (Kv) repolarization. 
The two actions enhance the propagation of membrane action potential (MacDonald et 
al., 2003). The spreading of action potential through the pancreatic β-cell plasma 
membrane opens the VDC channels leading to increased influx of Ca
2+
 into the 
cytoplasm (Kang et al., 2003). In addition, activation of PKA and Epac leads to an 
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increase in the release of intracellular Ca
2+
 from endoplasmic reticulum (ER) stores via 
activation of inositol trisphosphate receptor (IP3R) activated by PKA (Taylor et al., 
2004). Elevation of cytosolic Ca
2+
 in turn promotes exocytosis leading to the secretion 
of insulin (Light et al., 2002). Increased cytoplasmic Ca
2+
 will also stimulate 
calcineurin, which is responsible for the translocation of nuclear factor of activated T 
cells (NFAT) into the nucleus. NFAT protein binds to insulin gene and initiates insulin 
transcription (Heit et al., 2006).  
Furthermore, PKA and Epac activate docking and union of insulin-containing vesicles 
during exocytosis of insulin (Kwan et al., 2007). PKA activation via cAMP can also 
cause a downstream activation and translocation of PDX-1 into the nucleus. At this 
point, PDX-1 initiates insulin gene expression resulting in increased β-cell proliferation 
and mitosis (Wang et al., 2005; Babu et al., 2007). PKA also stimulates cAMP response 
element binding protein (CREB) in the nucleus, which results in increased IRS-2 gene 
transcription. IRS-2 is translocated from the nucleus to the cytoplasm and help in the 
activation of phosphatidylinositol-3 kinase (PI-3K) (Kemp and Habener, 2001).  
Moreover, sustained GLP-1 binding to its GLP-1R leads to the activation of Gβγ-
receptor subunit of GLP-1R, which in turn activates directly the PI-3K or indirectly via 
activation of cytoplasmic tyrosine kinase (cSrc) that enhances β-cellulin, which 
stimulates the epidermal growth factor receptor (EGFR) on β-cell membrane. EGFR is 
a stimulator of PI-3K (Buteau et al., 2003). Downstream activation of PI-3K and 
protein kinase B (PKB) and protein kinase C-δ (PKC-δ) pathways regulate β-cell 
mitosis and proliferation. PKB is also involved in the prevention of β-cell death by 
suppression of the apoptotic factor, caspase-3 and forkhead box O1 (FoxO1). In turn, 
FoxO1 is deactivated by nuclear exclusion (Wang and Brubaker, 2002). Consequently, 
PKB prevents the inhibitory effects of both caspase-3 and FoxO1 on PDX-1 that 
promotes β-proliferation (Buteau et al., 2004). Elevation in ATP production and 
activation of PKB will both lead to stimulation of a mammalian target of rapamycin 
(mTOR) activity, which is involved in increasing β-cell mitosis (Kwon et al., 2004). 
In conclusion, GLP-1 binding to its GLP-1R activates  a large variety of signalling 
cascades which eventually lead to increased transcription of insulin and its secretion, β-
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cell mitosis, enhancement of β-cell proliferation, suppression of β-cell apoptosis and 
improved β-cell functions (Salehi et al., 2008).  
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Figure 4.1:  A schematic diagram showing a pancreatic β-cell and the processes taking 
place within the cell to regulate insulin homeostasis including synthesis and secretion 
via signalling pathways triggered by the activation of GLP-1 receptor by its ligand (As 
modified from Salehi et al., 2008). Further explanations (Different events 1-19 and 
abbreviations) are given on the next two pages. 
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The major pathways numbered 1-19 in Figure 4.1 is summarized as follows: 
1. Binding of GLP-1 or exenatide to GLP-1R. 
2. Glucose uptake by GLUT-2 and activation of glycolysis leading to production of 
pyruvate and ATP. 
3. Entrance of pyruvate into mitochondria activates the Kreb‟s cycle and more ATPs 
are release into the cytoplasm leading to increase in cytosolic ATP and ATP/ADP 
ratio.  
4. ATP elevation induces closure of KATP channel leading to membrane 
depolarization leading to opening of VDC channels and influx of Ca
2+
. 
5. Gαs, the subunit of GLP-1R, activates the conversion of the ATP into cAMP via 
adenylate cyclase. 
6. cAMP activates PKA and Epac, leading to Ca2+ release from the ER. 
7. PKA and PI-3K both induce membrane action potential via closure and 
depolarization of KATP channel leading to a delayed repolarization of Kv channel 
eventually resulting in the opening of VDC channels and influx of Ca
2+
. 
8. Elevated levels of cytosolic Ca2+ fuses with insulin vesicles and initiates exocytosis 
of insulin granules with the help of PKA and Epac.  
9. Exocytosis of insulin-containing granules. 
10. The expression of insulin gene and other β-cell regulatory genes are also activated 
through stimulation NFAT in the nucleus which is stimulated by calcineurin after 
elevation of cytosolic Ca
2+
. 
11. PKA activates the translocation of PDX-1 into the nucleus to initiate the expression 
of insulin gene and other related regulatory genes. At the same time, PKA 
stimulates CREB in the nucleus to initiate IRS-2 gene transcription, which will in 
turn induce insulin gene expression via PDX-1 stimulation. 
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12. IRS-2 is translocated from the nucleus to the cytoplasm and share in the activation 
of PI-3K.   
13. The Gβγ subunit of GLP-1R stimulates PI-3K either directly or indirectly by 
activation the binding of β-cellulin to EGFR via cSrc. Then EGFR stimulates PI-
3K. 
14. PI-3K activates both PKB and PKC-δ pathways. 
15. The downstream activation of both PKB and PKC-δ initiate the expression of 
insulin gene and other β-cell regulatory genes through stimulation PDX-1. 
16. PKB also inhibits β-cell apoptosis through suppression of caspase-3 and FoxO1. 
17. PDX-1 and NFAT stimulate insulin and other regulatory genes leading to more 
insulin synthesis and increased β-cell proliferation. 
18. Both ATP and PKB stimulate mTOR, which induces β-cell mitosis. 
19. In conclusion, GLP-1 binding to its GLP-1R leads to elevation of insulin gene 
expression, insulin synthesis and insulin secretion. In addition, activation of GLP-
1R improves the function, neogenesis, proliferation of pancreatic β-cell.  
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Abbreviations used in Figure 4.1 
 
Abbreviations Meanings 
AC Adenylate cyclase 
ADP Adenosine diphosphate 
ATP Adenosine triphosphate 
Ca
2+
 Calcium ion 
cAMP Cyclic adenosine monophosphate  
CREB cAMP response element binding protein 
cSrc Cytoplasmic tyrosine kinase 
EGF receptor Epidermal growth factor receptor 
Epac Exchange protein activated by cAMP 
ER Endoplasmic reticulum 
FoxO1 Factor forkhead box O1 
GLUT-2 Glucose transporter-2 
IP3R Inositol trisphosphate receptor 
IRS-2 Insulin receptor substrate-2 
KATP channel Potassium adenosine triphosphate channel 
Kv channel Potassium voltage channel 
mTOR Mammalian target of rapamycin 
NFAT Nuclear factor of activated T cells 
PDX-1 Pancreatic duodenal homeobox-1 
PI-3K Phosphatidylinositol-3 kinase 
PKA Protein kinase A 
PKB Protein kinase B 
PKCδ Protein kinase C-δ 
RyR Ryanodine receptor 
VDC channel L-type voltage dependant calcium channel 
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4.10 Conclusions 
From this study, it can be concluded that the treatment of normal and diabetic rats with 
either GLP-1 or exenatide can result in marked improvements in the body weight and 
glucose tolerance as well as concurrent decreases in blood glucose levels. Similarly, 
both GLP-1 and exenatide can significantly improve the biochemical parameters of 
both normal and diabetic rats. Both incretins improve the status of liver enzymes, 
kidney functions and lipid profile, which were deranged in STZ-induced diabetic rats. 
Both GLP-1 and exenatide can stimulate the release of insulin from isolated pancreatic 
fragments in a dose-dependent manner in age-matched healthy control and diabetic rats. 
The number of insulin immunopositive cells was significantly reduced in STZ-induced 
diabetic rat pancreas and treatment with either GLP-1 or exenatide significantly 
increased insulin-positive cells in both diabetic and normal rat pancreas. Similarly, 
significant improvement and increase in immunopositive cells of either catalase or 
glutathione reductase as antioxidant protective markers were detected in the pancreas of 
diabetic rats. Treatment with either GLP-1 or exenatide decreased the number of 
glucagon immunopositive cells in STZ-induced diabetic rats. Similar results were also 
seen in electron micrograph microscopy studies. Pancreatic β-cells of both normal and 
diabetic rats treated with either GLP-1 or exenatide have increased secretory granules 
compared to controls. At the molecular level, this study shows that treatment of normal 
and diabetic rats with either GLP-1 or exenatide can enhance insulin gene expression 
through significant increases in mRNA levels of many transcription factors, which have 
positive impacts on insulin gene biosynthesis and its secretion. The results obtained in 
this study have enhanced the knowledge and understanding of the possible cellular and 
molecular mechanisms of the hypoglycaemic effect of either GLP-1 or exenatide (see 
Figure 4.1). They may provide additional impact to the arsenal of drugs to treat diabetes 
mellitus, not only as hypoglycaemic agents, but also as protective agents for increasing 
and maintenance of β-cell integrity and the proliferation of new β-cells. GLP-1 
improves glucose-stimulated insulin secretion, restores glucose competence in glucose-
resistant β-cells and stimulates insulin gene expression and biosynthesis (see Figure 
4.1). Furthermore, GLP-1 acts as a growth factor by promoting β-cell proliferation, 
survival and neogenesis. Therefore, GLP-1 addresses both the defect in insulin 
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secretion and the decline in β-cell mass that contribute to the deterioration of β-cell 
function in the aetiology of diabetes. 
 
4.11 Scope for future work       
More studies would provide further insights into new ways to treat or even cure 
diabetes, one of the most endemic chronic diseases that is rapidly increasing at present. 
New studies have to be done to discover promising and novel peptides that could cure 
and stop the progress or even delay the onset and appearance of diabetic complications. 
These investigations would employ a diverse range of scientific techniques including 
confocal microscopy, establishment and maintenance of cell and tissue culture and 
molecular biological techniques. These techniques can be used in a number of possible 
studies to support the following: 
(A) Investigating the actions of the new peptides by focusing on their roles on the 
stimulation of insulin gene expression in collaboration with different related 
genes sharing in glycaemic homeostasis. 
(B) Investigating the mechanism(s) of actions of these new peptides starting from 
their binding to different cell receptors until the synthesis and secretion of insulin 
from pancreatic β-cells. 
(C) Investigating the role of the oxidative stress and antioxidant defense systems in 
the preservation of pancreatic beta cell mass. 
(D) Imaging of apoptotic and proliferation of β-cell signals using confocal and 
electron microscopic studies. 
(E) An in vitro investigation of the effects of new peptides on insulin secretion, cell 
proliferation and cell mass growth through β-cell line culture technique. 
(F) An investigation into the use of stem cells in the treatment of diabetes mellitus. 
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(G) An investigation into the use of β-cell transplantation in the treatment of diabetes 
mellitus. 
(H) An investigation into the use of gene therapy to replace the defect in insulin gene 
in diabetic rats. 
 
In general, there are a number of new studies, which can help to control and to treat 
DM, a disease which has affected more than 250 million people worldwide and which 
is spreading rapidly, almost beyond control. 
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1. Phosphate buffer saline (pH 7.4) 
1. Distilled water    800 ml. 
2. Sodium chloride    8 g. 
3. Potassium chloride    0.2 g. 
4. Sodium dihydrogen phosphate  1.44 g. 
5. Potassium dihydrogen phosphate  0.24 g. 
6. Add distilled water to a total volume of 1 liter. 
7. Adjust the pH to 7.4 
2. Citrate buffer (pH 4.5) 
1. 0.1 M Sodium citrate solution  220 ml 
2. 0.1 M Citric acid solution   280 ml 
3. Distilled water    500 ml 
4. Adjust the pH to 4.5 
3. Karnovsky’s fixative  
1. Formaldehyde 40%   80 ml. 
2. Glutaraldehyde 25%  160 ml. 
3. Sodium cacodylate buffer  360 ml. 
4. Distilled water    400 ml.  
 
4. Resin (Total = 51.25 gm) 
1. Agar  24 g. 
2. DDSA  16 g. 
3. MNA  10 g. 
4. DMP-30 1.25 g. 
 
 
286 
 
5. Sodium cacodylate buffer (pH 7.4) 
1. 80 g of paraformaldehyde dissolved in 696 ml of distilled water. 
2. Paraformaldehyde    696 ml. 
3. Picric acid (aqueous)    300 ml. 
4. 0.2 M Phosphate buffer   1000 ml. 
 
6. Antibodies 
 
Number Antibody 
Source 
Dilution Manufacturer 
1 Anti-Insulin Rabbit 1:1000 Dako, Copenhagen, Denmark 
2 Anti-Glucagon Rabbit 1:1000 Dako, Copenhagen, Denmark 
3 Anti-GLP-1 Rabbit 1:1000 
Phoenix Pharmaceuticals, 
Burlingame, California, USA 
4 Anti-Exenatide Rabbit 1:1000 
Phoenix Pharmaceuticals, 
Burlingame, California, USA 
5 Anti-GSH Rabbit 1:100 Sigma-Aldrich, Missouri, USA 
6 Anti-Catalase Rabbit 1:200 Sigma-Aldrich, Missouri, USA 
 
 
 
 
 
 
 
 
287 
 
 
 
 
 
 
 
 
PUBLICATIONS 
 
 
 
 
 
 
 
 
288 
 
Full-length papers 
1. Lotfy, M., Singh, J., Kalász, H., Tekes, K. and Adeghate, E. (2011). Medicinal 
Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of 
Type 2 Diabetes Mellitus. The Open medicinal Chemistry Journal 5(2), 82-92. 
 
2. Amin, A., Lotfy, M., Mahmoud-Ghoneim, D., Adeghate, E., Al-Akhras, M., Al-
Saadi M.A., Al-Rahmoun, S. and Hameed, R. (2011). Pancreas-protective effects of 
chlorella in STZ-induced diabetic animal model: insights into the mechanism. 
Journal of Diabetes Mellitus 1(3), 36-45. 
 
3. El Keblawy, A., Al-Shamsi, N., Lotfy, M., Al Shaik, N.S. and Al-Yammahi, A. 
Impact of Crop Residues on Seed Germination of Native Desert Plants Grown as 
Weeds. Weed Biology and Management, (In Press).  
 
4. Amr, A., Motfy, M., Shafiullah, M. and Adeghate, E. (2006). The Protective effect 
of Tribulus Terrestris in Diabetes. Annals of New York Academy of Sciences. 1084, 
391-401. 
 
5. El-Agouza I.M.; Doss S.H.; Lotfy M. (1997). The Effect of Some Amino Acids on 
Human Sperm Motility and Their Possible use as a Local Contraceptives. Egypt. 
Journal of  Zoology, 29, 255-272. 
 
 
 
289 
 
Abstracts 
1. Lotfy, M., Singh, J. and Adeghate, E. (2011). The beneficial effect of GLP-1 
treatment in type 1 diabetic rats. Proceedings of The Physiological Society 
Conference, July 11-14, University of Oxford, UK, 23, PC222.  
 
2. Lotfy, M., Singh, J. and Adeghate, E. (2010). Protective and Antioxidant Effects of 
GLP-1 and Exenatide on Rat Pancreatic Beta Cells. The 10
th
 Annual Faculty 
Graduate School Conference, June 30, Uclan, Preston, UK. 
 
3. El-Keblawy, A., and Lotfy, M. (2009). Crop Residues with Allelopathic Capability: 
Toward Searching for Natural Herbicides. The 10
th
 Annual UAE University 
Research Conference, April 13-16, Al Ain - United Arab Emirates. UAEU, Al-Ain, 
United Arab Emirates. 
 
4. Lotfy, M., Singh, J. and Adeghate, E. (2008). Pattern of distribution of glucagon-
like peptide-1 and exenatide in pancreas of normal and diabetic rats. The 9
th
 Annual 
Faculty Graduate School Conference, June 18, Uclan, Preston, UK. 
 
5. Adeghate, E., Lotfy, M. and Rashed, H. (2008). Effect of Glucagon-like Peptide-1 
and Exenatide on Insulin Release in Diabetic Rats. The 9
th
 Annual UAE University 
Research Conference. April 21-23, UAEU, Al-Ain, United Arab Emirates. 
 
6. Amr, A., Lotfy, M. and Adeghate, E. (2006). The Protective effect of Tribulus 
Terrestris in Diabetes. International Conference on Recent Advances in Diabetes 
Mellitus and its Complications. 6-9 March, Al Ain, United Arab Emirates. 
 
290 
 
 
 
 
 
 
 
 
MEETINGS ATTENDED 
AND COLLABORATIVE 
WORK 
 
 
 
 
 
 
 
291 
 
1. Participation in “The First Faculty of Science Forum on Teaching and Learning” 
October 13, 2011, AL Ain, UAE University. 
2. Participation in "Abu Dhabi Genomics and Systems Biology Meeting", New York 
University Abu Dhabi Institute and NYU Center for Genomics and Systems 
Biology. 2010. 
3. Participation in workshop on "Affymetrix Gene Expression Micro-Arrays" during 
Arab Health, held by Gulf Scientific Corporation, Dubai. UAE. 2010. 
4. Attendance of seminar on "Life Beyond DNA " by Dr. Stefan Dimitrov. (Gernoble 
Institute, France). 2010. 
5. Attendance of seminar on "The Oncogene Aurora Kinase Family " by Dr. Stefan 
Dimitrov. (Gernoble Institute, France). 2010. 
6. Attendance of seminar on "Histone Variant Nucleosomes: From Structure To 
Epigenetic Function " by Dr. Stefan Dimitrov. (Gernoble Institute, France). 2010. 
7. Attendance of seminar on “Critical role of chromatin acetylation in genome 
expression and maintenance” By Prof. Jacques Côté, Université Laval, Canada, 
Faculty of medicine and Health Science, UAE University, 2010. 
8. Participation in “14th  Annual workshop on diabetes mellitus and its complications” 
April 4, 2009, presented by “Diabetes and cardiovascular research group, FMHS, 
UAE University, Al Ain diabetes research group, and Emirates diabetes society. 
April 4, 2009. 
9. Participation in Research Project funded by the Research Affairs of the United Arab 
Emirates University, in collaboration with Professor. Ernest Adeghate, “The effect 
of incretin on gene expression in pancreatic islet cells in diabetes mellitus”. 2008-
2009 
10. Participation in workshop on "ADInstruments for Physiology" Faculty of Medicine 
and Health Sciences, at UAEU. 2009. 
292 
 
11. Attendance of seminar on "Protein Complexes that Modify Chromatin for 
Transcription" by: Professor Jerry L. Workman, Stowers Institute for Medical 
Research, Kansas City, Missouri, USA, Faculty of medicine and Health Science, 
UAE University. 2008. 
12. Participation in workshop "Discussion Forum on Diabetes" Organized by: Professor 
Ernest Adeghate, Faculty of medicine and Health Science, UAE University. 2007. 
13. Participation in Research Project funded by the Research Affairs of the United Arab 
Emirates University, in collaboration with Professor. Ernest Adeghate “Effects of 
GLP-1 and Exenatide on Insulin Release in Diabetic Rats”. 2006-2007. 
14. Participation in Research Project funded by the Research Affairs of the United Arab 
Emirates University, in collaboration with Dr. Amr Amin and Professor Ernest 
Adeghate, “Examining the Anti-Diabetic Protective Effects of a Selected Local 
Herb in Mammals”. 2004-2005. 
 
